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Abstract 
High risk neuroblastoma poses a significant clinical problem in paediatric oncology 
and new treatment strategies are needed. Antibody-derived bispecific T cell engagers 
(BiTEs) and chimeric antigen receptors (CARs) are novel treatment options that 
redirect a patient’s own T cells to recognise and eliminate tumour cells; both have 
demonstrated promise in clinical trials for haematological malignancies. In this study 
I explored an empirical approach to BiTE design in order to identify the optimal 
format for redirecting T cell cytotoxicity against neuroblastoma cells. GD2 was used 
as a target antigen, based on its high level of expression across neuroblastoma 
tumours and limited expression on healthy tissues. BiTEs were designed with 
different single chain variable fragments (scFv) to bind GD2 and CD3 (T cell) 
antigens. We demonstrated that a high affinity for GD2 was determinant of improved 
cytotoxicity of T cells against neuroblastoma cell lines and an optimal linker length 
between the two scFvs impacted tumour cell targeting. The secretion of interferon-γ 
and proliferation by activated T cells occurred in a CD3-specific and GD2-specific 
manner, confirming target specificity of the BiTEs.  
In a second strategy; as an attempt to reduce the on-target off-tumour toxicity of 
targeting GD2, novel antigen O-acetyl-GD2 was explored as an improved target 
antigen due to its restricted tumour expression pattern. The latter is a requirement 
when aiming to induce a persistent anti-tumour response with CAR T-cell therapy. 
An O-acetyl-GD2 specific CAR was generated which showed selective specificity to 
the O-acetylated form of GD2.  
Finally, as a pre-clinical approach to develop BiTE and CAR T cell therapy for 
neuroblastoma in vivo, pilot experiments were performed in a transgenic 
neuroblastoma mouse model which has co-expression of the ALKF1174L mutation and 
MYCN oncogene. This work indicated that this murine model appears suitable to 
develop T cell based immunotherapy into an effective therapeutic approach for 
neuroblastoma.  
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1.1 Childhood cancer neuroblastoma 
Neuroblastoma is the most common extracranial solid tumour in childhood and the 
most frequently diagnosed neoplasm during infancy (Maris et al., 2007). The tumour 
arises from the aberrant growth of neural crest progenitor cells of the sympathetic 
nervous system. The most common sites of tumour origin tend to be the adrenal 
medulla of the kidney or paraspinal sympathetic ganglia and as a result tumours 
present as masses in the abdomen, chest or neck (Maris, 2010). Clinical 
manifestations of neuroblastoma can vary depending on the site of presentation and 
commonly include abdominal pain, weight loss, fatigue and bone pain (Adair et al., 
1994). Neuroblastoma is most common in children under five years of age, with a 
median age of 17 months at diagnosis. The disease accounts for 7% of malignancies 
in patients younger than 15 years and is disproportionately related to around 15% of 
all paediatric oncology deaths due to a high rate of relapse after therapy (Smith, 
2010). 
1.1.1 Neuroblastoma genetic predisposition 
A number of underlying genetic events drive neuroblastoma tumourigenesis. A small 
subset of neuroblastoma cases (1-2%) are inherited in an autosomal dominant pattern 
while the majority of cases are sporadic. Genome-wide association studies (GWAS) 
have identified a number of genomic loci which are significantly associated with 
neuroblastoma predisposition (Bosse, 2016). In particular, patients with metastatic 
disease harbour driver oncogenes that are essential in maintaining tumourigenicity in 
established tumours (Bosse, 2016). The most common focal genetic lesion in 
sporadic neuroblastoma is the amplification of the V-Myc Avian Myelocytomatosis 
Viral Oncogene Neuroblastoma Derived Homolog (MYCN) gene. MYCN 
amplification occurs in approximately 25% of cases and correlates with clinically 
aggressive advanced stage disease and treatment failure (Brodeur et al., 1984, Seeger 
et al., 1985). MYCN encodes a transcription factor which activates the transcription of 
downstream target genes involved in multiple cellular processes including 
proliferation (Tweddle et al., 2001), metastasis (Zaizen et al., 1993) and angiogenesis 
(Meitar et al., 1996). Although MYCN is a major oncogenic driver, there are currently 
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no clinical trials targeting MYCN directly due to the difficulty of developing 
molecular targeted therapies to transcription factors. Much attention is being directed 
to the therapeutic targeting of molecules that modulate the activities of this potent 
oncoprotein (Huang, 2013).    
Gain-of-function mutations in the anaplastic lymphoma kinase (ALK) gene have been 
found in approximately 50% of familial and 7% of sporadic neuroblastoma cases 
(Mosse et al., 2008, Janoueix-Lerosey et al., 2008).  ALK is a receptor tyrosine 
kinase (RTK) which acts as a major oncogenic driver by activating signal 
transduction pathways involved in proliferation, migration and cell survival as a 
result of kinase domain mutations (described further in section 1.1.4) (Soda et al., 
2007).  Several other genomic alterations including DNA ploidy and chromosomal 
gains and deletions impact patient prognosis (Bosse, 2016). 
1.1.2 Neuroblastoma staging system 
One of the hallmark features of neuroblastoma is the remarkable heterogeneity of the 
disease, this may account for the broad spectrum of clinical presentation, response to 
treatment and overall patient prognosis. In order to determine the appropriate level of 
therapy and care a patient will require; neuroblastoma is risk stratified into categories 
using the international neuroblastoma staging system. Prognostic factors taken into 
account include patient age at diagnosis, stage of disease, MYCN oncogene 
amplification, DNA ploidy and specific recurrent segmental chromosomal 
aberrations. Based on these factors patients are stratified into three broad categories, 
consisting of low risk, intermediate risk and high risk disease.  
Low risk disease 
Patients with low risk neuroblastoma lack MYCN amplification and have localised 
tumour which can mostly or completely be removed by surgery. The five year event-
free survival rates are >85% and 75 – 85% for very low risk and low risk patients 
respectively. A unique group of neuroblastoma cases termed special neuroblastoma or 
stage MS (formally 4S) also fall into the low risk category. Metastases in stage 4MS 
neuroblastoma are restricted to the bone marrow, liver or skin. The uniqueness about 
23 
 
this sub-group is the spontaneous regression of the tumour and cure of the patient 
without the need of therapy.  
Intermediate risk disease 
Patients with intermediate risk disease lack MYCN amplification and include 
localised tumours in which < 50% of the tumour mass is removable by surgery and 
require additional chemotherapy. This group includes tumours that have started to 
spread to surrounding areas near the tumour or to other organs such as the bone 
marrow, liver or skin in children younger than 18 months. Patients typically have a 50 
– 75% five-year event free survival.  
High risk disease  
At the time of diagnosis, up to 60% of cases are classified as high-risk due to 
metastatic disease and/or the presence of MYCN oncogene amplification. High risk 
disease is typically found in children 18 months or older. Despite intensive 
combination therapies available, the five-year even free survival for patients with 
high risk disease is less than 50% (Figure 1.1).  
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Figure 1.1: Kaplan-Meier estimate of overall survival in neuroblastoma 
patients.  Overall 10 year survival of children with (A) Stage 4 (high risk) or 
(B) localised neuroblastoma after treatment with high dose chemotherapy with 
bulsufan and melphalan compared with carboplatin, etoposide and melphalan. 
Figure taken from (Ladenstein et al., 2017). 
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1.1.3 Current treatment of high-risk neuroblastoma 
High-risk neuroblastoma patients are treated with multi-modal therapies which each 
have their own associated toxicities. During the treatment regimen patients initially 
receive induction chemotherapy for a period of 4-6 months. This involves alternating 
regimens of several drugs including cisplatin and cyclophosphamide which help to 
reduce the size of the primary tumour and any metastatic lesions present. Following 
chemotherapy the tumour mass is removed by surgery. The patient then receives 
consolidation therapy involving high dose chemotherapy and radiation therapy to 
remove remaining cancerous cells. High dose chemotherapy has the side effect of 
destroying the bone marrow and so this treatment is followed by autologous 
haematopoietic stem cell transplantation which enables bone marrow recovery. The 
stem cells are normally harvested from the patient during induction chemotherapy.  
Despite the majority of the tumour being removed with this multi-modal approach, 
low or undetectable levels of cancer cells that remain put the patient at risk of relapse. 
At this stage of minimum residual disease (MRD), two modes of 
maintenance therapies are available to sustain remission. Firstly, 13-cis retinoic acid 
(isotretinoin) is a vitamin A derivative which is taken orally over a period of 6 
months. 13-cis retinoic acid induces differentiation of rapidly dividing neuroblastoma 
cells into mature nerve cells.  However, greater than 40% of children develop 
recurrent disease during or after 13-cis retinoic acid treatment (Sonawane, 2014).  
A second form of maintenance therapy is cancer immunotherapy which targets 
tumour cells using the immune system’s cytotoxic mechanisms. Monoclonal 
antibodies (mAb) (described further in section 1.3) recognise tumour cells by 
detection of a specific cell surface antigen and upon binding to the antigen can initiate 
an anti-tumour immune response. In a randomised phase III clinical trial, high risk 
neuroblastoma patients treated with a mAb, ch14.18, specific for neuroblastoma 
antigen disialoganglioside GD2 and combined with the cytokines GM-CSF and IL-2 
plus isotretinoin had a significantly improved event-free and overall survival 
compared to patients who received isotretinoin treatment alone (66% vs. 46% at 2 
years) (Yu et al., 2010) (Figure 1.2). These results led to the regulatory approval of  
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Figure 1.2: Kaplan–Meier estimates of overall survival of high-risk 
neuroblastoma patients treated with immunotherapy or standard 
therapy alone. Immunotherapy includes anti-GD2 mAb ch14.18, cytokines 
IL-2 and GM-CSF in addition to isotretinoin. Standard therapy includes 
isotretinoin alone. Taken from (Yu et al., 2010). 
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dinutuximab by the US Food and Drug Administration (FDA) and European 
Medicines Agency (EMA) in 2015 for treatment of patients with high-risk 
neuroblastoma. This treatment and associated side effects will be further discussed in 
section 1.3. 
Clinical studies like this as well as others (Pule et al., 2008, Gargett et al., 2016) have 
highlighted the potential of harnessing the patient immune system in the treatment of 
neuroblastoma. Such tumour specific therapies require the presence of a cell surface 
antigen in abundance on the tumour cell with limited or absence of expression on 
normal and healthy tissues. The immune system is then manipulated to recognise the 
tumour cells through identification of a specific tumour antigen. The next section 
focusses on antigens specific to neuroblastoma which are favourable targets for 
immunotherapy. 
1.1.4 Neuroblastoma cell surface antigens  
Neuroblastoma cells have been shown to express defined tumour associated antigens 
which represent potential targets for immunotherapy. A discussion of all possible 
antigens expressed on neuroblastoma is beyond the scope of this thesis. Table 1.1 
provides a summary of selected antigens alongside their function and tumour vs. 
normal tissue expression. Antigens GD2, O-acetyl-GD2 and ALK which are 
abundantly expressed on neuroblastoma with limited or absence of expression on 
normal tissues are further described in this section. 
Disialoganglioside GD2 
The disialoganglioside GD2 is abundantly expressed on the surface of a broad 
spectrum of human cancers including neuroblastoma (Cheung et al., 1985), 
melanoma (Hersey et al., 1988), small cell lung cancer (Yoshida et al., 2001), 
glioblastoma (Longee et al., 1991), osteosarcoma and breast cancer (Chang et al., 
1992, Orsi et al., 2017). The limited expression of GD2 in normal tissue, which is 
largely limited neurons (Marconi et al., 2005), skin melanocytes and peripheral nerve 
fibres makes GD2 a favourable target for cancer immunotherapy (Lammie et al., 
1993).  
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Antigen Function / description Tumour expression 
(examples) 
Normal expression References 
Disialoganglioside GD2 Sialic acid containing glycosphingolipid 
that functions to repair and maintain the 
nervous tissue 
Neuroblastoma 
Melanoma 
Osteosarcoma 
Soft-tissue sarcoma 
Neuroectodermal tumours 
Neuronal tissues (including 
peripheral sensory nerve fibres),  
melanocytes and the CNS 
(Ohmi, Tajima et al. 
2011) (Kushner et al 
2011) 
O-Acetyl GD2 Derived from a 9-O Acetyl post-
translational modification of GD2. 
OAcGD2 is normally expressed during 
neuronal development, very little is 
known about its role. 
Neuroblastoma 
Melanoma 
Osteosarcoma 
Soft-tissue sarcoma 
Neuroectodermal tumours 
Faint expression on Purkinje cells, 
Bergmann glia cells in the 
cerebellum and dorsal horns in the 
spinal cord. 
(Alvarez-Rueda, Desselle 
et al. 2011)(Fleurence et 
al., 2016) 
Anaplastic lymphoma 
kinase (ALK) 
A receptor tyrosine kinase expressed as a 
transmembrane protein during neuronal 
development. ALK is down regulated 
soon after birth. 
Neuroblastoma 
Melanoma 
Glioblastoma 
Non-Hodgkin’s lymphoma 
Neuroectodermal tumours 
Restricted CNS expression limited to 
rare neurons, pericytes and 
endothelial cells. 
(Webb, Slavish et al. 
2009) 
B7H3 (CD276) Functions as both a T cell co-stimulator 
(through the TLT-2 receptor on CD8 T 
cells) and a T cell co-inhibitor. 
Neuroblastoma 
Non-small cell lung cancer 
Prostate cancer 
Mature dendritic cells (Modak, Kramer et al. 
2001)(Altan et al., 2017, 
Yuan et al., 2011) 
PSA-NCAM Cell surface glycan with a large hydrated 
volume that serves to modulate the 
distance between cells by promoting 
neural plasticity 
Neuroblastoma 
Glioblastoma 
Small-cell lung carcinoma 
Renal cell carcinoma 
Embryonic nervous system and adult 
nervous system including specific 
regions of the olfactory system, 
visual system and hypothalamus. 
(Rutishauser 2008) 
(Bonfanti 2006) 
L1CAM Neural cell adhesion molecule. Plays an 
important role in nervous system 
development including neuronal 
migration and differentiation 
Neuroblastoma 
Ovarian cancer 
Breast cancer 
Melanoma 
Foetal brain 
Amniocyte 
Frontal cortex 
(Novak-Hofer 2007) 
Table 1. 1 Candidate cell surface targets for MHC non-restricted immunotherapy of neuroblastoma 
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GD2 is a sialic acid containing glycosphingolipid. The glycosphingolipid consists of 
a ceramide backbone made of sphingomyelin and cholesterol, which anchors GD2 
into the plasma membrane. This lipid anchor enables the formation of membrane 
microdomains which play important roles in cell – cell communication and signal 
transduction. The oligosaccharide portion of the glycosphingolipid which contains 
two sialic acid residues is exposed as a pentasacharide head group on the surface of 
the cell (Furukawa et al., 2002).  
GD2 biosynthesis begins in the endoplasmic reticulum and involves the stepwise 
addition of monosaccharides to ceramide (Figure 1.3 A). The ceramide is synthesised 
first by the ceramide transfer protein, CERT, and is subsequently transferred to the 
Golgi apparatus where it is converted to glucosylceramide (Glc-Cer) by addition of a 
glucose sugar residue. Next, the addition of galactose to Glc-Cer forms 
lactosylceramide (Lac-Cer / Gal-GlcCer). This is the basic framework of the majority 
of gangliosides. Addition of a sialic acid residue to LacCer by sialyltransferase I, also 
called GM3 synthase forms GM3, an a-series ganglioside. A second sialic acid is then 
added by sialyltransferase II or GD3 synthase to form the b-series ganglioside GD3, 
the precursor of GD2. Finally, the addition of N-acetylneuraminic acid to LacCer by 
the enzyme GM2/GD2 synthase converts GD3 to GD2. Upon completion of 
synthesis, GD2 undergoes vesicle sorting and fusion with the plasma membrane 
(Suzuki and Cheung, 2015). The structure of GD2 is depicted in Figure 1.3 B. 
In embryonic development, GD2 is involved in neural differentiation and 
proliferation, but the precise function of GD2 remains unclear. After birth, GD2 
expression is limited to a few cell types and is thought to play a role in the 
maintenance and repair of nervous tissues in humans (Svennerholm et al., 1989). 
Ganglioside biosynthesis in tumour cells is controlled by a network of enzymes, the 
key members of which for induction of GD2 are GM2 and GD3 synthases and the 
availability of the precursor ganglioside lactosyl ceramide. Neuroblastoma cells have 
high levels of GM2/GD3 synthase transcripts and thus increased GD2 expression 
(Yamashiro et al., 1993). As a component of the glycolipid enriched microdomain 
(GEM) / rafts on the cell membrane, GD2 is able to promote proliferation, invasion 
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and motility in tumour cells by activation of tyrosine kinase signalling. In GD2 
positive breast cancer, GD2 induces tyrosine phosphorylation of the hepatocyte 
growth factor (HGF) receptor in the absence of HGF, leading to the activation of c-
Met, engaging MEK/ERK and PI3K/Akt pathways, resulting in increased 
proliferation and cell migration (Furukawa et al., 2012).  
In osteosarcoma, GD2 induces the phosphorylation of either the focal adhesion kinase 
or Lyn kinase, a member of Src family of tyrosine kinases. This leads to the 
activation of paxillin, a signal transduction protein, and subsequently the inhibition of 
integrin-mediated cell adhesion resulting in enhanced cell migration (Shibuya et al., 
2012). Given the abundant expression of GD2 on neuroblastoma, the interaction of 
GD2 with integrins in GEM / rafts is likely to be important for controlling the 
malignant potential of the disease (Wu et al., 2008). 
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Figure 1.3: Biosynthesis and structure of Disialoganglioside GD2. (A) 
Biosynthesis of GD2 and (B) structure of GD2, Glc: glucose, Gal: galactose, SA: 
sialic acid, NAc: N-acetylneuraminic acid. Adapted from Suzuki and Cheung, 2015. 
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O-Acetyl-GD2  
The accumulation of tumour-associated gangliosides in malignant cells is associated 
with aberrant acetylation of the sialic acid side chains. O-acetyl GD2 (OAcGD2) is 
the O-acetyl derivative of the GD2 ganglioside and is expressed alongside GD2 on 
the tumour cell surface (Ye and Cheung, 1992). The outer negatively charged α2-8 
linked sialic acid residue of GD2 is modified on the C7 and/or C9 hydroxyl group in 
the Golgi apparatus. The reaction is catalysed by the CASD1 sialate O-
acetyltransferase via a covalent acetyl-enzyme intermediate (Figure 1.4) (Sjoberg et 
al., 1992, Arming et al., 2011, Baumann et al., 2015). The spontaneous migration of 
the O-acetyl group from the C7 to C9 position is observed when O-acetylated sialic 
acids are exposed to mild alkaline conditions. Thus it can be easy to lose the O-
acetylation during sample collection and stringent control of buffer pH and 
temperature are required (Kamerling et al., 1987).  
The O-acetyl group modifies a number of chemical properties of the ganglioside 
acceptor, such as a decrease in the polarity and hydrophobicity of the ganglioside but 
does not affect the overall conformation (Siebert, 1996). The synthesis of OAcGD2 
can be regulated by the amount of acetyl CoA concentrations within the Golgi 
apparatus and as a result, the presence of GD2 and level of O-acetylation present on 
tumour cells varies. The ratio between the amounts of OAcGD2 to GD2 is between 
10 - 50% (Higa et al., 1989, Kaneko et al., 2010).  
The biological and functional roles of OAcGD2 are not yet known, however 
functional roles for OAcGD3 are well defined as OAcGD3 was the first identified 
member of the O-acetyl family. Understanding the roles of OAcGD3 may provide an 
insight into the roles of OAcGD2. Araujo et al. studied the impact of blocking 
OAcGD3 signalling on dorsal root ganglion neurons using the anti-OAcGD3 Jones 
mAb in vitro. The results indicated that blocking induced microtubule depolarisation 
both in growth cones and neurites and thus OAcGD3 was concluded to be involved in 
modulating growth cone motility and axonal branch formation (Araujo et al., 1997).  
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Further, the induction of O-acetylated sialoglycoproteins on lymphoblasts of 
childhood acute lymphoblastic leukaemia (ALL) cell lines promoted survival of 
lymphoblasts by preventing apoptosis (Erdmann et al., 2006, Mukherjee et al., 2007). 
Due to the close relation of the OAcGD2 and OAcGD3 gangliosides, it is likely that 
OAcGD2 has similar roles in promoting tumour cell survival, although the 
mechanisms are not yet known. 
Unlike GD2, OAcGD2 is reportedly expressed on tumour tissue and not on peripheral 
nerves. Alvarez-Rueda et al. studied the distribution of OAcGD2 expression across a 
range of malignant and healthy tissue samples by immunohistochemistry. OAcGD2 
expression was detected on 35/35 glioblastoma samples 12/12 GD2 positive 
neuroblastoma samples and 3/4 melanoma and small cell lung cancer samples. On 
healthy tissue GD2 expression was detected on 12 peripheral nerve samples tested 
whilst OAcGD2 expression was not. Thirty-two other normal tissues recommended 
for screening by FDA guidelines, including the skin, spleen and brain were also 
negative for OAcGD2 expression. Only a few cell types such as Purkinje cells, the 
Bergmann glia in the cerebellum, and the dorsal horns in the spinal cord showed faint 
staining for OAcGD2. The staining results indicated that targeting OAcGD2 with 
immunotherapy may have a safer reactivity profile in comparison to targeting GD2 
by avoiding on-target off-tumour toxicities (Alvarez-Rueda et al., 2011, Fleurence et 
al., 2016). 
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Figure 1.4: Structure of OAcGD2. O-acetylation of GD2 occurs on the outer 
sialic acid residue by the CASD1 sialate O-acetyltransferase via a covalent 
acetyl-enzyme intermediate. Glc: glucose, Gal: galactose, SA: sialic acid, NAc: 
N-acetylneuraminic acid, red circle: acetyl group. Adapted from (Suzuki and 
Cheung, 2015). 
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Anaplastic lymphoma kinase (ALK) 
ALK is a RTK kinase belonging to the insulin receptor superfamily. ALK was first 
described as a fusion partner in the t(2;5)(p23;q35) chromosomal rearrangement. This 
rearrangement fuses the cytoplasmic domain of ALK to the N-terminal portion of the 
nucleolar phosphoprotein NPM in anaplastic large cell lymphoma (ALCL) (Morris et 
al., 1994). ALK was subsequently found to be rearranged, mutated or amplified in a 
series of tumours including lymphoma, neuroblastoma and non-small cell lung cancer 
(Soda et al., 2007). 
The full length ALK RTK consists of an extracellular ligand-binding domain, a 
transmembrane domain and an intracellular tyrosine kinase domain (Figure 1.5) 
(Iwahara et al., 1997, Wellstein and Toretsky, 2011). ALK becomes activated only 
upon ligand-induced homo-dimerisation, and inactivated through de-phosphorylation 
by receptor protein tyrosine phosphatase beta and zeta complex (PTPRB/PTPRZ1) 
when there is no stimulation by a ligand. Reported ligands for ALK include the 
family with sequence similarity 150A (FAM150A) and family with sequence 
similarity 150B (FAM150B) (Guan et al., 2015). Proteins midkine and pleiotropin 
have also been reported as ligands of ALK, but this remains controversial (Perez-
Pinera, 2007).  
ALK is highly conserved across species and is transiently expressed in specific 
regions of the central and peripheral nervous systems and in the developing 
sympatho-adrenal lineage of the neural crest (Iwahara et al., 1997). Although the 
normal function of full length ALK is not entirely clear, mammalian ALK is believed 
to play roles in the development and function of the nervous system as mRNA is 
detected throughout the nervous system during mouse embryogenesis (Vernersson et 
al., 2006).   
Dominant germline mutations in ALK have been identified in approximately 50% of 
familial neuroblastoma cases (Mosse et al., 2008). Three distinct germline mutations, 
R1275Q, R1192P and G1128A have been described, with R1275Q being the most 
frequent (Janoueix-Lerosey et al., 2008, Mosse et al., 2008). Additionally, somatic 
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activating mutations have been identified in conserved positions in the tyrosine 
kinase domain; and R1275 and F1174 are the two major mutational hotspots. Both 
are associated with constitutive phosphorylation of ALK and of downstream targets 
such as ERK, STAT2 and AKT leading to proliferation and differentiation (Chen et 
al., 2008). ALK is also amplified in the absence of mutations in approximately 2% of 
neuroblastoma cases (De Brouwer et al., 2010).  
ALK may provide an ideal target for immunotherapy due to its reported expression 
on the cell surface of most neuroblastoma tumours and restricted distribution in 
normal tissues.  
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Figure 1.5: Structure of anaplastic lymphoma kinase. The RTK consists of 
an extracellular ligand binding domain (LBD), transmembrane domain (TM) 
and intracellular kinase domain. The major mutations found in the kinase 
domain and their relative frequencies are shown. Adapted from (Wellstein and 
Toretsky, 2011) 
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1.2 Adaptive immunity: a focus on T cells  
The major aim of the work described in this thesis is to develop an improved 
immunotherapeutic approach for the treatment of high-risk neuroblastoma. 
Mechanisms employed by neuroblastoma tumours to actively avoid detection by the 
immune system and how this can be overcome through targeted therapy using T cells 
is described in the following sections, beginning with a focus on T cell development 
and function.  
The human immune system comprises both innate (non-specific) and adaptive 
(specific) defence mechanisms to eliminate a wide variety of pathogens. One of the 
most important features of the immune system required for host defence is the ability 
to distinguish between the structural aspects of a pathogen (non-self) and its own host 
tissue (self). Whilst the innate arm specialises in the recognition and elimination of 
pathogens containing pathogen associated molecular patterns (PAMPs) (Medzhitov 
and Janeway, 2002), the adaptive arm comprises B and T lymphocytes which are 
capable of rearranging their genomic elements to create clonotypic antigen receptors 
(B and T cell receptors) that mediate humoral and cellular immune responses.  
1.2.1 T cell development   
The majority of peripheral T cells contain the αβ T cell receptor (TCR) and are the 
main population of interest in the context of this thesis. CD8+ T cells are cytotoxic 
lymphocytes which are capable of detecting and eliminating virally infected or 
neoplastic cells. CD4+ T cells on the other hand, are helper T lymphocytes which can 
be classified into four subsets, Th1, Th2, Th17 and Thf and play a central role in 
immune protection. Major roles include their capacity to help B cells make antibodies 
and induce macrophages to develop enhanced microbial activity.  
During T cell development (Figure 1.6), committed lymphoid progenitors arise in the 
bone marrow and migrate to the thymus (Scimone et al., 2006). Early committed T 
cells lack the expression of co-receptors CD4 and CD8 and are termed double 
negative (DN) thymocytes. These are subdivided into a further four stages (DN1 - 
DN4) based on the expression of the CD44 adhesion molecule and the CD25 
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interleukin-2 receptor chain (Aifantis et al., 2008, Naito et al., 2011). As cells 
progress through the DN2 - DN4 stages, they express the pre-TCR, composed of the 
non-rearranging pre-Tα chain and a rearranged TCR β-chain (von Boehmer and 
Fehling, 1997).  
Successful pre-TCR expression leads to substantial cell proliferation and transition to 
a double positive (DP) stage where cells have a CD4+CD8+ phenotype. DP cells 
subsequently undergo positive and negative selection by interacting with cortical 
epithelial cells that express a high density of MHC class I and class II molecules 
associated with self-peptides. Too little or too much signalling results in negative 
selection and apoptosis of the DP cell, while an intermediate level of signalling 
results in positive selection (von Boehmer et al., 1989). Thymocytes become single 
positive (SP) CD8+ T cells upon recognition of self-peptide-MHC class I complexes 
and become SP CD4+ T cells upon recognition of self-peptide-MHC class II 
complexes.  T cells are then ready for migration out of the thymus to the peripheral 
lymphoid organs.  
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Figure 1.6: αβ-T cell development in the thymus. Early thymocyte progenitors 
(ETP) undergo transition from double negative (DN) to double positive (DP) 
thymocytes through regulation of markers CD44, CD25, CD4 and CD8. Positive 
and negative selection tests thymocyte interaction with self-peptide-MHC 
complexes and further divides cells into single positive (SP) CD8+ or CD4+ T cells. 
Adapted from Fayard et al, 2010. 
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1.2.2 TCR signalling  
The ability of T cells to respond to their specific antigen is central to adaptive 
immunity. Although the αβ TCR has exquisite specificity to antigen, it is unable to 
initiate signalling within the T cell alone. The TCR is associated with invariant 
accessory proteins to form the TCR complex that initiates signalling when the 
receptor binds antigen. Together with signalling from co-receptors and co-stimulatory 
receptors, full lymphocyte activation can be achieved.   
As part of the TCR complex the αβ TCR heterodimer is associated with the CD3 
signalling complex comprised of CD3γ, CD3δ and CD3ε chains and the ζ chain 
which is present as a disulphide-linked heterodimer (Figure 1.7) (Janeway, 2001). 
The cytoplasmic regions of the CD3ζ chains contain immune-receptor tyrosine-based 
activation motifs (ITAMs) which are phosphorylated by the lymphocyte specific 
protein tyrosine kinase Lck upon TCR engagement with peptide-MHC. Lck is found 
constitutively associated with the cytoplasmic regions of the CD4 and CD8 co-
receptors which cluster to the TCR by binding invariant regions of the MHC 
molecule (Kersh et al., 1998).  
Phosphorylated ITAM residues become docking sites for the tyrosine kinase ZAP-70 
(ζ-chain-associated protein). Once ZAP-70 is recruited to the receptor complex, it is 
phosphorylated and activated by Lck (Chan et al., 1995). ZAP-70 is then able to 
phosphorylate both the scaffold protein LAT (linker of activated T cells), a 
transmembrane protein with a large cytoplasmic domain and another adaptor protein, 
SLP-76 which are then both linked by adaptor protein Gads. The subsequent steps in 
the T cell signalling pathway involve the activation of Phospholipase C-γ (PLC-γ), a 
key signalling protein.  PLC-γ is recruited to the inner leaflet of the plasma membrane 
by binding to PIP3 (formed by phosphorylation of PIP2 by PI 3-kinase) where it is 
then able to bind to phosphorylated LAT and SLP-76 and is subsequently activated 
by the membrane-associated tyrosine ItK (Berg et al., 2005).  
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Figure 1.7: T cell receptor signalling. Upon engagement of a TCR with a 
peptide-MHC complex, Lck phosphorylates ITAMs on intracellular regions of 
CD3ζ chains, leading to recruitment and phosphorylation of ZAP-70. ZAP-70 in 
turn phosphorylates LAT and SLP76, to which PLC-γ binds and is activated by 
ITK. PIP2 is cleaved by PLC-γ to yield IP3 and DAG which subsequently lead to 
the translocation of NFKB, AP-1 and NFAT transcription factors in to the 
nucleus to induce gene transcription leading to cell proliferation and 
differentiation. Adapted from (Schwartzberg et al., 2005) 
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Activated PLC-γ cleaves phosphatidylinositol bisphosphate (PIP2) to yield the 
membrane lipid diacylglycerol (DAG) and the diffusible second messenger inositol-
trisphosphate (IP3). This subsequently leads to three distinct branches of the TCR 
pathway. In one branch of the pathway, IP3 diffuses through the cytosol and binds to 
ligand gated Ca2+ channels on the endoplasmic reticulum (ER) membrane. Ca2+ is 
released from membrane sequestered calcium stores, leading to a rapid increase in 
cytosol Ca2+ concentration. The cytosolic Ca2+ binds a ubiquitous calcium dependent 
regulatory protein called calmodulin, which in T cells targets the protein phosphatase 
calcineurin. Calcineurin dephosphorylates the NFAT (nuclear factor of activated T 
cells) transcription factor which then enters the nucleus and is able to turn on many 
genes crucial for T cell activation (Hogan et al., 2003).  
A second branch of signalling leading from PLC-γ is activation of RasGRP by DAG. 
RasGRP is a guanine-nucleotide exchange factor which activates Ras and in turn 
activates the mitogen activated protein (MAP) kinase cascade. Erk is the final kinase 
of this pathway and acts indirectly to generate the AP-1 transcription factor. The third 
branch of signalling involves the activation of PKC-θ which activates the scaffold 
protein CARMA leading to the activation of the NFKB transcription factor. All three 
transcription factors: NFAT, AP-1 and NFKB induce specific gene transcription 
leading to cell proliferation and differentiation (Leevers and Marshall, 1992, 
Matsumoto et al., 2005).   
1.2.3 T cell activation 
Naïve T cells (which have not yet encountered antigen) require two signals delivered 
by antigen presenting cells (APC) for activation to occur. The interaction of TCR 
with peptide-MHC complex on the APC delivers signal 1 and secondary co-
stimulation delivers signal 2. Signal 1 involves the activation of intracellular 
signalling pathways as described above, however signal 1 alone is not sufficient to 
activate a T cell and when delivered solely can result in T cell anergy (Valitutti, 
2012).  
For activation and proliferation to occur, co-stimulation is required and is achieved by 
engagement of T cells with co-stimulatory receptors on APCs. The two main receptor 
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families are: the CD28 family, including CD28 and ICOS, which interact with 
CD80/CD86 and B7-H2 and the TNF receptor superfamily including 41BB, CD27 
and OX40 which interact with 4-1BBL, CD70 (CD27L) and OX40L on APCs. These 
signals enable a number of effects on the T cell including survival, effector function 
and memory formation. Upon antigen priming, resting naïve T cells undergo dramatic 
changes in metabolism and proliferation. Once a T cell is activated, signal 2 is no 
longer required upon subsequent encounter of antigen. 
1.2.4 CD8+ T cell mediated cytotoxicity 
Cytotoxic CD8+ T cells kill their target cells by inducing apoptosis (programmed cell 
death). To achieve this, T cells need to be in direct contact with their target cell 
through a TCR and peptide-MHC interaction and have efficient formation of an 
immunological synapse (Figure 1.8). The immunological synapse is also known as 
the supramolecular activation cluster (SMAC) which is composed of three concentric 
rings, each containing segregated clusters of proteins. 
 All nucleated cells express MHC class I molecules, which present processed 
intracellular peptide from pathogens that reside in the cytosol. Once the TCR engages 
a peptide-MHC complex, TCRs begin to cluster around the site of contact along with 
co-stimulatory receptors (e.g. CD28), tyrosine kinases (Lck and ZAP70), serine 
kinases (PKC-θ) and adaptor molecules (LAT, SLP76) to form the central-SMAC 
(cSMAC) (Varma et al., 2006, Monks et al., 1998). 
Next, the binding of LFA-1 on T cells to ICAM-1 on APCs creates a molecular seal 
that surrounds the TCR and its co-receptor, this is known as the peripheral SMAC 
(pSMAC). The pSMAC is surrounded by a more distal ring (dSMAC), containing 
membrane proteins with large ectodomains such as phosphatases CD45 and CD148. 
The phosphatases are excluded from the synapse and allow TCR induced tyrosine 
phosphorylation to be initiated (Leupin et al., 2000).  
The clustering of TCRs signals a reorientation of the cytoskeleton that polarises the 
CD8+ T cells and allows the release of pre-formed cytotoxic granules containing the 
cytotoxic proteins perforin and granzyme B. Perforin enables the formation of pores 
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in the target cell membrane and allows entry of granzyme B into the target cell. 
Granzyme B cleaves and activates caspase 3 to trigger a proteolytic cascade, 
ultimately leading to DNA degradation. Apoptotic cells are ingested by phagocytic 
cells which detect phosphatidylserine expressed on the outer leaflet of the plasma 
membrane (Heusel et al., 1994) . T cells also release cytokines such as IFN-γ and 
TNF-α. IFN-γ inhibits viral replication directly and induces the increased expression 
of MHC class I. Both IFN-γ and TNF-α recruit macrophages to the site of infection. 
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Figure 1.8: Formation of an immunological synapse. After a TCR binds to 
peptide-MHC, interactions between LFA-1 and ICAM-1, exclude larger 
phosphatases like CD45 from the forming synapse to allow sufficient 
downstream signalling. The synapse allows controlled release of perforin and 
granzymes from cytotoxic granules within the T cell to the target cell. Perforin 
forms pores in the target cell membrane and allows the entry of granzyme B 
which cleaves caspases and subsequently leads to DNA fragmentation and 
apoptosis of target cell. 
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1.2.5 Cancer immunoediting  
The concept that the immune system is able to recognise and eliminate developing 
tumour cells was originally proposed by Burnet and Thomas in 1957. Now, several 
decades later, this concept has developed to appreciate the dual role the immune 
system plays in cancer, of not only suppressing tumour growth but also promoting 
tumour progression, and is termed cancer immunoediting (Dunn et al., 2002, 
Schreiber et al., 2011).  
The importance of T cells in immune surveillance has been demonstrated by a 
number of studies showing that patients appear to live significantly longer if their 
tumours are infiltrated by T cells. A landmark study by Naito et al. analysed the 
distribution of CD8+ T cells within or around colorectal cancer cell populations and 
demonstrated that T cells specifically infiltrating cancer cell nests were most 
significantly associated with a better survival of patients (Naito et al., 1998). 
Subsequent studies in colon cancer, melanoma and ovarian cancer demonstrated the 
distribution patterns of infiltrating T cells were critical determinants of prognosis 
(Sato et al., 2005, van Houdt et al., 2008, Galon et al., 2006). In addition, there is a 
reportedly increased incidence of tumours in patients with primary immunodeficiency 
and those who are immunosuppressed after organ transplant (von Boehmer et al., 
2013). 
Despite the crucial role of T cells in eliminating tumour cells, the ability of T cells to 
recognise tumour antigens leads to immunological destruction or sculpting of the 
antigen, and thus promotes outgrowth of pre-existing clones that may not be 
recognised by T cells (Matsushita et al., 2012). A study of relapsed melanoma 
patients demonstrated that immunoediting occurs as a consequence of 
immunotherapy, resulting in absence of the initial target antigen in the relapsed 
tumour (von Boehmer et al., 2013).  
The cancer immunoediting hypothesis is composed of three phases: Elimination; 
Equilibrium and Escape. During the elimination phase, both the innate and adaptive 
immune systems actively detect and destroy nascent transformed cells before they 
become clinically detectable. In the equilibrium phase, which is likely the longest 
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phase, the immune system and surviving tumour cell variants enter into a dynamic 
equilibrium in which tumour cells are maintained in a state of dormancy. In the 
escape phase tumours that have acquired the ability to circumvent immune 
recognition and or destruction through genetic or epigenetic changes, proliferate in an 
unrestricted manner leading to clinically apparent tumours (Schreiber et al., 2011).  
Neuroblastoma escapes the immune system  
Neuroblastoma cells have developed sophisticated mechanisms to evade detection by 
the host immune system.  In particular, tumour cells down regulate HLA (MHC in 
humans) to evade T cell recognition (Raffaghello et al., 2005). Further, there is 
downregulation or release of NKG2D ligands, which bind the NKG2D activating 
immunoreceptor expressed by cytotoxic T cells and natural killer (NK) cells. NK 
cells belong to the innate arm of the immune system and are able to recognise and 
eliminate stressed or infected cells, independent of MHC expression (Raffaghello et 
al., 2004).  
Neuroblastoma tumours have developed a highly immunosuppressive 
microenvironment. The production of pro-inflammatory cytokines such as membrane 
bound TNF-α, TGF-β and IL-10 enable recruitment of tumour associated 
macrophages which produce chemokines to disable infiltrating lymphocytes (Liu et 
al., 2012). Myeloid derived suppressor cells (MDSC) are a major component of the 
tumour microenvironment. MDSCs can use enzymes involved in L-arginine 
metabolism to deplete arginine from the tumour microenvironment (Mussai, 2015). 
L-arginine plays a central role in regulating cell cycle progression in T cells and is 
correlated with cell cycle arrest, impaired proliferation and reduced activation 
(Rodriguez et al., 2007, Zea et al., 2004).  
In addition, neuroblastoma cells carry high levels of gangliosides on their surface 
which contribute to migration, adhesion and metastasis (Dong et al., 2011). Li et al. 
demonstrated that the presence of GD2 on the tumour surface has an 
immunosuppressive function.  In vivo studies in mice showed that transplanted GD2+ 
tumour cells were not efficiently killed by the local immune system in comparison to 
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a GD2- control and was due to downregulation of the cellular immune response (Li et 
al., 1996).  
1.3 Immunotherapy for neuroblastoma  
Immunotherapy has evolved over the last few decades as a tool to redirect and utilise 
the immune system to control and eliminate malignant cells. Both humoral and 
cellular components of the immune system can be employed to enhance an anti-
cancer response through recognition of tumour associated antigens.  
1.3.1 Monoclonal antibody therapy 
An immunoglobulin is a four-chain structure consisting of two identical heavy and 
light chains. Fragment antigen binding (Fab) regions mediate antigen recognition 
through variable heavy (VH) and variable light (VL) chains containing hypervariable 
complementarity determining regions (CDRs). A fragment crystallisable (Fc) region 
interacts with cell surface receptors.  
The advent of mAb production by Köhler and Milstein in 1975 paved the way for the 
development of novel and effective cancer immunotherapies. By 1997, FDA approval 
was given to the first mAb for the treatment of cancer (anti-CD20 Rituximab for non-
Hodgkin’s lymphoma); subsequently many other mAbs have been developed and 
received FDA approval.  
Upon binding to a target antigen, mAbs can elicit multiple mechanisms to eliminate 
malignant cells. Apoptosis can be induced by the direct binding of a mAb to a tumour 
antigen. The Fc portion of the mAb is able to trigger complement dependent 
cytotoxicity (CDC), NK cell or myeloid cell mediated antibody dependent cell 
mediated cytotoxicity (ADCC) and monocyte mediated antibody dependent cellular 
phagocytosis (ADCP). Many tumour target antigen specific antibodies can bind target 
antigen but lack cytolytic capacity. In this scenario, antibodies can instead be used as 
a vehicle to deliver a payload to the cell, examples include antibody drug conjugates 
(Lode et al., 1998), immunotoxins and targeted nano-particles (Thomas et al., 2002, 
Pastorino et al., 2013) . 
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GD2 as a target antigen for monoclonal antibody therapy 
In the treatment of neuroblastoma, GD2 has been used as a successful target antigen 
in mAb therapy for over two decades. A number of GD2-specific mAbs have been 
developed and tested in clinical trials, details of various anti-GD2 mAbs that have 
recently been under pre-clinical or clinical testing are reviewed by Ahmed and 
Cheung, 2013. The first anti-GD2 mAbs to be tested in patients with neuroblastoma 
were of murine nature and elicited human anti-mouse antibody (HAMA) responses, 
which limited dose escalations and compromised the clinical efficacy of the 
therapeutic.  
Chimerisation and/or humanisation efforts were made to overcome the intrinsic 
immunogenicity of murine-based mAbs. Chimerisation involves the engraftment of 
the antibody binding domains (VH - VL) on to human IgG constant domains leading 
to a significant reduction in immunogenicity. However, HAMA responses can still 
occur due to the murine antibody variable regions. Humanisation involves 
engraftment of the complementarity determining regions (CDR), directly involved in 
antigen recognition, and a few structurally significant residues (if necessary) on to 
human IgG constant domains. One of the limitations of this approach is often a 
reduction in avidity, however this is not always significant.  
To date the most significant clinical results in mAb therapy for neuroblastoma have 
been seen with a chimeric anti-GD2 mAb: ch14.18 (dinutuximab). As described 
earlier, high-risk neuroblastoma patients treated with immunotherapy (ch14.18 mAb, 
IL-2, GM-CSF) and isotretinoin in a randomised phase III clinical trial had an 
improved event-free and overall survival compared to patients who received 
isotretinoin treatment alone (Yu et al., 2010).  
Toxicities associated with GD2 targeted mAbs 
Treatment with anti-GD2 mAbs is often associated with acute toxicities. Within the 
ch14.18 mAb phase III trial, the main toxicity associated with antibody treatment was 
pain in over a third of patients, the abdomen being the most common site of pain. 
Non-target antigen related side effects included fever, hypotension and capillary leak 
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syndrome in the treated group compared with minimal side effects observed in the 
group receiving standard therapy. These toxicities were more severe when mAb 
therapy was combined with IL-2 (Yu et al., 2010).  A recent study also reported that 3 
high-risk neuroblastoma patients receiving dinutuximab developed transverse 
myelitis during or after the second cycle of immunotherapy. The study theorised this 
was possibly due to an anti-idiotypic reaction, patients were discontinued from 
dinutuximab therapy and recovered after receiving corticosteroid therapy (Ding et al., 
2017). 
The acute toxicities associated with anti-GD2 mAbs are thought to be due to the on-
target off-tumour binding of mAbs to GD2-positive sensitive nerve fibres, followed 
by complement activation. The complement cascade involves the production of 
inflammatory peptides which increase the symptoms of pain. In an attempt to reduce 
complement activation, Sorkin et al have shown that the specific point mutation 
K332A in the Fc region of the humanised form of mAb 14.18 (hu14.18) resulted in a 
significant reduction in antibody induced pain in a rat model. Further studies in rats 
have demonstrated that complement activation can be avoided by disruption of the 
binding of C1q by the Fc portion of the antibody through incubation of the antibody 
at 56 °C for 30 minutes (Sorkin et al., 2010).   
1.3.2 Redirected T cell-based therapy 
Several strategies have been used to enhance the efficacy of antibody-based 
immunotherapy. In particular, the antigen specific portion of a mAb (VH - VL) can be 
expressed as a single polypeptide chain by joining VH and VL with a short flexible 
liker to form a single chain variable fragment (scFv). The scFv can be used to re-
direct T cell specificity to tumour cells and will be the focus of the remainder of this 
thesis. 
There are a number of advantages of using T cells as an effective tool for cancer 
therapy, these include: (1) The specificity of the T cell response  through the native 
receptor or an engineered antigen specificity allows potential differentiation between 
healthy and cancerous cells; 2) Following activation in response to antigen, there is a 
robust clonal expansion; 3) T cells are able to infiltrate effectively throughout the 
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body and identify areas where the antigen of interest is expressed; 4) Memory T cells 
are able to mount an antigen specific response upon re-encounter of the antigen at a 
later time point, resulting in ongoing tumour surveillance. 
1.3.2.1 Bispecific antibodies 
Bispecific antibodies (bsAb) are bivalent molecules which combine the specificities 
of two mAbs to enable simultaneous binding of two antigens located on different cell 
types. Their most promising use is their ability to redirect T cells to recognise and 
eliminate tumour cells. 
There are three methods for producing bispecific antibodies: 1) chemically cross-
linking by chemical conjugation 2) fusion of two different hybridoma cell lines by 
quadroma technology and 3) genetic approaches using recombinant DNA technology 
(Graziano and Guptill, 2004, Milstein and Cuello, 1983). The latter approach has 
yielded the greatest range of bsAbs through artificial manipulation of genes and 
represents the most diverse approach for bsAb generation. This method overcomes 
some of the limitations of the former approaches, including purity, large scale 
production of homogeneous batches, poor stability and decreased avidity of the 
antibodies.  
BsAbs largely fall into two main categories: IgG-like and small bispecific formats, a 
comprehensive description of all formats is beyond the scope of this work. Both 
trifunctional antibodies (triomabs) which are an IgG-like format and bispecific T cell 
engagers (BiTEs) which represent a type of small bispecific format were the two 
earliest types of bsAb to yield responses in clinical trials (Figure 1.9).  
Trifunctional antibodies combine the halves of two separate mAbs, ideally a tumour 
antigen specific mAb and CD3-specific mAb. They have the ability to engage the 
tumour cell, T cell and through the Fc region, Fc receptor expressing cells such as NK 
cells and macrophages, combining both innate and adaptive immunity. Catumaxomab 
combines a rat anti-human CD3 Fab with a murine anti-human EpCAM Fab resulting 
in a rat/murine Fc fusion. Catumaxomab received clinical approval in 2009 and has 
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been licensed for malignant ascites for patients with EpCAM positive tumours 
(Seimetz et al., 2010).  
Surek is a GD2 and CD3 specific trifunctional antibody. Initial studies of Surek were 
unable to demonstrate activity similar to catomaxomab. Further studies identified the 
requirement of dendritic cells (DC) in order to improve tumour rejection in murine 
melanoma models, with the proposal of combining both Surek and DC based 
vaccines as a vaccination strategy (Ruf et al., 2012, Deppisch et al., 2015). 
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Figure 1.9: Two main bispecific antibody formats. (A) A tumour antigen-
specific mAb and (B) a CD3-specific mAb are combined to form (C) a 
trifunctional antibody. (D) A Bispecific T cell Engager is derived from 
combining the variable regions of two mAbs in the form of single chain variable 
fragments.    
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1.3.2.1.1 Bispecific T cell engagers (BiTEs) 
BiTEs are bivalent molecules that combine the specificity of two mAbs in the form of 
tandem scFvs linked by a short flexible linker. The entire BiTE is expressed as a 
single polypeptide chain and is approximately 55 kDa in size. One scFv has 
specificity for a tumour antigen and the second scFv has specificity for the invariant 
CD3ε component of the TCR signalling complex on T cells. By simultaneously 
binding to both antigens, BiTEs can bring T cells and target cells into close 
proximity, resulting in T cell activation, proliferation and T cell induced target cell 
lysis. Out of the plethora of recombinant CD3 bsAb formats that exist, BiTEs have 
demonstrated the most promising efficacy in their ability to redirect T cells (Byrne et 
al., 2013).  
BiTEs are able to redirect both CD4+ and CD8+ T cell subpopulations (with the 
exception of naïve T cells) in a polyclonal manner without the requirement of co-
stimulation. CD28 co-stimulation is thought to be fundamental for early activation of 
naïve T cells; but of less significance in memory and effector T cell responses. 
Although the reason for lack of co-stimulation requirement is unclear, one possibility 
is that BiTEs lead to an increase in the number of TCRs clustering with the induced 
immunological synapse, triggering more potent signalling than with physiological 
TCR engagement (Huehls, 2015). Another explanation is that memory T cells may be 
the predominant effector cells in BiTE mediated cytotoxicity.  Dreier et al. have 
demonstrated that CD8+/CD45A+ naïve T cells do not mediate tumour cell lysis in the 
presence of BiTE while CD8+/CD45O+ memory T cells respond rapidly in the 
presence of BiTE (Dreier et al., 2002).  
BiTE constructs bypass MHC I restriction and thus may overcome some of the 
evasion mechanisms commonly employed by tumour cells. Brandl et al. 
demonstrated that upon engagement of BiTE with resting peripheral T cells, there is 
upregulation of activation markers CD69 and CD25 on the cell surface, upregulation 
of cell adhesion molecules such as CD2 and the transient release of inflammatory 
cytokines such as IFN-γ, TNFα, IL-2, IL-6 and IL-10. Moreover, this can be achieved 
at low nanomolar concentrations, without the need for co-stimulation (Brandl et al., 
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2007).  BiTE-mediated T cell activation is only observed in the presence of target 
cells expressing the antigen of interest and is one of the hallmark features of the 
therapeutic.  
Upon engagement of T cells with tumour cells, the BITE is able to mediate the 
formation of an immunological synapse (Figure 1.10). Hoffmann et al. used video-
assisted microscopy to further understand the mechanism of T cell engagement by 
BiTE. Individual T cells were highly motile and able to serially eliminate multiple 
target cells, inducing nuclear fragmentation and membrane blebbing after a few hours 
of co-culture. The binding of BiTE antibody to target cells alone was not sufficient to 
lead to tumour cell death and specifically required the presence of cytotoxic T cells 
expressing granzymes and perforin (Hoffmann et al., 2005).  
Gruen et al. also demonstrated that cytotoxic T cells were the main mediators of 
tumour cell killing after engagement with BiTE antibody. The study showed that the 
presence of an extracellular calcium chelator in co-culture medium was able to 
prevent BiTE mediated tumour cell lysis by T cells. Calcium ions are needed for both 
T cell signalling and assembly of perforin subunits into functional pores after their 
secretion, suggesting that redirected lysis predominantly lies in cytotoxic vesicle 
fusion by T cells (Gruen et al., 2004).   
The benchmark BiTE: blinatumomab 
Blinatumomab is a CD19/CD3 specific BiTE which received FDA approval in 2014 
for the treatment of relapsed and/or refractory Philadelphia chromosome negative 
acute lymphoblastic leukaemia (ALL). The initial in vitro studies performed with 
blinatumomab demonstrated the half maximal concentration for redirected lysis of 
CD19+ target cells was 10-100 pg/mL in vitro, which was unprecedented for any 
other type of bsAb format at the time (Dreier et al., 2002).  
Initial phase I clinical trials involved short intravenous infusions of blinatumomab to 
treat patients with CD19+ malignancies such as non-Hodgkin’s lymphoma. However, 
clinical studies were terminated early due to toxicity, mainly neurotoxicity which 
were caused by T cell cytokine release (Nagorsen et al., 2012). Further studies 
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involved continuous infusion to sustain plasma levels of blinatumomab and balance 
the rapid on-going clearance. A dosing strategy was used to determine the maximum 
tolerated dose (MTD) alongside treatment with corticosteroids to manage toxicities.  
Subsequently, a phase I clinical trial of adults with relapsed non-Hodgkin’s 
lymphoma (NHL) showed a 69% overall response rate (Goebeler et al., 2013). More 
recently a large randomised phase III trial named the TOWER study demonstrated 
that a subset of ALL patients treated with blinatumomab had a significantly longer 
overall survival compared to patients who received standard of care chemotherapy 
(Kantarjian et al., 2017). BiTEs targeting solid tumours are also in clinical 
development (Fiedler et al., 2012, De Vries et al., 2015).  
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Figure 1.10: BiTE mediated immunological synapse formation between a T 
cell and tumour cell. T cell mediated tumour cell lysis through formation of a 
cytolytic immunological synapse induced by TCR/peptide-MHC interaction (A) 
or BiTE action (B and C). Variations in BiTE linker length may facilitate 
optimal synapse formation for different target antigens.   
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1.3.2.2 Chimeric antigen receptors (CARs) 
Chimeric antigen receptors (CARs) are artificial T cell receptors which combine an 
scFv against a tumour associated antigen with the intracellular activation domain of 
the TCR. These receptors are transduced into T cells and are able to recognise intact 
membrane antigens irrespective of MHC restriction or antigen processing. Upon 
binding to their ligand, CAR transduced T cells are activated in a similar way to that 
of the endogenous TCR. CARs typically consist of four components: 
1) An antigen binding domain: A scFv derived from the variable portion of an 
antibody, the choice of scFv can vary in affinity or antigen epitopes 
recognised, which can lead to marked differences in the immunological 
properties of the CARs (Chmielewski et al., 2004, Hudecek et al., 2013).    
2)  Linker/spacer region: The linker anchors the scFv to the membrane and 
mediates the formation of a synapse between a CAR and target cell, this is 
influenced by the scFv’s epitope location and the spacer region, relative to the 
distance from the tumour cell’s plasma membrane (Hudecek et al., 2013). The 
length and flexibility has implications for antigen engagement and clustering 
of the CARs, longer linkers may allow access to membrane proximal epitopes 
which may not be accessible to shorter linkers (Moritz and Groner, 1995, 
Hombach et al., 2000, Guest et al., 2005). 
3) Transmembrane domain: This is normally derived from the linker or 
membrane-proximal endodomain. The transmembrane domain is responsible 
for keeping the CAR membrane bound and for stable CAR expression 
(Bridgeman et al., 2010).  
4) Intracellular activation domain: Required to initiate downstream signalling 
and T cell activation as described below.  
Evolution of CAR generations 
The first generation of CARs contained CD3ζ as part of their intracellular activation 
domain. These proved to be sufficient to induce signals with similar potency to 
normal TCR/CD3 signalling. Initial clinical outcomes however were disappointing 
due to the failure of the CAR expressing T cells to persist in the recipient (Till et al., 
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2008). This was likely due to the inadequate signal strength provided by the CD3ζ 
endodomain alone.  
To enable effective activation and T cell proliferation, co-stimulation was necessary. 
The fusion of the CD3ζ chain and the cytoplasmic portions of co-stimulatory 
receptors including CD28, 4-1BB and OX40 led to the creation of second and third 
generation CARs (Figure 1.11). The CD28 signalling domain was first introduced as 
a co-stimulatory moiety and demonstrated that T cells transduced with this construct 
showed enhanced activation, proliferation and cytokine production by CAR T cells in 
vitro (Finney et al., 1998, Friedmann-Morvinski et al., 2005).  
The most successful demonstration of a CAR based immunotherapy to date has been 
in the treatment of CD19+ B cell tumours. In a Phase I/IIA study, T cells expressing a 
second generation anti-CD19 CAR bearing CD3ζ and 41BB induced complete 
remission in 90% of relapsed ALL patients, with responses sustained over 6 months 
in 67% of patients (Maude et al., 2014).  
The first GD2 specific CAR was developed by Rossig et al. based on an scFv derived 
from mAb 14G2a and was tested in a Phase I clinical trial (Pule et al., 2008, Louis et 
al., 2011). The trial evaluated a first-generation GD2-specific CAR in children with 
relapsed/refractory neuroblastoma and compared safety, persistence and anti-tumour 
persistence of two effector cell populations: activated T cells (ATC) and Epstein-Barr 
virus specific cytotoxic T lymphocytes (EBV-CTLs) (Pule et al., 2008). No dose 
limiting toxicity was found, the therapy was well tolerated, and some patients had 
long-term complete tumour regression. The GD2-CAR expressing EBV-CTLs 
persisted significantly longer and were associated with better anti-tumour efficacy 
(Louis et al., 2011).  
Given the limited persistence of adoptively transferred GD2 CAR T cells, 
development of second and third generation CARs consisting of additional co-
stimulatory domains have shown the ability to release cytokines, proliferate and kill 
tumour cells in vitro  (Ahmed and Cheung, 2014, Thomas et al., 2016). 
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Figure 1.11: Evolution of Chimeric Antigen Receptors.  (A) First generation 
CARs incorporate a CD3ζ activation domain. (B) Second generation CARs 
additionally have a costimulatory domain (CD I), either CD28 or 4-1BB. (C) 
Third generation CARs have two co-stimulatory domains CD28/4-1BB/OX-40.  
TM: transmembrane domain. 
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1.3.2.3 Comparisons of BiTEs and CARs 
Both BiTE and CAR therapeutics are evolving technologies that have demonstrated 
promise in the clinical setting, in particular with haematological malignancies. Due to 
the differences in therapeutic strategy and production; both have unique advantages 
that may be optimal for treatment of a particular disease setting, such as solid tumour 
or MRD. Compared to CARs, BiTEs have the advantage of being easier to produce as 
a readily available off-the-shelf therapeutic. The production of CAR T cells requires 
the use of Good Manufacturing Practice (GMP) facilities and bespoke manufacture 
for each patient. If CAR T cells demonstrate promising clinical efficacy, this may 
outweigh many manufacturing issues.   
The small size of BiTEs gives the potential to infiltrate solid tumours and redirect 
resident lymphocytes to mediate cytolysis. Infiltrating lymphocytes may however be 
tolerised or exhausted under conditions of the tumour microenvironment. Conversely, 
adoptively transferred CAR-expressing T cells are conditioned in vitro, away from 
tolerising influences and could be further transformed to deliver immunostimulatory 
factors upon activation to counteract tumour mediated-immunosuppression. Although 
one of the great advantages of CARs is the potential long-term persistence of effector 
T cells, the short half-life of BiTEs may also serve as a safety mechanism allowing 
immediate therapeutic withdrawal in the event of treatment related toxicity.   
The choice of therapeutic for a particular disease setting (i.e. liquid vs solid tumour or 
localised vs. metastatic disease) can be influenced by numerous factors including 
choice of target tumour antigen. Stone et al. performed a direct comparison of the in 
vitro sensitivity of BiTEs and CARs directed against a tumour-specific glycopeptide 
epitope on the transmembrane glycoprotein OTS8. The study demonstrated that CAR 
T cells had greater sensitivity to a low number of epitopes per target cell in 
comparison to BiTE- targeted T cells. The study concluded that CARs might be an 
appropriate therapeutic for tumour specific epitopes, when epitope densities are low, 
or when down regulation of targeted epitopes is known to limit effectiveness (Stone 
et al., 2012).  
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In contrast, BiTE based approaches may be best used in scenarios where a particular 
therapeutic window is available to select between normal and malignant cells. Other 
studies have demonstrated that the avidity of CAR transduced T cells is also 
determined by the density of CAR expression on the T cells. High levels of CAR 
expression lead to T cells being triggered by both low and high expressed tumour 
antigens, whereas low levels of CAR expression lead to CAR T cells being unable to 
lyse the target cells (Walker et al., 2017).  
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1.4 Hypotheses 
The overarching aim of this project is to investigate both BiTE and CAR T cell 
mediated immunotherapy for neuroblastoma by targeting the GD2 or OAcGD2 
antigens. For the design of a BiTE we hypothesise that the binding affinity of GD2 
and CD3 specific scFvs will impact T cell mediated tumour cell lysis. Firstly, a low-
affinity CD3-specific scFv may resemble natural peptide:MHC-TCR interactions 
while a high-affinity GD2 specific scFv will ensure optimal tumour cell specific 
binding. In addition, we hypothesise that the length of the linker between the GD2 
and CD3-specific scFvs will influence the formation of an optimal immunological 
synapse between the T cell and tumour cell, and the optimal linker length of the 
linker may be influenced by the size of the tumour target antigen. As a second 
strategy, to avoid on-target off-tumour toxicity associated with targeting GD2, we 
hypothesise that OAcGD2 may serve as a more tumour specific target antigen which 
will be tested using CAR T cell therapy. 
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1.5 Aims and objectives  
1. To investigate the expression of neuroblastoma antigens GD2, OAcGD2 
and ALK on neuroblastoma cell lines and patient derived primary 
neuroblastoma cell lines in order to explore the clinical utility of targeting 
these antigens.  
2. To determine the optimal format of a GD2 and CD3 targeted BiTE by 
comparing BiTE production, stability, T cell-mediated cytolytic function, 
T cell proliferation and cytokine release. 
3. To explore novel antigen OAcGD2 as a target for immunotherapy using a 
CAR approach.  
4. To develop a suitable in vivo model of neuroblastoma to study T cell 
based immunotherapy approaches.    
Chapter 3 details an approach to target validation of neuroblastoma antigens. Chapter 
4 describes the design, production, purification and characterisation of GD2 and CD3 
targeted BiTEs. Chapter 5 describes the in vitro functional comparisons of different 
BiTE formats and the ability of BiTEs to redirect T cells to lyse neuroblastoma cell 
lines. Chapter 6 focusses on an approach to reduce on-target off-tumour toxicity of 
targeting GD2 by targeting OAcGD2 with CAR therapy. Lastly, an approach to 
compare BiTE and CAR therapeutics in a transgenic mouse model for 
neuroblasatoma is described in chapter 7.  
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CHAPTER 2: 
MATERIALS AND METHODS 
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2.1 Reagents and Buffers  
2.1.1 Reagents 
Chemicals and all tissue culture reagents were purchased from Sigma Aldrich, 
Dorset, United Kingdom. Restriction enzymes and PCR reagents were purchased 
from New England Biolabs LTD, United Kingdom. Oligonucleotides were purchased 
from Integrated DNA Technologies, Glasgow, United Kingdom.  
Formulations of buffers and solutions are provided in Table 2.1. Details of cell lines 
used in this study, and culture methods are provided in Table 2.2. 
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Buffer or solution Final concentration of components 
Antibody staining buffer for Western 
Blot  
5% non-fat milk in TBS-T 
Blocking buffer for Western Blot 5% non-fat milk in TBS 
Coomassie Blue staining solution 0.1% Coomassie Blue R250, 10% acetic acid, 
50% methanol, 40% H2O 
De-stain solution 10% acetic acid, 50% methanol, 40% H2O 
FACs staining buffer Phosphate buffered saline (PBS) containing 
0.5% bovine serum albumin (BSA) and 2.5mM 
EDTA 
LB broth 1.0% tryptone, 0.5% yeast extract, 1.0% NaCl, 
pH 7.0 
TBS 50 mM Tris base and 150 mM NaCl, pH 7.5 
TBS-T 50 mM Tris base, 150 mM NaCl and 0.05% 
Tween-20, pH 7.5 
TAE buffer 40mM Tris-acetate and 1mM EDTA pH 8.3 
MOPS SDS running buffer 50 mM MPS, 20 Mm Tris Base, 0.1% SDS, 1 
mM EDTA, pH 7.7 
Protein transfer buffer 25 mM Bicine, 25 mM Bis-Tris, 1 mM EDTA, 
pH 7.2 
Histrap HP binding buffer 20 mM sodium phosphate, 0.5 M NaCl, 20 mM 
imidazole, pH 7.4 
Histrap HP wash buffer 20 mM sodium phosphate, 0.5 M NaCl, 40 mM 
imidazole, pH 7.4 
Histrap HP elution buffer  20 mM sodium phosphate, 0.5 M NaCl, 10 – 
500 mM imidazole, pH7.4 
Histrap HP stripping buffer 20mM sodium phosphate, 0.5 M NaCl, 50 mM 
EDTA, pH7.4 
Histrap HP recharging solution 0.1 M NiSO4 
Protein A binding buffer 20 mM sodium phosphate 
Protein A elution buffer 0.1 M sodium citrate, pH 3.4 
Protein A neutralisation buffer 1 M Tris-HCL, pH 9 
Table 2. 1 Buffers and solutions 
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Cell line, origin Culture method Source 
293T, 
human embryonic kidney  
DMEM with 10% FBS,  
37 °C, 5 % CO2 
ATCC 
A204,  
rhabdomyosarcoma  
RPMI with 10% FBS,  
37 °C, 5 % CO2 
ATCC 
CT26,  
colon carcinoma  
RPMI with 10% FBS,  
37 °C, 5 % CO2 
Gift from Martin Pule 
(University College London) 
GD2.CT26,  
colon carcinoma 
RPMI with 10% FBS,  
37 °C, 5 % CO2 
Gift from Martin Pule 
(University College London) 
IMR32,  
neuroblastoma 
RPMI with 10% FBS,  
37 °C, 5 % CO2 
Gift from Andrew stoker 
(University College London) 
Jurkat,  
T cell lymphoma 
RPMI with 10% FBS,  
37 °C, 5 % CO2 
Gift from Martin Pule 
(University College London)  
Jurkat TCR ko,  
T cell lymphoma 
RPMI with 10% FBS,  
37 °C, 5 % CO2 
Gift from Martin Pule 
(University College London) 
K562,  
T cell lymphoma 
RPMI with 10% FBS,  
37 °C, 5 % CO2 
ATCC 
Lan-1,  
neuroblastoma 
RPMI with 10% FBS,  
37 °C, 5 % CO2 
ECACC 
SKNDZ,  
neuroblastoma 
RPMI with 10% FBS,  
37 °C, 5 % CO2 
ATCC 
SKNSH,  
neuroblastoma 
RPMI with 10% FBS,  
37 °C, 5 % CO2 
ATCC 
SupT1,  
T cell lymphoma  
RPMI with 10% FBS,  
37 °C, 5 % CO2 
ECACC 
GD2.SupT1,  
T cell lymphoma  
RPMI with 10% FBS,  
37 °C, 5 % CO2 
Gift from Martin Pule 
(University College London) 
ALK.SupT1,   
T cell lymphoma 
RPMI with 10% FBS,  
37 °C, 5 % CO2 
Generated by Maria Alonso-
Ferrero (University College 
London) 
Phoenix 
human embryonic kidney 
DMEM with 10% FBS,  
37 °C, 5 % CO2 
Gift from Martin Pule 
(University College London) 
Table 2. 2 Cell lines 
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2.2 Molecular biology techniques 
2.2.1 SFG γ-retroviral vector for gene transfer  
Retroviruses including γ-retroviruses, are capable of reverse transcribing their single 
stranded RNA genome into double stranded DNA, which will be stably integrated 
into the host cell genome (Temin and Mizutani, 1970).  Retroviruses can be 
manipulated and utilised as a delivery tool to introduce a desired gene-of-interest 
(GOI) into a host cell. Steps have been taken to avoid the generation of replication 
competent retrovirus and ensure their safety of use. This includes placing the genes 
encoding the structural and replication proteins (gag/pol) and envelope glycoproteins 
(env) from the retroviral genome in different vectors, whilst incorporating the GOI 
into the γ-retroviral vector containing the remaining features of the retroviral genome 
(Maetzig et al., 2011). 
As shown in Figure 2.1 the γ-retroviral vector contains long terminal repeats (LTR) 
which consist of transcriptional enhancer and promoter sequences. A U3 region 
functions as a promoter, the R region is where transcription begins and the U5 region 
is involved in reverse transcription followed by a primer binding site (PBS) and 
major splice donor (SD). Retroviral vectors can be transiently expressed in a cell line 
by transfection, or stably expressed by co-expression with both Gag/Pol and Env.  
The tropism of a virus for a target cell is determined by the viral envelope, for 
transduction of human cells we have selected the RD114 envelope (Gift of Mary 
Collins, University College London) (Cosset et al., 1995). In the making of γ-
retroviral particles, only the retroviral vector contains the MMLV Ψ packaging signal 
(derived from the Maloney murine leukaemia virus) and so viral structural proteins 
only recognise the Ψ-containing retroviral vector leading to preferential packaging of 
retroviral vector genomes into infectious particles. After entry of the particle into the 
target cell, only nucleic acid of the retroviral vector construct is reverse transcribed 
and stably integrated into the host genome. Since gag/pol and env are only transferred 
in the form of proteins (and not nucleic acid) the generation of replication competent 
retroviral vector progeny is prevented (Maetzig et al., 2011).  
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The splicing oncoretroviral SFG vector which is based on the Maloney Murine 
Leukaemia Virus was the vector used for either transiently or stably expressing the 
DNA constructs described in this thesis from the human embryonic kidney 293T 
packaging cell line (Riviere et al., 1995). The complete design of the vector is shown 
in Figure 2.2. In addition to the features described in Figure 2.1, the vector also 
contains the following components: 
1) The ampicillin resistance gene β lactamase, which is expressed when bacteria are 
transformed with the retroviral vector and enables selection of successfully 
transformed clones of bacteria growing on LB agar plates with ampicillin.  
2) The open reading frame (ORF) which contains two constructs that are co-
expressed from a single transcript incorporating ECMV IRES sequence (Bochkov 
and Palmenberg, 2006); these are the GOI and the enhanced green fluorescent protein 
(eGFP) or enhanced blue fluorescent protein 2 (eBFP2) reporter genes (Ai et al., 
2007). The constructs are separated by a sequence which encodes a cleavable peptide 
derived from the Foot & Mouth 2A virus, which is cleaved during post translational 
modification of the synthetic protein.  
3) The origin of replication (ori) gene is where replication is initiated. SFG vectors 
containing different ORF sequences are designated characters MP and assigned a 
unique identification number e.g. MP15587.  
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Figure 2.1: Engineering of γ-retroviral vector system. (A) The gene of interest 
(GOI) is placed in the retroviral vector with long terminal repeats (LTR) containing 
transcription and enhancer sequences and the MMLV Ψ packaging signal. (PBS: 
primer binding site, SD: splice donor) (B) Gag/pol and (C) env (pseudotyped 
RD114) are placed in a heterologous DNA context (Prom: promoter, pA: polyA 
signal). Adapted from (Maetzig et al., 2011) 
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Figure 2.2: Oncoretroviral SFG vector. Features include LTRs containing 
promoter and transcription elements, MMLV Ψ packaging signal, ORF: open 
reading frame, SAR: scaffold attachment region, AMP: ampicillin resistance and 
ori: origin of replication. The NcoI, BamHI and MluI restriction sites allow for cut 
and paste of various DNA fragments in to the ORF. 
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2.2.2 Construction of BiTE variants  
BiTEs are expressed as a single polypeptide chain consisting of two scFvs joined by a 
flexible linker (see Figure 1.9 D). 18 humanised BiTE variants were generated by 
combination of two GD2-specific scFvs, three CD3-specific scFvs and three linkers 
ranging in size and sequence. The scFv and linker combinations are described in 
Table 2.3.   6 murinised BiTEs were also generated and components are described in 
Table 2.4. 
 
Key: hu = humanised 
 
 
 
 
Portion scFv clone / linker Reference / sequence 
GD2 specific 
scFvs 
huK666 (Nakamura et al., 2001) 
 hu14.18 Patent: US7767405 B2 
Linkers Short linker:  
glycine - serine linker 
GGGGSGGGGSGGGGS  
(15 amino acids) 
 Medium linker:  
IgG1 hinge 
DPAEPKSPDKTHTCPPCPKDPK  
(22 amino acids) 
 Long linker:  
CD8 stalk region 
SDPTTTPAPRPPTPAPTIASQPLSLR 
PEACRPAAGGAVHTRGLDFACD 
(48 amino acids) 
CD3 specific 
scFvs 
huOKT3 (Adair et al., 1994) 
 huUCHT-1 (Shalaby et al., 1992) 
 huYTH (Routledge et al., 1991) 
Table 2. 3 Components of humanised BiTEs 
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2.2.2.1 Generation of scFvs by PCR assembly of overlapping nucleotides 
All three humanised CD3-specific scFvs (huOKT3, huUCHT-1 and huYTH) and one 
GD2-specific scFv (hu14.18) in combination with short, medium or long linkers were 
generated by de novo gene synthesis using PCR assembly of overlapping nucleotides 
(IDT DNA) briefly described in Figure 2.3.  
HuK666 scFv DNA was available in the SFG vector designated MP15587, MuK666 
scFv was available in vector MP5945and 17A2 scFv in vector 14375. To assemble 
the DNA fragment, PCR reactions were set up using three concentrations of each of 
the overlapping nucleotides (25 µM, 12.5 µM and 6.25 µM) in a reaction volume of 
50 µL containing 36.5 µL nuclease-free water, 10 µL 5x Phusion HiFid buffer, 1 µL 
10 mM dNTPs, 0.5 µL of 2000 units/mL Phusion hot-start polymerase and 2 µL of 
pooled overlapping nucleotides. Thermal cycling conditions were as follows: 98 °C 
for 2 minutes, 98 °C for 1 minute, 65 °C for 45 seconds, 72 °C for 60 seconds, steps 2 
– 4 repeated 35 times and 72 °C for 10 minutes.  
Portion scFv clone / linker Reference / sequence 
GD2 specific 
scFvs 
MuK666 (Nakamura et al., 2001) 
 14.18 (Gillies et al., 1989) 
Linkers Short linker:  
glycine - serine linker 
GGGGSGGGGSGGGGS  
(15 amino acids) 
 Medium linker:  
IgG1 hinge 
RGPTIKPCPPKCCPAPNLLGGP  
(22 amino acids) 
 Long linker:  
CD8 stalk region 
SDPTTTKPVLRTPSPVHPTGTSQP 
QRPEDCRPRGSVKGTGLDFA 
(44 amino acids) 
CD3 specific 
scFv 
17A2 (Adair et al., 1994, Alegre et al., 1995)  
Table 2. 4 Components of murine BiTEs 
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Figure 2.3. Construction of a DNA fragment by assembly PCR. (A) The desired DNA sequence (pink boxes) is assembled by 
splicing overlapping forward and reverse oligonucleotides in to a larger polynucleotide using ligation by PCR. (B) A second PCR 
further amplifies the DNA fragment using the first forward and last reverse oligonucleotides.      
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2.2.2.2 Purification of PCR product 
The PCR product was purified using a PCR purification kit (Qiagen) according to the 
manufacturer’s instructions. Briefly, the PCR product was mixed with a high-salt 
binding buffer (PB) and applied to a spin column containing a silica membrane to 
absorb the nucleic acids. The columns were centrifuged at 17,900 x g for 60 seconds in a  
microcentrifuge at room temperature, followed by a second spin in wash buffer (PE) to 
remove impurities (primers, enzymes etc.) from the PCR product. A third spin allowed 
removal of residual buffer and a final spin eluted the DNA from the column after 
addition of 30 µL nuclease-free H2O and incubation of the column for 1 minute at room 
temperature. 
2.2.2.3 Amplification of assembled overlapping nucleotides by PCR 
Purified DNA was further amplified (Figure 2.3) in a 50 µL reaction volume containing 
35.5 µL nuclease-free water, 10 µL Phusion HiFid buffer, 1 µL of purified DNA, 1 µL 
25µM first (forward) primer and 1 µL 25µM last (reverse) primer (from the overlapping 
oligonucleotides), 1 µL dNTPs and 0.5 µL Phusion polymerase. Thermal cycling 
conditions were as described in 2.2.2.1. 
2.2.2.4 Detection of PCR product by agarose gel electrophoresis 
To determine the optimal oligonucleotide concentration (25 µM, 12.5 µM or 6.25 µM) 
required to achieve the highest PCR yield; 12 µL of PCR product was mixed with 3 µL 
5x DNA loading buffer and run by electrophoresis on a 1% agarose gel at 100 V for 1 
hour. PCR fragments were detected under UV light and the optimal oligonucleotide 
concentration selected. The assembly and amplification PCRs were repeated with an 
additional 3 tubes using the optimal oligonucleotide concentration. These three tubes 
were then pooled with PCR product from the original PCR and cleaned using the PCR 
purification kit as described in 2.2.2.2 and eluted in 80 µL nuclease-free H2O. 
2.2.3 Construction of anti-O-acetyl-GD2 specific antibody 8B6 heavy and light 
chains by overlap extension PCR 
To generate the 8B6 antibody heavy (VH - CH) and light (VL - CL) chains,  the variable 
and constant regions were amplified individually by overlap extension PCR and then 
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fused together in a subsequent ‘fusion’ PCR. Overlap extension PCR introduces 5’ 
overhangs at the junction where two DNA fragments are to be joined (Figure 2.4). The 
overhang is created by using primers which are extended at their 3’ ends to contain a 
complementary sequence to the 5’ end of the other DNA fragment. When the primers 
anneal to the DNA template during the PCR, the DNA is extended by a new sequence 
which is complementary to the molecule it is to be joined to. In a second PCR, known as 
a fusion PCR, the overlapping complementary sequences introduced serve as primers 
and the two sequences are fused.  
A first round of PCR amplified the DNA fragments. Reactions were carried out in 50 µL 
volume consisting of 35.5 µL nuclease-free H2O, 10 µL 5 X HiFid buffer, 1 µL dNTPs, 
0.5 µL Phusion polymerase, 1 µL DNA template and 1 µL each of forward and reverse 
primers. Thermal cycling conditions were as described in 2.2.2.1. After confirmation of 
correct PCR fragment sizes on a 1% agarose gel, remaining PCR product was purified 
using a PCR purification kit (as described in 2.2.2.2) and variable and constant regions 
fused (VH - CH) or (VL - CL) in a second amplification PCR using the first and last 
primers to generate the heavy and light chains (as described in 2.2.2.3).  
  
 
  
Figure 2.4: Overlap extension PCR. Fragment A and B are amplified individually by 
respective forward and reverse primers (FP and RP). The central primers (RP-A and 
FP-B) are extended at their 3 primer ends (diagonal lines) to include sufficient DNA 
from the opposite DNA fragment and allow extension of the DNA fragments for 
subsequent fusion.  
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2.2.4 Digestion of PCR product or SFG vector using restriction endonucleases 
The cloning sites outside the open reading frame in the SFG vector are NcoI and MluI. 
The DNA fragment of interest has the same restriction sites at the start and end of the 
sequence and allows a convenient cut and paste method of inserting the DNA into the 
vector. Both PCR fragment and vector were digested with identical enzymes in a 100 µL 
reaction volume. The reaction mixture contained 10 µL 10x buffer (New England 
Biolabs), 5 µL enzyme 1, 5 µL enzyme 2, 5 µg vector DNA / 80 µL purified PCR 
product and the appropriate volume of nuclease-free H2O to total 100 µL. Reactions 
were incubated at 37 °C for 2 hours. 
2.2.4.1 Digestion of GD2/CD3 specific scFvs for generation of BiTEs 
To clone BiTE constructs into the SFG vector, the GD2-specific and CD3-specific scFv 
PCR fragments are flanked with NcoI/BamHI and BamHI/MluI restriction sites 
respectively to enable combinations of the two scFvs to be assembled in the vector. To 
clone the linker-anti-CD3 scFvs into vector MP15587 (containing huK666 scFv), both 
MP15587 and purified PCR product were digested with BamHI/MluI restriction 
endonucleases. To later generate the GD2-specific hu14.18 scFv based BiTEs, vectors 
containing huK666-scFv in combination with three CD3 specific scFvs were digested 
with NcoI/BamHI restriction endonucleases. 
2.2.4.2 Digestion of 8B6 antibody heavy and light chain PCR fragments 
To clone the 8B6 antibody heavy chain into an SFG vector (MP3279) containing co-
expression of enhanced green fluorescent protein (eGFP2), digestion with NcoI/MluI 
restriction nucleases occurred as described in 2.2.4. Likewise the 8B6 antibody light 
chain and SFG vector (MP3593) with co-expression of enhanced blue fluorescent 
protein (eBFP2) were digested with the same enzymes. The newly synthesised antibody 
heavy and light chain plasmids are designated MP14603 and MP14604 respectively.   
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2.2.5 Construction of GD2 and OAcGD2 specific CARs 
SFG vectors containing GD2-specific (MP13311) and OAcGD2-specific (MP5421) 
second generation humanised CARs (scFv-CH2CH3-CD28-CD3ζ) were provided by 
Martin Pule (Department of Haematology, Cancer Institute).  
GD2-specific murine CARs were generated by cloning GD2-specific scFvs (MuK666 
from vector MP5945 and 14.18 from vector MP24845) in to vector MP20493 containing 
a second generation murine CAR (scFv-CD8 stalk-CD28-CD3ζ) or vector MP20504 
containing CAR and co-expression of luciferase. The vectors were digested with 
NcoI/BamHI restriction endonucleases as described in 2.2.4. 
2.2.6 DNA extraction from agarose gel 
Digested PCR and/or vector DNA were run on a 1% agarose gel (100 V, 1 hour). The 
bands of interest were cut from the gel under a blue light transilluminator and DNA 
extracted using a gel extraction kit (Qiagen), according to the manufacturer’s 
instruction.  
2.2.7 Ligation  
The digested PCR product (insert DNA) and vector were ligated at ratios 3:1 and 5:1 
using amounts obtained from the formula: 
(kb of insert)  ×  (ng of vector)
(kb of vector)
 × 
3
1
 (ratio)      = ng of insert needed for a 3: 1 molar ratio. 
The reactions consisted of 10 µL 2 X quick ligase buffer, appropriate volumes of 
digested vector and insert DNA at 3:1 and 5:1 ratios and addition of nuclease-free H2O 
to a total volume of 20 µL. 1.5 µL of quick ligase was added to join the vector and insert 
DNA strands together by catalysing the formation of a phosphodiester bond between the 
cohesive ends. The reaction was left at room temperature for 5 minutes and then kept on 
ice prior to transformation.  
2.2.8 Transformation of chemically competent Escherichia coli with plasmid DNA 
To introduce the newly ligated plasmid into E. coli cells (NEB5-α, high efficiency), 2 
µL of ligation reaction mix was added to 25 µL of E. coli competent cells and incubated 
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on ice for 30 minutes. The competent cells were heat shocked by incubation at 42 °C for 
35 seconds and subsequently transferred to ice for 5 minutes. The cells were then added 
to 250 µL SOC medium and shaken at 200 rpm at 37 °C for 40 minutes. Transformed 
bacteria were spread on to ampicillin (100 µg/mL) containing agar plates and cultured at 
37 °C for 16 hours.  
2.2.9 Small scale plasmid preparation (Miniprep) 
3 mL of LB broth with ampicillin was inoculated with a bacterial colony and cultured 
overnight at 37 °C with shaking at 200 rpm. Plasmid DNA was extracted from 1.5 mL 
of bacterial culture by an alkaline lysis method using QIAprep Spin Miniprep Kit 
(Qiagen) according to the manufacturer’s instructions.  
2.2.10 Medium scale plasmid preparation (Midiprep) 
100 mL of LB broth with ampicillin was inoculated with 100 µL bacterial miniculture 
(from 2.2.11) and cultured overnight at 37 °C with shaking at 200 rpm. Plasmid DNA 
was extracted from 100 mL of bacterial culture using a plasmid midiprep kit 
(NucleoBond Xtra, Machery Nagel) according to the manufacturer’s protocol. The final 
DNA pellet was air dried for 5 minutes followed by resuspension in 300 µL nuclease-
free H2O.   
2.2.11 Quantification of DNA  
The absorbance of final midiprep solution was measured on a spectrophotometer 
(Nanodrop ND1000) set to record at 260/280 nm wavelength. To determine the purity of 
DNA a ratio of A260/280 > 1.8 was pursued.  
2.2.12 DNA sequencing 
DNA sequencing was carried out by Sanger Sequencing Service, Source Bioscience, 1 
Orchard Place, Nottingham Business Park, Nottingham, NG8 6PX, United Kingdom. 
Forward primer: TTACACAGTCCTGCTGACCACC, reverse primer: CAAGCGGCTT 
CGGCCAGTAAC.  
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2.3 Cell culture techniques 
2.3.1 Transient transfection of 293T cells   
Human embryonic kidney derived 293T cells were plated at a density of 1.5 x 106 cells 
per 10 cm diameter tissue culture plate in 10 mL IMDM, supplemented with 10% FBS 
and 5 mM L-glutamine. Cells were cultured at 37 °C in a 5% CO2 incubator and 
transfected when 60% confluency was reached (after approximately 30 hours). First 470 
µL IMDM and 30 µL Genejuice transfection reagent (Novagen) were mixed and 
incubated at room temperature for 5 minutes, followed by addition of 12.5 µg plasmid 
DNA and incubation for a further 15 minutes. The transfection mixture was added 
dropwise to the plated cells. 
BiTE production 
For experiments requiring non-purified BiTEs, supernatant was harvested from the 
transfected cells after 72 hours, centrifuged at 400 x g for 10 minutes and filtered 
through both 0.45 µm and 0.22 µm filters and stored at -20 °C.  
For experiments requiring purified BiTEs, five 10 cm diameter plates were transfected 
per BiTE construct. After 16 hours of transfection, the media was removed and the cells 
gently washed with 5 mL PBS. The media was replaced with 5 mL phenol-free X-
VIVO-15 (Lonza) and cells cultured for a further 48 hours before harvest of the BiTE 
containing supernatant. A total of 25 mL supernatant was centrifuged (400 xg, 10 
minutes) and filtered through both 0.45 µm and 0.22 µm filters and stored at -20 °C. 
2.3.2 Retroviral vector production 
Retrovirus for transduction of human cells 
293T cells were chosen as the packaging cell line for the production of the retroviral 
particles due to their ease of transfection. Vectors were produced by transient 
transfection into 293T cells. Cells were plated at a density of 1.5 x 106 cells per 10 cm 
diameter tissue culture plate in 10 mL IMDM, supplemented with 10% FBS and 5 mM 
L-glutamine, cells were cultured at 37 °C in a 5% CO2 incubator. The cells were 
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transfected when 60% confluence was reached (after approximately 30 hours). First 470 
µL IMDM and 30 µL Genejuice transfection reagent (Novagen) were mixed and 
incubated at room temperature for 5 minutes followed by addition of 12.5 µg plasmid 
DNA (4.75 µg envelope RD114, 4.75 µg gag/pol and 3.75 µg transfer vector). 
Supernatant was harvested twice at 48 and 72 hours after transfection and, after snap 
freezing the samples (in ethanol and dry ice) to remove any remaining live cells; 
samples were stored at -80 °C.  
Retrovirus for transduction of mouse splenocytes 
Retrovirus was made by transfection of Phoenix cells. The process was as described 
above with the following modifications: 1.3 x 106 Phoenix cells were plated and DNA 
added to the transfection mixture consisted of 2.6 µg pCL-Eco retrovirus packaging 
vector and 4.68 µg transfer vector.  
2.3.3 Human peripheral blood mononuclear cell isolation 
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood using 
Ficoll density centrifugation. An equal volume of blood was mixed 1:1 with plain 
RPMI-1640 and 20 mL blood/RPMI mix layered on 10 mL ficoll (Stem Cell 
technologies). After centrifugation at 750 x g for 40 minutes at 25 °C, mononuclear cells 
were collected using a Pasteur pipette and washed twice in 30 mL RPMI-1640 at 400 x 
g for 5 minutes. Cells were counted and again centrifuged as above followed by 
resuspension in RPMI containing 10% FBS at a density of 1 x 106 cells/mL and plated 
at 2 mL / well of a 24 well tissue culture plate. 
2.3.4 Activation and expansion of human T cells 
For experiments requiring stimulated T cells, PBMCs were activated with 1 µg/mL anti-
CD3/anti-CD28 antibodies (Miltenyi Biotec). After 24 and 48 hours cells were fed 
100IU/mL recombinant human Interleukin--2 (Proleukin, Novartis).  
2.3.5 Enrichment of human T cells 
For experiments requiring unstimulated T cells, T cells were enriched from PBMCs by 
depletion of B cells and monocytes using a human T cell enrichment column (R&D 
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systems) following the manufacturer’s instruction.  Up to 100 x 106 cells were applied to 
the columns which are coated with anti-immunoglobulin (Ig) and Ig beads to bind B 
cells and monocytes. A 30 - 40 % yield was usually achieved.  
2.3.6 Production of Retronectin coated plates 
In order to improve T cell and cell line (e.g. K562) transduction, 24 well plates were 
pre-treated with Retronectin® (Takara), a recombinant human fibronectin fragment. 8 
µL of Retronectin (at concentration 1 mg/mL) was resuspended in 1 mL PBS for every 2 
wells of a non-tissue culture treated 24 well plate and 500 µL added to each well. Plates 
were then incubated for 24 hours at 4 °C. 
2.3.7 Retroviral transduction  
Transduction of human PBMCs 
Forty-eight hours after activation, T cells were transduced on Retronectin coated plates. 
250 µL retroviral supernatant was added to each well and incubated at room temperature 
for 30 minutes and then removed. Activated T cells were counted by trypan blue 
exclusion and 500 µL of viable cells at a concentration of 6 x 105/mL added to each well 
along with 1.5 mL retroviral supernatant and 100 IU/mL IL-2. Plates were centrifuged 
for 40 minutes at 1000 x g and cells were subsequently incubated for 60 hours. Cells 
were then pooled and centrifuged at 400 x g for 5 minutes and transferred to tissue-
culture treated plate at 1 x 106/mL along with 50 IU/mL IL-2.  
Transduction of K562 cells 
To generate an 8B6 antibody secreting cell line, K562 cells were co-transduced with 
retroviral supernatant for the 8B6 antibody heavy and light chains. The transduction 
method was as described in 2.3.6.1 with the following modifications: IL-2 was omitted 
and 0.75 mL each of 8B6 heavy chain and 8B6 light chain retroviral viral supernatant 
were used to transduce the cells.   
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Activation and transduction of mouse splenocytes 
For in vivo mouse experiments, CAR-T cells were prepared by transduction of mouse 
splenocytes. Spleen was obtained from mice of 129/SvJ strain and mechanically 
disaggregated using the plunger of a 1 mL syringe and passed through a 70 µM cell 
strainer.  Cells were incubated in 3 mL ACK lysis buffer (Lonza) for 5 minutes followed 
by 3 mL RPMI, 10% FBS. Cells were washed twice in PBS and centrifuged at 400 xg 
for 5 minutes. To activate T cells, cells were cultured at 1 x 106 cells/ mL concentration 
in RPMI containing conconavlin A, IL-7 and β-mercaptoethanol. 
Splenocytes were transduced 24 hours after activation, 2 x 106 cells were mixed with 
1.25 mL retroviral supernatant per well of a retronectin coated non-tissue culture treated 
24 well plate. Retronectin coated plates were incubated with 2% BSA in PBS for 30 
minutes prior to use. Plates were centrifuged at 2000 RPM for 90 minutes at 32 °C. 
Wells were supplemented with 0.75 mL complete RPMI with IL-2.  
2.3.8 CD56 depletion  
To prevent non-specific target cell killing, proliferation or cytokine production by 
natural killer cells (NK cells) in the PBMC preparation used for transduction, cultures 
were depleted for CD56 expressing cells using CD56 Microbeads (Miltenyi Biotec), 
according to the manufacturer’s protocol. Depletion was performed one day prior to set 
up of further in-vitro functional testing, corresponding to 5 days post transduction.  
2.3.9 Labelling of cells with CFSE 
CFSE is a fluorescent cell staining dye used for cell identification and proliferation 
studies. CFSE readily crosses intact cell membranes, where the CFSE acetate groups are 
cleaved to yield the fluorescent molecule and the succinimidyl ester group reacts with 
primary amines within the cell to crosslink the dye to intracellular proteins allowing 
CFSE to be retained in the cell. Cell divisions result in sequential halving of 
fluorescence and can be detected by flow cytometry. 5 x 106 unstimulated T cells / cell 
lines were labelled with a CFSE cell division assay kit (Cayman Chemical) according to 
the manufacturer’s instruction. After labelling cells were resuspended between 1 x 105 to 
5 x 105 cells/mL RPMI, 10% FBS.  
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2.3.10 Single cell cloning by limiting dilution 
Transduced cells can express a varying amount of desired transcript. At times, a cell line 
of very homogenous expression is desired and one way to achieve this is by single cell 
cloning. Transduced K562 cells were counted by trypan blue exclusion and resuspended 
at 1 x 106/mL in RPMI containing 10% FBS. Dilution 1 was made by adding 39 µL of 
this cell suspension to 30 mL media, obtaining a concentration of 1.293 x 104 /mL. 39 
µL of dilution 1 was added to 30 mL media to obtain dilution 2 of concentration 1.67 
cells /mL. Each 30 mL of dilution 2 is sufficient for seeding one 96 well plate with 200 
µL/well. The plates were incubated at 37 °C in a 5% CO2 incubator and inspected after 1 
week followed by daily inspection. Once a single cell clone occupied 25% of the well, 
100 µL was removed and inspected by flow cytometry to determine all cells were from a 
single clone. The remaining 100 µL was transferred to culture in 24 well plates followed 
by transfer to T25 and T75 flasks upon expansion. 
2.3.11 Large scale antibody production using a bioreactor 
K562 cells transduced to secrete the 8B6 antibody were cultured in a bioreactor 
(Wilson-Wolf, CELLine) for antibody production. The bioreactor consists of two 
compartments: a top nutrient media compartment of 1 L capacity and a bottom cell 
compartment of 15 mL capacity. The design allows cells to grow to at a very high 
concentration and produce concentrated antibody in the cell compartment with sufficient 
diffusion of nutrients from the nutrient compartment and diffusion of oxygen through 
the bottom of the cell compartment.  
To inoculate the bioreactor, 50 mL phenol-free IMDM was added to the nutrient 
compartment to equilibrate the dialysis membrane and then removed. 1 x 108 K562 cells 
were centrifuged at 400 x g for 5 minutes and resuspended in 15 mL phenol-free IMDM 
containing 375 µL ultra-low FBS. Cells were added slowly to the cell compartment and 
950 mL phenol-free IMDM supplemented with ultra-low FBS added to the nutrient 
compartment. After 1 week the antibody rich supernatant was harvested from the 
bioreactor and centrifuged twice, first at 400 x g for 5 minutes to remove the pelleted 
cells and next at 4000 x g for 10 minutes to remove remaining cell debris. The 
supernatant was sterile filtered through 0.45 µM and 0.22 µM and stored at -20 °C.  
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2.4 Protein purification and analysis  
2.4.1 Protein purification  
Protein purification was performed using two types of purification column: Histrap HP 
columns (GE Healthcare) for purification of BiTEs by capture of the C-terminal 6 x his 
tag by metal ion affinity chromatography (IMAC) and HiTrap Protein A HP columns 
(GE Healthcare) for purification of 8B6 antibody by capture of the antibody Ig. For 
buffer formulations see Table 2.1 under section 2.1. 
Protein was purified according to the manufacturer’s instruction. Briefly, protein 
containing supernatant was mixed 1:1 with binding buffer and passed through the 
appropriate purification column at a rate of 1 mL/minute using a peristaltic pump 
(Econo pump, Bio-Rad). The column was subsequently washed with 15 mL wash buffer 
/ binding buffer, followed by elution of the bound protein by addition of 10 mL elution 
buffer and collection in 1 mL aliquots. A further 10 mL elution buffer was applied to the 
column to ensure efficient removal of protein and the column washed with 5 mL binding 
buffer before storage at 4 °C in 20% ethanol. 
2.4.2 Quantification of protein 
The absorbance of final purified protein was measured on a spectrophotometer (Protein 
A280, Nanodrop ND1000) set to record at 280 nm wavelength. Final protein 
concentration was obtained by division of the reading with the respective protein 
extinction coefficient value (ExPasy ProtParam online tool). 
2.4.3 Dialysis of purified protein into PBS 
Eluted protein fractions 2 - 4, which consistently had the highest protein concentration 
were pooled and dialysed into PBS using a 3 mL capacity dialysis cassette (Slide-A-
Lyzer). 3 X 1.5 L PBS washes at 4 hours, overnight and a final 4 hours were performed 
at 4 ° C with gentle mixing. 
2.4.4 Concentration and storage of purified protein 
Purified and dialysed protein was sterile filtered through a 0.22 µM filter and 
concentrated from 3 mL to 0.5 mL using a centrifugal filter column (Millipore) 
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according to the manufacturer’s instruction. Briefly, 3 mL purified protein was applied 
to the column filter and centrifuged at 4000 x g for 2 minutes 2-3 times at 4°C. Protein 
was stored in 50 - 100 µL aliquots at -80°C. 
2.4.5 Preparation of protein samples for SDS-PAGE 
Protein samples were mixed with 4x Laemmli sample buffer (Bio-Rad) containing 10% 
2-ME and denatured by incubation at 95 °C for 10 minutes. Samples were stored at -20 
°C.  
2.4.6 Protein separation by SDS-PAGE 
Purified protein was resolved by electrophoresis in 4-12% Bis - Tris precast gels 
(NuPAGE, Invitrogen). SDS-PAGE was carried out using Mini Protean III apparatus 
(BioRad) and gels were electrophoresed in NuPage running buffer (Table 2.1) at 160 V 
for 1 hour. 
2.4.7 Coomassie Blue staining method  
To detect all proteins present in the samples; gels were stained with 10 mL Coomassie 
Brilliant Blue R-250 dye (Thermo Scientific) (Table 2.1) and microwaved for 1 minute, 
followed by gentle shaking on an orbital rotor for 10 minutes. Three washes in 10 - 20 
mL de-stain solution (Table 2.1), removed excess Coomassie Blue dye from the gel and 
allowed visualisation of individual bands present in the sample.  
2.4.8 Protein transfer to nitrocellulose membrane 
Proteins were transferred from the precast gels on to a nitrocellulose membrane 
(Amersham Biosciences) in protein transfer buffer (Table 2.1) using a BioRad Mini 
Trans-Blot Electrophoretic Transfer system. Gels were transferred at 360 mA for 1 hour.  
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2.4.9 Western Blotting analysis 
 
 
Membranes were washed in TBS (Table 2.1) for 10 minutes and blocked in blocking 
buffer containing 5% non-fat milk for 1 hour at room temperature followed by two 
additional washes in TBS-T (Table 2.1). Membranes were incubated with primary 
antibody (Table 2.5) for 1 - 2 hours at room temperature or 4 °C overnight and washed 
twice in TBS-T for 10 minutes each at room temperature. Membranes were incubated in 
appropriate detection secondary antibody (Table 2.5) for 1 - 2 hours at room 
temperature and washed four times in TBS-T for 10 minutes each at room temperature. 
Proteins were visualised using a chemiluminescent film after incubation in 1 mL ECL 
substrate solution (GE healthcare).  
2.4.10 Protein thermal stability measurements using differential scanning 
fluorimetry 
The thermal stabilities of the BiTE variants were measured by differential scanning 
fluorimetry using the Protein Thermal Shift assay (Life Technologies, Grand Island, 
NY). BiTEs (0.2 mg/mL) were mixed with SYPRO Orange dye (1:1000) in a 40 µL 
volume in optical 96 well plates (Thermofisher) and fluorescence monitored using a 
StepOnePlus quantitative PCR machine (Applied Biosystems, Foster City, CA) with a 
1% thermal gradient from 25 °C to 99 °C. Data were analysed using Protein Thermal 
Shift Software (Applied Biosystems, Foster City, CA) to calculate the Tm using the 
Derivative method (Niesen et al., 2007).  
Name  Catalogue no. Manufacturer Dilution 
Penta-his-biotin 34440 Qiagen 1:50,000 
Streptavidin-HRP N100 Thermo-Fisher 
Scientific 
1:20,000 
Anti-mouse IgG-HRP 43C-CB1569-FIT Stratech 1:2000 
Table 2. 5 Antibodies and HRP-conjugates used for Western Blotting analysis 
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2.5 In vitro functional assays  
2.5.1 Cytotoxicity assay by flow cytometry 
The ability of BITEs to redirect effector cells (unstimulated T cells) to kill CFSE 
labelled target cells (SupT1, GD2.SupT1, Lan-1, SKNDZ, IMR32, A204) was studied 
by flow cytometry. Cells were co-cultured in 96 well plates at a 5:1 effector: target ratio 
with an increasing concentration of BiTEs (0-1000 ng/mL), in a total volume of 200 µL 
RPMI containing 10% FBS. Each condition was set up in duplicate wells. After 16, 24, 
40, 48 or 64 hours, target cell death was analysed by measurement of apoptosis and 
necrosis of CFSE labelled cells. Plates were first centrifuged at 400 x g for 5 minutes 
and supernatant removed by pipetting. After two washes in 200 µL FACs buffer (Table 
2.1) and centrifugation as above, cells were washed with 200 µL Annexin buffer 
(eBioscience) and subsequently incubated in 0.5 µL Annexin V, 0.5 µL PI (eBioscience) 
and 10 µL Annexin buffer per well for 15 minutes in the dark at room temperature. 
Wells were supplemented with 195 µL annexin buffer and 5 µL counting beads 
(CountBright Absolute counting beads, Invitrogen) before analysis on BD FACS 
Calibur using the Cell Quest software. Specific lysis was calculated as follows: 
100 −  
(viable cells of treatment group) x 100
(viable cells of control group)
= % lysis 
EC50 values were calculated by non-linear regression using Prism v5 software. 
2.5.2 T cell proliferation assay by flow cytometry 
T cell proliferation induced by engagement of T cells with BiTEs and GD2 positive 
target cells was measured by detection of CFSE using flow cytometry. Assays were 
prepared as described in 2.5.1 including the following modifications: T cells were 
labelled with CFSE and target cells were irradiated one day prior to experimental set up. 
After 5 days co-culture, cells were stained with CD4 and CD8 specific antibodies 
(Table 2.6) for identification of T cell subsets and the 7-AAD viability dye 
(eBioscience). Wells were analysed as described in 2.5.1. 
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2.5.3 51Cr release cytotoxicity assay  
Standard 51Cr release assays were performed to determine cytotoxic activity of GD2 and 
OAcGD2 specific CAR T cells against GD2+ / OAcGD2+ SupT1 cell targets as well as 
a GD2 negative target SupT1. 1 x 106 target cells were labelled with 20 µL 51Cr (Perkin 
Elmer) for 1 hour at 37 °C during which cells were intermittently flicked to improve the 
exposure to 51Cr. Cells were washed five times in 4 mL complete media and co-cultured 
with effector cells at the following effector: target ratios 32:1, 16:1, 8:1 and 4:1 in 96 
well v-bottom plates. Untransduced T cells served as a negative control.  After 4 hours 
of co-culture at 37 °C in a 5% CO2 incubator, plates were centrifuged as above and 150 
µL of supernatant transferred to High Binding Isoplate-96 HB96-well plates (Perkin 
Elmer). Wells were supplemented with of 50 µL scintillation liquid (Perkin Elmer) and 
the plates were incubated overnight. 51Cr release was counted in assay supernatants a 
1450 MicroBeta TriLux (Perkin Elmer). Specific cell lysis was calculated as follows: 
(Experimental release − spontaneous lysis) x 100
(maximum lysis − spontaneous lysis)
= % lysis 
2.5.4 Interferon gamma (IFN-γ) detection by ELISA 
The presence of IFN-γ in co-culture supernatant was detected using a human IFN-γ 
ELISA kit (Biolegend). 100 µL supernatant was harvested after 24 hours co-culture 
between effector and target cells and stored at -80 °C. 96 well ELISA plates were coated 
with human IFN-γ specific capture antibody and stored overnight at 4 °C. After 
blocking plates for 1 hour, the ELISA was performed according to the manufacturer’s 
instructions. Human IFN-γ standards were used to generate a standard curve of range 0 - 
500 pg/mL. Absorbance was read at 450 nm on a microplate reader (Tecan). 
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2.6 In vivo animal work 
2.6.1 Animals  
Both Th-ALKF1174L mice (derived from CBA× C57BL/6J mice) and Th-MYCN mice of 
the 129/SvJ strain were a gift from Louis Chesler (Institute of Cancer Research, UK). 
The two mouse strains were genetically crossed to generate 
ALKF1174L/MYCN transgenic mice which were used in the experiments. Tail DNA of all 
animals was analysed for ALK and MYCN transgenes by qRT-PCR (Transnetyx, Inc.). 
All animal experiments were performed under a project license approved by the UK 
Home Office following University College London Biological Services Ethical Review. 
Animal experiments were designed in line with the AcoRD principles. 
2.6.2 Total body irradiation 
Unless otherwise stated, mice received 3.1 Gy total body irradiation.  
2.6.3 Intravenous injection of mice 
After irradiation, mice were heated for 15 minutes in a warming box to facilitate 
vasodilation of the tail veins. Intravenous inoculation with 6 x 106 bulk splenocytes (6 
days post-transduction) was done in a volume of 0.2 mL PBS with a 1 mL syringe and 
29G needle.  
2.6.4 Bioluminescence imaging of mice 
Mice were anesthetised with isoflurane and given 0.1 mL (10 mg/mL) Luciferin 
(Stratech) by intraperitoneal injection. Mice were scanned after 15 minutes using a 
PhotonIMAGERTM optical imaging system (Biospace Lab). 
2.6.5 Magnetic Resonance Imaging 
Images were acquired on a low magnetic field small animal 1T ICON MRI (Bruker) 
scanner. Images were acquired using a T2 weighted sequence, slice thickness = 0.5 mm, 
15 or 30 averages were acquired with an acquisition time of 6 or 13 minutes, depending 
on number or averages. Differences in structure and the higher water content of the 
tumour translate in longer relaxation time (T2). 
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2.7 Flow cytometry  
2.7.1 Antibodies 
 
Specificity  Clone Isotype Manufacturer Fluorochrome Dilution 
ALK 13 Mouse IgG1 Gift from  
Marc Vigney 
N/A 1:100 
CD4 OKT4 Mouse IgG2b, κ Biolegend PE 1:100 
CD4 RM4-5 Rat IgG2a, κ BD Biosciences Pacific Blue 1:100 
CD8 SK1 Mouse IgG2a, κ Biolegend APC 1:100 
CD8 SK1 Mouse IgG2a, κ Biolegend FITC 1:100 
CD11b M1/70 Rat IgG2b, κ Biolegend BV 711 1:100 
CD14 Sa14-2 Rat IgG2a, κ Biolegend PE 1:100 
CD16 3G8 Mouse IgG1 κ Biolegend PerCP 1:100 
CD19 HIB19 Mouse IgG1 κ Biolegend APC 1:100 
CD34 RAM34 Rat IgG2a, κ eBioscience FITC 1:100 
CD45 30-F11 Rat IgG2b, κ Tonbo biosciences PE-Cy7 1:100 
GD2 14G2a Mouse IgG2a, κ Biolegend PE 1:100 
GD2 14G2a Mouse IgG2a, κ Biolegend N/A 1:100 
OAcGD2 8B6 Mouse IgG2a Made in-house AF-647 10:100 
Anti-mouse  
IgG 
polyclonal Goat Stratech  FITC 2.5:100 
Anti-mouse  
F(ab)2 
polyclonal Goat Stratech AF-647 2.5:100 
Penta-his   Qiagen AF-647 1:100 
Annexin V   eBioscience APC 10:100 
Annexin V   eBioscience FITC 10:100 
Fixable  
viability dye 
 Life technologies APC-Cy7 1:1000 
 
 
Table 2. 6 Antibodies used for flow cytometry 
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2.7.2 Staining for cell surface markers 
Immunostaining of 1 x 105 to 1 x 106 cells was performed with antibodies at dilutions 
stated in Table 2.6. Cells were stained for 30 minutes on ice and washed twice in cold 
FACs buffer. Cells were fixed in 100 µL fixation buffer (eBioscience) for 20 minutes at 
room temperature. Cells were washed twice in FACs buffer and subsequently analysed 
on the LSR II flow ctytometer using BD FACSDiva software 6.0. Acquired data was 
analysed on FlowJo v8. 
2.7.3 Measure of transfection/transduction by detection of eBFP2/eGFP2  
To enable measurement of transfection or transduction efficiencies; the expression of 
eBFP2 / eGFP2 co-expressed in the SFG vector was measured by flow cytometry using 
the Pacific blue / FITC channels respectively. 2.5 x 105 cells were washed twice with 1 
mL FACs buffer (Table 2.1) and centrifuged at 400 x g for 5 minutes. Cells were 
analysed on the LSRII flow cytometer using BD FACSDiva software 6.0. Acquired data 
was analysed on FlowJo v8. 
2.7.4 Detection of BiTE staining to cell lines 
To detect binding of BiTEs to cell lines, supernatants were harvested from 293T cells 
transiently transfected with constructs encoding the BiTE variants. 1 x 105 target cell 
lines (SupT1, GD2.SupT1, Jurkat and Jurkat TCR ko) were incubated with 250 µL 
harvested supernatants for 30 minutes at room temperature. Cells were subsequently 
washed in FACs buffer and stained 1:100 with penta-his-Alexa Fluor 647 secondary 
antibody for 30 minutes on ice. After washing twice in FACs buffer cells were analysed 
on FACs Calibur flow cytometer using Cell quest Software. Acquired data was analysed 
on FlowJo v8. 
2.7.5 Quantification of cell surface epitopes by flow cytometry 
The expression levels of cell-surface antigens on a cell lines were quantified by flow 
cytometry using an antigen quantification kit (QIFIKIT, Dako). Cell lines were stained 
with 10 µL of purified anti-GD2, anti-OAcGD2 or anti-ALK antibodies (Table 2.6) at 4 
°C for 1 hour. Cells were washed twice with FACs buffer (Table 2.1) with 
centrifugation at 400 x g for 5 minutes. Cells and calibrated mouse IgG-binding beads 
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were stained for one hour on ice with a fluorescein-labelled goat anti-mouse IgG 
antibody (Dako North America, Inc.). The cells and beads were washed three times in 2 
mL FACs buffer and resuspended in 200 µL FACs buffer immediately prior to analysis 
by flow cytometry (CYAN analyser). Quantification of bound antibodies per cell was 
accomplished by comparing the increase in fluorescence between antibody labelled cells 
and isotype control. A calibration curve determined by the increase in fluorescence for 
the IgG-binding beads related to the number of IgG molecules bound per peak.  
2.7.6 Disaggregation of tumours from ALKF1174L/MYCN transgenic mice 
Tumours were cut into small pieces using a scalpel and further disaggregated using the 
flat-end of a plunger from a 1 mL syringe. Cells were passed through a 70 mm cell 
strainer and washed twice in 5 mL RPMI; cells were centrifuged at 400 x g for 5 
minutes. Cells were resuspended in 5 mL RPMI and 3 mL Histopaque (Sigma) layered 
below the media using a 1 mL pipettor. Cells were centrifuged at 700 x g for 30 minutes 
with no break. The cells in the interphase between the RPMI and histopaque were 
removed and washed twice in FACs buffer. Cells were stained for cell surface antigens 
as described in 2.7.2. 
2.8 Statistical analysis  
All statistical analyses were performed in GraphPad Prism v5. Unless otherwise stated, 
data were expressed as mean ± SEM. EC50 values for cytotoxicity or proliferation assays 
were determined by non-linear regression and statistically compared using the 
comparison of Fits (F) test. Statistical analyses of in vitro assays were undertaken by 1-
way ANOVA with donor matching and Bonferonni’s post-test for multiple comparisons. 
Statistical significance was indicated as follows in the figures **p<0.001 and *p<0.01.  
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CHAPTER 3: 
Results (I) 
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An approach to target validation of 
neuroblastoma antigens for T cell 
immunotherapy 
3.1 Introduction  
The choice of tumour associated antigen (TAA) in cancer immunotherapy can influence 
the efficacy and toxicity profile of a particular T cell based therapy (Offringa, 2009). 
Ideally, a suitable target antigen is expressed homogenously and abundantly on the 
tumour cell surface and has a minimal level or absence of expression on healthy tissues 
to avoid on-target off-tumour toxicities (Scott et al., 2012). It is also optimal that the 
TAA be essential to tumour cell survival, as this decreases the likelihood of immune 
editing and tumour escape, through its downregulation (Goldberger et al., 2008).  
In neuroblastoma, GD2 provides an attractive target antigen for immunotherapy due to 
its high level of expression across several tumour types and restricted expression pattern 
on normal tissues (Suzuki and Cheung, 2015). The National Cancer Institute pilot 
programme for the prioritisation of cancer antigens ranks GD2 in place 12 out of 75 
potential targets for cancer therapy. The criteria include therapeutic function, 
immunogenicity, role of antigen in oncogenicity,  specificity to tumour cells, stem cell 
expression and cellular location of antigen expression (Cheever et al., 2009). Despite 
this, the main problems associated with targeting GD2+ tumours with immunotherapy 
are the on-target off-tumour toxicities associated with the minimal but restricted level of 
GD2 expression on healthy tissues (Lammie et al., 1993).   
More recently, novel antigen OAcGD2 has been described to have a highly tumour 
specific expression pattern. Targeting OAcGD2 as opposed to GD2 may overcome some 
of the limitations associated with GD2-specific therapies (Alvarez-Rueda et al., 2011). 
In addition ALK may also serve as a favourable target for therapy as it is overexpressed 
in some neuroblastoma tumours (Lamant et al., 2000).  
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A crucial step in the development of any T cell based immunotherapy is target 
validation; this indicates whether a target antigen is a suitable TAA based on expression 
profiles across both tumour and healthy tissue samples. We have developed an approach 
to explore the expression pattern of tumour antigens across neuroblastoma cell lines and 
clinical samples by flow cytometry; the process is outlined in Figure 3.1.  
The first step of our target validation process involves the confirmation of antigen 
expression on reference cell lines which have been modified to express our antigen of 
interest (described in section 3.2.1). This first step confirms the antibodies being used 
detect the respective antigen. The subsequent steps determine antigen expression on 
materials which to an increasing extent reflect the actual neuroblastoma tumour, whilst 
at the same time becoming a more limited resource. These include established 
neuroblastoma cell lines, primary neuroblastoma cell lines and ultimately fresh 
neuroblastoma tumour samples and healthy paediatric tissue samples. Target validation 
described in this chapter is limited to work on cell lines.  
As a second arm of the validation process, the amount of antigen on reference and 
neuroblastoma cell lines was quantified to determine and compare the range of 
expression between GD2, OAcGD2 and ALK. The level of antigen expression can 
influence the sensitivity and efficacy of T cell therapies including approaches using 
BITEs and CARs (Weijtens et al., 2000, Stone et al., 2012) 
Aims 
1. To set up an approach to target validation by measuring expression of GD2, 
OAcGD2 and ALK antigens on established neuroblastoma cell lines and primary 
neuroblastoma cell lines by flow cytometry 
2. To quantify the levels of antigen expressed across neuroblastoma cell lines 
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Figure 3.1: An approach to target validation and quantification of 
neuroblastoma antigens. This step-by-step approach enables the optimisation of 
antigen detection using flow cytometry and/or immunohistochemistry. 
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3.2 Results 
3.2.1 Target validation on reference cell lines 
As part of the target validation process, SupT1 lymphoma cells were used as a reference 
cell line. These cells have been transduced to express antigens of interest on the cell 
surface and can be used as positive or negative controls for detection of GD2, OAcGD2 
or ALK expression by flow cytometry, immunohistochemistry and other immunological 
methods.  
SupT1 cells positive for GD2 expression (and named GD2.SupT1) were generated by 
transduction of cells with the oncoretroviral SFG vector encoding both GD3 synthase 
and GM2/GD2 synthase separated by a cleavable in-frame 2A peptide. The enzymes 
work in sequence to convert membrane expressed GM3 to GD3 and subsequently to 
GD2 (GD2 biosynthesis is described in section 1.1.4). The cell line was generated by the 
Martin Pule group (UCL Cancer Institute). GD2 expression was confirmed on 
GD2.SupT1 cells by flow cytometry (Figure 3.2 A), additionally OAcGD2 was also 
detected on approximately 50% of GD2.SupT1 cells (Figure 3.2 B), indicating active 
O-acetylation on GD2.    
SupT1 cells positive for ALK expression (and named ALK.SupT1) were produced by 
transduction of cells with the SFG vector encoding the ectodomain and transmembrane 
domain of ALK; leading to ALK expression on the cell surface and absence of the RTK 
intracellular signalling domains. The cell line was generated by Maria-Alonso Ferrero 
(UCL Great Ormond Street Institute of Child Health). ALK expression was detected on 
ALK.SupT1 cells (Figure 3.2 C). These staining results confirmed the antibodies used 
for flow cytometry are appropriate for antigen detection. 
3.2.2 Target validation on neuroblastoma cell lines 
For the next step of the target validation process; the presence of GD2, OAcGD2 and 
ALK were determined on neuroblastoma cell lines Lan-1, SKNDZ, SKNSH and IMR32 
(Figure 3.3). Cells were incubated in equal quantities of primary unconjugated 
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antibody, followed by detection of antibody binding with FITC-conjugated anti-mouse 
IgG.  
GD2 expression was the brightest (approx. MFI 30,000 - 75,000) on Lan-1, SKNDZ and 
IMR32 cell lines, whereas dim or absence of expression was detected on SKNSH. The 
presence of OAcGD2 was also detected on the three GD2 bright cell lines (approx. MFI 
10,000) and dim or absence of expression on SKNSH. In comparison to GD2 and 
OAcGD2, ALK stained more dimly (approx. MFI 200 - 600) on all cell lines. This 
demonstrates that our antigens of interest are uniformly expressed across 3/4 of our 
neuroblastoma cell lines.  
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Figure 3.2: Expression of neuroblastoma antigens on reference SupT1 cell lines. 
Detection of (A) GD2 and (B) OAcGD2 expression on SupT1 cells transduced with 
GD3/GD2 synthase enzyme (GD2.SupT1). Detection of (C) ALK on SupT1 cells 
transduced with a gene encoding the ALK ectodomain and transmembrane domain 
(ALK.SupT1). Non-transduced SupT1 cells were used as a control for staining. Cells 
were stained with primary unconjugated antibody (anti-human GD2, anti-human 
OAcGD2 and anti-ALK purified antibodies) and antibody binding detected with 
FITC-conjugated anti-mouse IgG secondary antibody by flow cytometry. Mean 
fluorescence intensity (MFI) is shown for transduced SupT1 cells. 
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Figure 3.3: Expression of GD2, OAcGD2 and ALK on neuroblastoma cell lines. 
Neuroblastoma cell lines Lan-1, SKNDZ, SKNSH and IMR32 stained for GD2 
expression (top panel), OAcGD2 expression (middle panel) and ALK expression 
(bottom panel). Cells were stained with primary unconjugated antibody (anti-human 
GD2, anti-human OAcGD2 and anti-ALK purified antibodies) and antibody binding 
detected with FITC-conjugated anti-mouse IgG secondary antibody by flow 
cytometry.  MFI values are shown for blue graphs. 
 
 104 
 
3.2.3 Target validation on primary neuroblastoma cell lines  
For the third part of the target validation process; antigen expression on material that 
more closely resembled the neuroblastoma tumour was determined. Primary 
neuroblastoma cell lines derived from patient biopsy or resection tumour samples at 
Great Ormond Street Hospital were established and cultured as neurospheres in stem 
cell media by Katherine Pacey and Tessa Kasia (UCL GOSH ICH). Table 3.1 
provides a summary of tumour characteristics for 10 patient samples received 
between 2014 -2016. 6/10 samples were from a patient biopsy and 4/10 were from a 
post-chemotherapy resection. 5/10 samples had confirmed CD56 (NCAM) expression 
by immunohistochemistry, CD56 is uniformly expressed and strongly positive in 
neuroblastoma cells (Krishnan et al., 2009). 2/10 samples had detectable levels of 
MYCN amplification. In total all primary cell lines underwent less than three cell 
culture passages. 
Unlike established cell lines, the primary cell lines have a mixed, heterogeneous cell 
population. To detect neuroblastoma tumour cells in the cell mixture, cells were 
stained with both CD56 and CD45-specific antibodies. CD56+/CD45- cells were 
identified as the neuroblastoma population and expression of antigens GD2, 
OAcGD2 and ALK were subsequently measured by flow cytometry. Figure 3.4 
provides an example of the gating strategy used to analyse neuroblastoma cells and 
Figure 3.5 provides a summary of the staining results on the 10 primary 
neuroblastoma cell lines. Both GD2 and OAcGD2 expression were detected on 10/10 
primary cell lines, indicating that both antigens are favourable targets for therapy. 
Dim ALK expression was only detected on 2/10 primary cell lines. This confirms 
findings reported in the literature of GD2 being abundantly expressed on 
neuroblastoma tumours but only a subset of tumours overexpress ALK (Lammie et 
al., 1993, De Brouwer et al., 2010).  
 105 
 
No Pathology 
number 
Histological diagnosis Nature of sample Diagnosis or relapse? Histology report 
1 4669 Neuroblastoma, 
poorly differentiated 
Biopsy,  
abdominal tumour 
Diagnosis CD56+, NB84+,  CD99-, MYCN amplified, 1p loss, 17q 
gain, no 11q imbalance 
2 4566 Neuroblastoma, 
poorly differentiated 
Biopsy, 
suprarenal tumour 
Diagnosis CD56+, NB84+, CD99-, S100-, MYCN amplified, 1p.1q 
imbalance, 11q imbalance, 17q gain 
3 3544 Neuroblastoma, 
differentiating 
Resection,  
abdominal tumour 
Diagnosis MYCN not amplified, no 1p/q imbalance, no 11q 
imbalance, no 17q imbalance 
4 4433 Neuroblastoma, 
poorly differentiated 
Resection,  
suprarenal tumour 
Diagnosis CD56+, NB84+, 1p/q imbalance, MYCN not amplified, no 
11q imbalance, inconclusive 17p/17q imbalance 
5 5045  Ganglioneuroblastoma, 
intermixed 
Resection,  
abdominal tumour 
Post chemotherapy resection No staining or molecular analysis described 
6 4519 Neuroblastoma, 
poorly differentiated 
Biopsy,  
abdominal tumour 
Diagnosis CD56+, NB84+, no 1p/1q imbalance, MYCN not amplified, 
11q imbalance, 17q imbalance 
7 2006 Neuroblastoma Resection,  
suprarenal tumour 
Post chemotherapy resection No staining or molecular analysis described 
8 4544 Neuroblastoma, 
poorly differentiated 
Resection,  
paraspinal tumour 
Post chemotherapy resection No staining or molecular analysis described 
9 1315 Neuroblastoma, 
poorly differentiated 
Biopsy, 
suprarenal tumour 
Diagnosis CD56+, NB84+, 1p/q imbalance, MYCN not amplified, no 
11q imbalance, 17q imbalance 
10 4467  Neuroblastoma Resection,  
adrenal tumour 
Post chemotherapy resection No staining or molecular analysis described 
Table 3. 1 Summary of neuroblastoma tumour characteristics 
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Figure 3.4: Gating strategy for phenotyping of primary neuroblastoma cell 
lines by flow cytometry. (A) Live cells were identified by exclusion of DAPI.  
(B) Neuroblastoma cells were determined to be the CD56+/CD45- population.  
Surface expression of (C) GD2 (D) OAcGD2 and (E) ALK on the 
CD56+/CD45- neuroblastoma cells were subsequently assessed. Cells were 
stained with anti-GD2-PE or primary unconjugated antibody and antibody 
binding detected with APC-conjugated anti-mouse IgG secondary antibody by 
flow cytometry. 
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Figure 3.5: Antigen expression on primary neuroblastoma cell lines. Antigen 
expression determined on live, CD56+/CD45- primary cell lines 1 - 10 by flow 
cytometry.  Expression of GD2, OAcGD2 and ALK (blue line) in comparison to 
isotype control (grey line). Cells were stained with anti-GD2-PE or primary 
unconjugated antibody and antibody binding detected with APC-conjugated anti-
mouse IgG secondary antibody by flow cytometry, n=10. 
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3.2.4 Detection of GD2 and OAcGD2 on reference SupT1 cell lines using 
immunohistochemistry 
The next step in the target validation approach is to determine antigen expression on 
frozen neuroblastoma tissue sections. This approach will provide a more accurate 
representation of antigen expression profiles on cells that have not been cultured in 
the laboratory, which can potentially influence antigen expression. To set up this 
validation process, our reference cell lines SupT1 and GD2.SupT1 were pelleted and 
snap frozen. Cells pellets were sectioned and stained for GD2 and OAcGD2 
expression by immunohistochemistry. Staining was performed by the Histopathology 
department at GOSH (Figure 3.6).  
Cell pellets were Expression of both GD2 and OAcGD2 was determined by  detected 
on the surface of GD2.SupT1 cells. Positive (brown) staining was present on the 
surface of all cells incubated with an anti-GD2 antibody (14G2a) (Figure 3.6B), 
confirming the 100% GD2 positive expression on GD2.SupT1 detected by flow 
cytometry (Figure 3.2 A).   
Less than 50% of cells stained positive for OAcGD2 expression (mAb 8B6) (Figure 
3.6 D) which correlates with the approximately 50% level of detection of OAcGD2 
on GD2.SupT1 measured by flow cytometry (Figure 3.2 B). The flow cytometry and 
immunohistochemistry data combined, confirm the presence of GD2 and OAcGD2 
on our reference target GD2.SupT1 cell lines. GD2 and OAcGD2 were not detected 
on non-transduced SupT1 cells (Figure 3.4 A, D). This approach has demonstrated it 
is possible to detect antigens GD2 and OAcGD2 by immunohistochemistry and will 
lead to the future set up of staining frozen neuroblastoma tissue sections.  
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Figure 3.6: Detection of GD2 and OAcGD2 on frozen cell lines by 
immunohistochemistry. GD2 expression on (A) Non-transformed SupT1 
(negative control) and (B) GD2.SupT1 cell pellets.  OAcGD2 expression on (C) 
SupT1 cells (negative control) and (D) GD2.SupT1 cells. Cells were stained with 
purified anti-GD2 or anti-OAcGD2 antibody followed by an anti-mouse IgG-
horseradish peroxidase conjugated antibody. Positive staining is determined by 
brown staining upon addition of DAB substrate solution.  
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Figure 3.7: Generation of low and high levels of antigen expression on reference 
cell lines. ALK.SupT1 cells were sorted in to (A) low and (B) high levels of ALK 
expression by fluorescence activated cell sorting. For sorting cells were stained with 
for ALK expression immediately after being sorted. MFI values are shown for blue 
graphs. 
3.2.5: Antigen quantification on reference and neuroblastoma cell lines 
Another part of the validation process is to quantify the levels of antigen expressed on 
our cell lines. This can give an indication of the type of T cell based therapy that may 
be more appropriate to target a given antigen with a specific expression (Stone et al., 
2012). It is important to have reference cell lines that have a range of antigen 
densities which can be used to determine the upper and lower limits of antigen 
detection. This can be achieved using fluorescence activated cell sorting. Reference 
ALK.SupT1 cell lines that have been sorted into high and low ALK expression have 
been produced in the lab (Figure 3.7).   
 
 
 
 
 
 
 
 
To quantify the level of antigen expression on our cell lines an antigen quantification 
kit was used (QIFIKIT®), this kit provides quantitative analysis of indirect 
immunofluorescence staining in flow cytometry. To perform the assay, both reference 
SupT1 and neuroblastoma cell lines were labelled with an unconjugated antigen-
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specific primary mouse mAb at saturating concentrations (e.g. anti-GD2, anti-
OAcGD2 or anti-ALK mAb). The number of bound antibody molecules corresponds 
to the number of antigenic sites. To detect the binding of the primary antibody; cells 
were labelled with saturating amounts of FITC-conjugated anti-mouse IgG secondary 
antibody and binding (MFI) measured by flow cytometry.   
To correlate the MFI with the corresponding number of antigenic sites per cell a set 
of calibrated beads coated with different but well-defined quantities of mouse IgG 
mAbs were labelled with the same secondary antibody and used to construct a 
calibration curve by correlating the MFI with the corresponding number of antigen 
molecules per bead. The number of antigenic sites on a given cell line were 
determined by interpolation of the calibration curve (Figure 3.8). 
Antigen density was first quantified on the SupT1 reference cell lines. GD2.SupT1 
cells have approximately 1 x 106 GD2 molecules expressed on their cell surface 
(Figure 3.9 A) and approximately 30,000 OAcGD2 molecules (Figure 3.9 B) on 
cells positive for OAcGD2 expression (Figure 3.9 B). ALK.low.SupT1 and 
ALK.high.SupT1 have approximately 30,000 and 170,000 ALK molecules expressed 
on the cell surface respectively (Figure 3.2 C). GD2, OAcGD2 and ALK were not 
detected on non-transduced SupT1 cells (Figure 3.9 A-C).  
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Figure 3.8: Antigen expression quantified by interpolation of a standard curve 
generated using calibration beads with known antigen levels and MFI values. 
(A) Calibration beads B – F with increasing and quantified levels of mouse IgG on 
the surface were incubated with saturating amounts of FITC-anti-mouse-IgG 
antibody and MFI values measured by flow cytometry. (B) Antigen quantity and 
MFI values for beads B – F were used to generate a standard curve for subsequent 
calculation of antigen quantity on cells after antibody labelling. 
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Figure 3.9: GD2, OAcGD2 and ALK antigen density on reference SupT1 cell 
lines. Quantification of antigens GD2 (A) and OAcGD2 (B) on the GD2.SupT1 
cell line and ALK (C) on ALK.low.SupT1 and ALK.high.SupT1 cell lines using 
the QIFIKIT antigen density kit. Cells were stained with saturating amounts of 
unconjugated anti-GD2, anti-OAcGD2 or anti-ALK antibody and saturating 
amounts of FITC-anti-mouse IgG secondary antibody. Cells were analysed by 
flow cytometry and MFI values used to determine antigen density by interpolation 
of a standard curve, n=1. 
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Next, the level of antigen expression was determined on Lan-1, SKNDZ, IMR32 and 
SKNSH neuroblastoma cell lines. The GD2 expression levels for these cell lines 
ranged from approximately 500,000 – 1,000,000 molecules per cell. SKNDZ cells 
had the highest level of GD2 expression (1,177,544 molecules per cell) similar to 
reference cell line GD2.SupT1. Lan-1 and IMR32 cells had 524,870 and 596,524 
molecules of GD2 per cell respectively and SKNSH had a dim GD2 expression (2421 
molecules per cell) (Figure 3.10A).  
The density of OAcGD2 on the neuroblastoma cell lines was five to ten-fold less in 
comparison to GD2, with a range of approximately 80,000 – 150,000 molecules per 
cell. Both Lan-1 and SKNDZ had approximately 150,000 OAcGD2 molecules per 
cell and IMR32 cells had 81,529 molecules per cell. SKNSH appeared negative for 
OAcGD2 expression (1,185 molecules per cell) in comparison to the other cell lines 
(Figure 3.10 B).  
Expression of ALK was the lowest and ranged between 500 – 5000 antigen 
molecules per cell. ALK expression was the highest in the IMR32 cell line (4785), 
followed by SKNDZ (2978), Lan-1 (844) and SKNSH (489) (Figure 3.10 C). This 
data highlights the differences in levels of antigen expression for a given antigen 
across a panel of cell lines.  
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Figure 3.10: GD2, OAcGD2 and ALK density on neuroblastoma cell lines. 
Quantification of antigens (A) GD2, (B) OAcGD2 and (C) ALK  on Lan-1, 
SKNDZ, IMR32 and SKNSH using the QIFIKIT antigen density kit. Cells were 
stained with saturating amounts of unconjugated anti-GD2, anti-OAcGD2 or 
anti-ALK antibody and saturating amounts of FITC-anti-mouse IgG secondary 
antibody. Cells were analysed by flow cytometry and MFI values used to 
determine antigen density by interpolation of a standard curve, n=1. 
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3.3 Discussion 
An approach to target validation was used to determine the expression of antigens 
GD2, OAcGD2 and ALK across neuroblastoma cell lines and patient derived primary 
cell lines. This work has shown that both GD2 and OAcGD2 are uniformly expressed 
across neuroblastoma samples. GD2 is a highly expressed antigen, with up to 1 x 106 
molecules per cell across neuroblastoma cell lines. The reported expression on 
neuroblastoma tissue is up to 1 x 107 molecules per cell (Wu et al., 1986).  OAcGD2 
has a lower level of expression than GD2, the antigen density across cell lines was 5 - 
10 fold lower in the range 80,000 - 150,000, SKNSH was the only GD2/OAcGD2 
dim cell line, which has been previously reported (Biedler et al., 1973). ALK was 
expressed at low levels across all neuroblastoma cell lines, but was only detected on 
2/10 primary cell lines.  
This work supports both GD2 and OAcGD2 as promising targets for immunotherapy. 
ALK is also a potential target but will not be pursued further in this project. One of 
the important features of a target antigen is the maintenance of expression after 
therapy. A number of studies have demonstrated the continued high level of 
expression of GD2 across tumour samples after multi-modal therapies including 
chemotherapy and radiotherapy and in particular after GD2-targeted treatment with 
antibodies. The loss of GD2 expression has only been described as a rare event 
(Kramer et al., 1998, Schumacher-Kuckelkorn et al., 2005, Poon et al., 2015). 
Antigen maintenance after therapy is yet to be explored for OAcGD2.  
One of the limitations of measuring antigen expression on cultured cell lines/primary 
cell lines is the potential change in the antigen expression profile over time. Cell lines 
may therefore not be truly representative of the original tumour sample. One of the 
ways to overcome this problem is to determine antigen expression on tumour samples 
by flow cytometry as soon as fresh tumour samples are received.   
Another approach is to preserve tumour tissue and measure antigen expression using 
immunohistochemistry. Fixation is a standard procedure during sample preparation in 
immunohistochemistry; however this process can mask epitopes of interest including 
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GD2. An alternative approach is to snap freeze tissue samples which will enable 
preservation and allow antibody access to potential antigens. We have demonstrated 
that snap freezing cell lines, preserves the GD2 and OAcGD2 antigens on 
GD2.SupT1 cells in a form that is readily detectable using available antibodies. 
Detection of ALK on ALK.SupT1 cell lines was not measured as the ALK detection 
antibody (mab13) is not compatible with this technique. 
Based on the high level of GD2 expression on tumour and minimal expression across 
healthy tissues, we explored GD2 as a target for BiTE therapy. Few GD2-specific 
BiTE approaches have been reported, in comparison to GD2-specific CAR studies 
(Yankelevich et al., 2012, Cheng et al., 2015, Pule et al., 2008, Prapa et al., 2015).  
We also explored OAcGD2 as a novel target for CAR T cell therapy based on the 
lower expression levels of OAcGD2 in comparison to GD2. Current targets of CAR T 
cell therapy have a low expression pattern on tumour cells. For example the median 
density of CD22 in ALL blasts was reported to be 3500 sites per cell, and the 
expression of CD19 on CLL cells was reported to be 13,000 sites per cell (Haso et al., 
2013) (Ginaldi et al., 1998).  
Future directions 
The next step in this target validation approach will be to screen tumour samples as 
well as healthy paediatric tissues to test presence or absence of antigen expression. 
Reference cell lines can be used to set up this approach, in particular, selective 
expression and a range of antigen densities across a reference cell line can help 
determine the limit of detection, this work is currently ongoing.  
Based on the set up of the target validation approach described in this chapter, flow 
cytometry on fresh tumour samples from neuroblastoma biopsy or resection samples 
is now routinely performed to assess GD2 and OAcGD2 expression. 
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CHAPTER 4: 
Results (II) 
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Development and characterisation of GD2 
and CD3 targeted Bispecific T cell 
Engagers (BiTE) 
4.1 Introduction 
4.1.1 Bispecific T cell Engagers (BiTE) 
This chapter describes the generation and characterisation of a series of BiTEs to 
redirect T cells to target GD2 positive tumours. An empirical approach to BiTE 
design was explored to determine the optimal BiTE format. In particular the choice of 
scFvs and linker sequence, which can impact the properties and pharmacodynamics 
(such as production, stability and affinity) of a BiTE therapeutic, were considered 
(Dreier et al., 2002, Cheng et al., 2015).  
A high binding affinity of an scFv to the respective tumour target antigen has been 
demonstrated to be a key requirement for achieving tumour cell killing by T cells at 
low BiTE concentrations (<10 pg/mL in vitro) and is one of the features of FDA 
approved BiTE Blinatumomab (Dreier et al., 2002). In contrast, a low binding affinity 
of an scFv to CD3ɛ on T cells is required to mimic the binding interaction of a TCR 
and its target MHC peptide complex to achieve efficient T cell signalling (Hoffmann 
et al., 2005). Additionally, the formation of an immunological synapse and 
subsequent potency of redirected T cell lysis is affected by epitope distance to the 
target cell membrane and antigen size (Bluemel, 2010) (Figure 1.10).  We therefore 
investigated differences in linker size between the two scFvs in the BiTE molecule to 
determine the effects on redirecting T cell cytolytic activity. 
In the context of antigen-antibody interactions, binding affinity is the strength of the 
binding interaction between an epitope and an antibody’s antigen binding site, this is 
described by the equilibrium dissociation constant (KD). The KD can further be 
described as a ratio between the association (Ka) and dissociation (Kd) rate of an 
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antibody-antigen complex. KD = Kd/Ka, the smaller the KD the greater the binding 
affinity. 
4.1.2 Selection of GD2 specific scFvs 
To select GD2 specific scFvs to compare in the BiTE design, the reported binding 
affinity of five GD2 specific monoclonal antibodies along with their chimerised (ch) 
and/or humanised (hu) versions were studied from the literature and are reported in 
Table 4.1. The two scFvs selected to study in the BiTE design are derived from 
mAbs hu14.18 and huK666. Hu14.18 is derived from parental mAb 14.18 of which 
14.G2a is an IgG2a-class switch variant (Mujoo et al., 1989). Hu14.18 was selected 
based on the proven efficacy of ch14.18 in the clinical setting (Yu et al., 2010); 
variations of this mAb under clinical testing are documented by Ahmed et al, 2014.  
 
        
 
 
 
 
 
 
 
Although the affinity of the hu14.18 mAb is not reported, the parental 14.18 mAb has 
a reported binding affinity of 35 nM. HuK666 derived from murine mAb muK666 
was selected to compare against hu14.18 as it has a lower binding affinity to GD2 and 
would be useful to observe differences in the ability of redirecting T cells (Nakamura 
et al., 2001).  
GD2 specific mAb Affinity (KD) References 
3F8 5 nM (Cheung, 2012) 
Ch.3F8 13 nM (Cheung, 2012) 
Hu.3F8 11 nM (Cheung, 2012) 
14.G2a 77 nM (Cheung, 2012) 
14.18 35 nM (Mujoo et al., 1987) 
Hu.14.18 Not reported  
Ch.14.18  Not reported  
ME36.1 19 nM (Cheung, 2012) 
MuK666 100 nM (Nakamura et al., 2001) 
HuK666 149 nM (Nakamura et al., 2001) 
60C3 212 nM (Alvarez-Rueda et al., 2007) 
Chimeric 60C3 206 nM (Alvarez-Rueda et al., 2007) 
Ch = chimeric; Hu = humanised
 
 
 
Table 4. 3 CD3 specific mAbs and corresponding binding affinitiesCh = 
chimeric; Hu = humanised
 
Table 4. 1 Reported GD2 specific mAbs and corresponding binding affinities 
 
Table 4. 2 Reported GD2 specific mAbs and corresponding binding affinities 
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4.1.3 Selection of CD3 specific scFvs  
It is well established that mere binding of different anti-CD3 mAbs trigger 
mitogenesis in T cells and induce the production of immune mediators like IFN-γ and 
IL-2 (Van Wauwe et al., 1980). In the context of a BiTE; the monomeric binding of 
the BiTE to the CD3ɛ subunit of the TCR complex in the absence of binding a target 
cell antigen is insufficient to allow robust T cell signalling and activation. This 
feature is desirable and avoids non-specific T cell activation (Dreier et al., 2002).  
In T cell biology, the duration of the TCR and peptide-MHC binding is a critical 
parameter in T cell activation. The upper limit of natural TCR affinity correlates to a 
dissociation constant (KD) of around 1 - 50 µM. To select a panel of scFvs to be 
tested in the BiTE format, the reported binding affinities of a selection of mitogenic 
CD3 specific mAbs were studied from the literature and are reported in Table 4.2.  
 . 
     
 
 
 
 
 
 
*Reported affinity of scFv 
The three humanised scFvs chosen to compare in the BiTE format were derived from 
mAbs huOKT3, huUCHT-1 and huYTH 12.5 (Adair et al., 1994, Shalaby et al., 
1992, Routledge et al., 1991). OKT3 is highly mitogenic and has a reported binding 
affinity to CD3 of 1.2 nM, the affinity of huOKT3 is 1.4 nM. Both forms have shown 
CD3 specific mAb Affinity (KD) References 
L2K  *260 nM (Dreier et al., 2002) 
OKT3 1.2 nM (Adair et al., 1994) 
HuOKT3 1.4 nM (Adair et al., 1994) 
UCHT-1 2.2 nM (Hexham et al., 2001) 
HuUCHT-1 2.5 nM (Beverley and Callard, 1981) 
YTH12.5 not reported  
HuYTH  not reported  
TR-66 36 nM (Jacobs et al., 1997) 
BMA030 8 nM  (Jacobs et al., 1997) 
SP34 150 nM (Hexham et al., 2001) 
Table 4. 4 CD3 specific mAbs and corresponding binding affinities 
 
 
Table 4. 5 Linkers considered in the BiTE designTable 4. 6 CD3 specific mAbs and 
corresponding binding affinities 
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the ability to bind and activate T cells in a number of bispecific antibodies directed at 
tumour antigens such as HER2. (Sen et al., 2001, Yoshida et al., 2003, Zhou et al., 
2006, Cheng et al., 2015) 
Parental mAb UCHT-1 and huUCHT-1 have reported binding affinities of 2.2 nM 
and 2.5 nM respectively (Beverley and Callard, 1981). The ability of UCHT-1 to 
retarget cytotoxic T cells efficiently has been demonstrated in a number of bispecific 
antibody formats (Shalaby et al., 1992, Kim et al., 2012, Durben et al., 2015). Both 
OKT3 and UCHT-1 monoclonal antibodies recognise the same epitope on CD3 
(Burns et al., 1982, Van Wauwe et al., 1984). Other studies have also demonstrated 
overlap between the binding sites of both antibodies (Arnett et al., 2004). 
The third CD3 specific scFv is derived from mAb clone YTH12.5 (Clark et al., 
1989), of which we refer to the humanised form as huYTH (Routledge et al., 1991). 
The avidity of the humanised mAb is 1.3 fold down compared to the parental 
antibody format, this is reported to compare favourably with changes in avidity and 
affinity observed after the reshaping of other antibodies (Routledge et al., 1991). 
Although the binding affinity of YTH12.5 and huYTH have not been reported, the 
mAbs have demonstrated the ability to redirect T cells to kill tumour target cells in 
the bispecific antibody format (Haagen et al., 1992, Haagen et al., 1995).  
4.1.4 Selection of a linker 
A non-immunogenic linker sequence is used to link the two scFvs of the BiTE 
molecule in tandem. The linker determines the distance between the two scFvs and is 
expected to allow a high degree of rotational flexibility as may be needed for 
simultaneous binding of the scFvs to two epitopes positioned on cell membranes of 
two separate cells (Figure 1.10).  
Bluemel et al. studied the impact of epitope distance and antigen size on the potency 
of target cell lysis by human cytotoxic T cells that were redirected by BiTE 
antibodies (Bluemel, 2010). The study demonstrated that despite a similar binding 
affinity of BiTE variants to the melanoma chondroitin sulphate proteoglycan (MCSP) 
tumour antigen; respective BiTE formats greatly differed in their potency of 
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redirected lysis of target CHO cells displaying various MCSP truncations. MCSP-
specific BiTE antibodies binding the most membrane proximal domain of MCSP 
were the most potent. A stepwise increase in the distance of domains to the plasma 
membrane of target cells decreased BiTE potency and this was concluded to be due to 
the ability to form an immunological synapse. The results indicated the synapse 
formation or function may be more efficient, the closer T cell and target cell 
membranes can adhere to each other. (Bluemel, 2010).  
An immunological synapse is typically 15 nm wide and although a BiTE induced 
immunological synapse has not been measured; the size of the synapse can be 
influenced by the length of the linker between the two scFvs. The length and 
sequence of the linker can impact BiTE stability as well as function. The most 
common protein linkers contain a combination of glycine and serine residues to 
provide flexibility and protease resistance (Huston et al., 1988). Other factors 
including oligomeric state and level of glycosylation can affect the stability, solubility 
and function of the BiTE. Reported BiTEs tend to have a short glycine-serine (Gly4- 
Ser) linker of 5 or 15 amino acids. Blinatumomab has a five amino acid Gly4-Ser 
linker; as CD19 has a large extracellular component, this size is thought to be 
efficient for optimal immunological synapse formation (Dreier et al., 2002). GD2 has 
a smaller membrane component; it is possible that an increased linker size can 
influence the efficient formation of an immunological synapse.  
 
Linker Abbreviation Sequence Length 
Glycine- serine   (G4S)3 / S GGGGSGGGGSGGGGS 15 
IgG1 hinge 
region 
HNG / H DPAEPKSPDKTHTCPPCPKDPK 22 
CD8α stalk 
region  
CD8-STK / C SDPTTTPAPRPPTPAPTIASQPLS
LRPEACRPAAGGAVHTRGLDF
ACD 
48 
Table 4. 7 Linkers considered in the BiTE design 
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Table 4.3 describes the three short (glycine-serine), medium (IgG1 hinge) and long 
(CD8 stalk) linkers used to join the GD2 and CD3 specific scFvs in the BiTE design 
which differ in their origin and sequence. Glycine-serine linkers are found natural 
occurring in many proteins and can be considered as independent proteins that do not 
affect the function of proteins to which they attach. As small amino acids, both 
glycine and serine provide flexibility and maintain stability of the linker structure 
(Argos, 1990).  
The IgG1 hinge linker is 15 amino acids in length; in this study extra amino acids 
have been incorporated at the start and end of the linker. The hinge region forms a 
flexible linker between the Fab arms and the Fc part of an IgG1 antibody and is the 
most flexible out of the hinge regions in the various IgG subclasses (IgG1 -IgG4) 
(Roux et al., 1997). The stalk region of the CD8α chain from the CD8 co-receptor 
found on cytotoxic T cells is 30 - 50 residues long and has a high degree of flexibility 
(Merry et al., 2003).  
Aims 
1. To generate 18 GD2/CD3 targeted BiTE variants by combination of two 
GD2-specific scFvs, three linkers and three CD3-specific scFvs.  
2. To optimise production and purification of the BiTE variants. 
3. To characterise the BiTE variants by measurement of thermal stability.  
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4.2 Results 
4.2.1 Cloning of 18 GD2/CD3 specific BiTE variants 
The 18 GD2/CD3 specific BiTE variants are shown in Table 4.4. 17 out of 18 of the 
BiTEs were successfully cloned into SFG retroviral vectors which co-express eBFP2. 
The GD2 specific scFvs were oriented as VH - VL and the CD3 specific scFvs as VL - 
VH. A hexa-histidine tag was positioned at the C-terminus to facilitate purification.  
4.2.2 BiTE production by transient transfection of 293T cells  
A small-scale production system was set up to generate the different BiTE variants. 
The BiTEs were produced by transient transfection of 293T cells followed by a 
harvest of BiTE containing supernatant at 72 hours post transfection. Successful 
transfection of the 293T cells was measured by detection of the co-expressed eBFP2 
protein using flow cytometry (Figure 4.1 A-B).  Transfection efficiencies were 
consistently between 60-80% for the 17 constructs tested (Figure 4.1 C).  
4.2.3 BiTE purification using immobilised metal ion affinity chromatography 
(IMAC) 
A column coated with nickel sepharose beads (His-trap HP) was used to purify the 
BiTEs from the cell culture supernatant by affinity purification. The BiTEs were 
captured on the nickel (II) via their C-terminal hexa-histidine tag. The imidazole side 
chain of histidine has a specific binding affinity for metal ions and facilitates this 
binding interaction to nickel (II); any non-specific proteins passed through the 
column and were discarded. Subsequent elution of the BiTE protein from the column 
was achieved by applying an elution buffer with a high concentration of imidazole to 
the column. The concentration of imidazole required in the elution buffer for efficient 
protein displacement is protein dependent. To determine the optimal concentration of 
imidazole required to elute the BiTEs from the column, elution buffers (formulations 
in Table 2.1 of Materials and Methods) containing increasing concentrations (10 
mM, 300 mM or 500 mM) of imidazole were applied consecutively and the eluates 
tested for presence of BiTEs by using an indirect flow cytometry based detection 
method.  
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 Table 4. 8 Structure of eighteen GD2/CD3 specific BiTE variations with short, medium or long linkers 
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Figure 4.1: Detection of eBFP expression in 293T cells transfected to express 
BiTE variants. EBFP expression used as a measure of transfection efficiency and 
detected by flow cytometry using the Pacific Blue channel in (A) Mock 
transfected and (B) BiTE (14-S-O) transfected 293T cells. (C) Average 
transfection efficiencies of 293T cells for 17/18 of the BITE variants (n=3). 
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First, the eluates were dialysed into PBS to remove salts from the protein solution and 
subsequently, GD2.SupT1 cells were incubated with equal volumes of the eluates. 
The presence of BiTE in the eluate was confirmed by detection of BiTE staining on 
GD2.SupT1 cells using an Alexa-Fluor 647-conjugated polyclonal anti-F(ab)2 
antibody, staining was measured by flow cytometry. An increased staining of 
GD2.SupT1 cells (compared to cells stained with a PBS control) was seen in 
conditions with 300 mM imidazole (86% positive stain) and 500 mM imidazole (17% 
positive stain) (Figure 4.2 A – D). The experiment was repeated twice and confirmed 
most of the BiTEs were eluted when 300 mM imidazole was used in the elution 
buffer (Figure 4.2 E).  
To confirm the optimal imidazole concentration for the elution buffer was 300 mM 
and not between 300 mM – 500 mM; a further range of imidazole concentrations in 
increments of 50 mM were tested in a similar experiment and confirmed that 300 mM 
was the optimal concentration (data not shown).  
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Figure 4.2: Determination of optimal imidazole concentration in elution buffer for maximum elution of BiTEs from His-
Trap column. Detection of BiTEs in eluants after purification measured by staining GD2+ GD2.SupT1 cells with eluants containing 
(A) Control (PBS) (B) 10 mM imidazole (C) 300 mM imidazole and (D) 500 mM imidazole. BiTE binding detected using AF647-
conjugated penta-his antibody by flow cytometry. (E) Average percentage binding to GD2.SupT1 cells from 3 experiments.  
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Coomassie Blue staining and Western Blotting analyses were used to directly confirm 
the purification of BiTEs from the His-trap HP column. During the purification process, 
BiTEs were eluted from the column in 1 mL aliquots called fractions and in total 10 
fractions were eluted from the column. Fractions 2 - 4 which consistently had the 
highest protein concentration were pooled and dialysed into PBS for each BiTE 
separately. Samples from all stages of the purification process were resolved on a gel by 
SDS-PAGE. 
Coomassie Blue staining confirmed the BiTE was the only protein present after 
purification. Figure 4.3 A is a representative example for BiTE K6-C-Y where a single 
band at 60 kDa is seen after purification. As a control, supernatant from non-transfected 
293T cells was also purified using the His-trap HP column, Coomassie Blue staining did 
not detect any protein bands after purification (Figure 4.3 B).  
Western Blotting analysis confirmed the single band purified was BiTE protein by 
detection with a his-tag specific antibody (Figure 4.4 A). All 17 BiTE variants were 
subsequently purified using the same IMAC method, 14 of 17 BiTE variants were 
successfully purified (Figure 4.3 B). The sizes of the BiTE variants are 56 kDa, 58 kDa 
and 60 kDa for BiTEs containing short ((G4S)3), medium (HNG) and long (CD8-STK) 
linkers respectively. Hu14.18/huOKT3 based BiTEs: 14-S-O, 14-H-O and 14-C-O were 
not detected after purification indicating the protein was not secreted by the 293T cells, 
despite successful transfection of the cells (Figure 4.1 C). m 
The total yield (µg) of BiTE obtained after purification is reported for each BiTE variant 
in Table 4.5. The table reports an average of three separate purifications which varied in 
yield by ± 20 µg. HuUCHT1 scFv-based BiTEs had a yield in the range of 60-190 µg, 
while huYTH scFv-based BiTEs had a yield in the range of 60-150 µg. However, the 
yield for huOKT3 scFv-based BiTEs was consistently poor in comparison (22-36 µg).   
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Figure 4.3: Confirmation of BiTE purification by Coomassie Blue staining 
on SDS-PAGE gel. (A) Samples from different stages of IMAC purification 
process were run on an SDS-PAGE gel, the gel was stained with Coomassie 
Blue stain to detect BiTE protein after purification. (B) Comparison of non-
purified and purified samples from non-transfected 293T cells and transfected 
293T cells secreting BiTE K6-C-Y. Black arrows indicate the purified BiTE 
K6-C-Y at 60 kDa. 
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Figure 4.4: Confirmation of BiTE purification by Western Blot analysis. (A) 
Detection of purified BiTE K6-C-Y (black arrow) at 60 kDa in elution fractions 2-5 
and in the pooled fractions. (B) Analysis of all 17 BiTEs purified from transfected 
293Ts. BiTEs were detected using anti-his-biotin antibody and streptavidin-HRP. 
Expected BiTE sizes are 56 kDa, 58 kDa or 60 kDa 14 = hu14.18 scFv, K6 = 
huK666 scFv, S = (G4S)3 linker, H = hinge linker, C = CD8 stalk linker, O = 
huOKT3 scFv, U = huUCHT1 scFv, Y = HuYTH scFv. 
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 BiTE  Total yield  
from 25ml media (µg) 
1 14-S-U 170.0 
2 14-S-Y 41.4 
3 14-H-U 182.3 
4 14-H-Y 114.1 
5 14-C-U 158.6 
6 14-C-Y 108.2 
7 K6-S-O 22.5 
8 K6-S-U 80.1 
9 K6-S-Y 60.9 
10 K6-H-O 35.7 
11 K6-H-Y 61.4 
12 K6-C-O 33.5 
13 K6-C-U 190.0 
14 K6-C-Y 130.3 
Values are an average of three purifications which had SD ± 
20 µg. 
Table 4. 5 Yield of individual BiTEs obtained after purification 
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4.2.4 Measurement of BiTE thermal stability by differential scanning fluorimetry 
The thermal stability of individual scFv domains in a bispecific antibody has shown to 
be correlated with increased antigen binding affinity and improved cytotoxicity of T 
cells against tumour cells at low BiTE concentrations.  (Cheng et al., 2015). A high 
thermal stability is often associated with high expression level and other desired 
properties including solubility and reduced protein aggregation (Michaelson et al., 
2009).  Factors that have been described to influence thermal stability include the 
orientation of scFv VH – VL domains, linker length and scFv sequence (Willuda et al., 
1999) 
To compare the thermal stability of individual BiTE variants used in this study, a 
differential scanning fluorimetry (DSF) assay was used. DSF involves exposure of the 
protein of interest to an increasing temperature gradient. The stability of a protein is 
related to its Gibbs free energy of unfolding ΔGu, which is temperature dependent. As 
the protein unfolds, the ΔGu decreases and becomes zero at equilibrium where the 
concentrations of folded and unfolded protein are equal, this point is considered as the 
melting temperature (Tm). The assay is performed in the presence of a fluorescent dye 
which binds to exposed hydrophobic sites of unfolded proteins and fluoresces. In DSF, 
fluorescence intensity is plotted as a function of temperature; this generates a sigmoidal 
curve; the inflection point of the transition curve is the Tm and is calculated using the 
Boltzmann equation:   
𝑦 = 𝐿𝐿 +
(𝑈𝐿 − 𝐿𝐿)
1 + exp (
𝑇𝑚 − 𝑥
𝑎 )
 
UL and LL are values of minimum and maximum intensities respectively and a denotes 
the slope of the curve within Tm. An alternative and easier way to calculate Tm is to 
calculate the maximum of the first derivative, which is performed by the Protein 
Thermal Shift Software.  
Melt curve analysis was performed for 11/14 of the BiTE variants; BiTEs with a CD3-
specific huOKT3 scFv were not produced in sufficient quantity to be included in the 
assay. A representative melt curve and derivative plot for BiTE 14-S-U is shown in 
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Figure 4.5.  In the melt curve two Tm peaks are seen which will be assumed to 
correspond to differences in melting temperatures of the GD2-specific scFv and CD3-
specific scFv in the BiTE. A summary of scFv Tm values are provided in Table 4.6. To 
determine the corresponding Tm for each scFv, the melting curves for each BiTE variant 
were compared. We found that Tm values of approx. 72 °C were only found when 
huUCHT1 scFv was present in the BiTE while a Tm of approx. 60 °C were found when 
huYTH scFv was present in the BiTE. Therefore, in Figure 4.5, the first Tm (Tm A) was 
inferred to correlate with the GD2-specific scFv and the second Tm (Tm B) inferred to 
correlate with the CD3-specific scFv in each BiTE variant. 
Both hu14.18 and huK666 scFv-based BiTEs had similar melting temperatures of 
approximately 55 °C, only in the combinations 14-S-U, K6-S-U and K6-C-U were the 
melting temperatures 2 - 6 °C lower. In contrast, BiTEs containing huUCHT1 and 
huYTH scFv-based BiTEs differed in Tm regardless of GD2 binder and linker 
combinations. Two combinations, K6-S-Y and K6-H-Y had a slightly lower Tm of 56 - 
57.3 °C. Linker combinations did not appear to influence scFv stability in the various 
BiTE combinations.  
  
 136 
 
 
 
 
 
 
 
 
 
  
Figure 4.5: Thermal stability of BiTEs by differential scanning fluorimetry. 
BiTEs were mixed with SYPRO-Orange dye and fluorescence was monitored 
using a StepOnePlus quantitative PCR machine with a 1% thermal gradient from 
25 to 99℃. Data were analysed using Protein Thermal Shift software to calculate 
the melting temperature (Tm) using the Derivative method. (A) Representative 
melt curve and (B) derivative plot to calculate Tm for BiTE 14-S-U. Each scFv of 
the BiTE correlates to a peak in fluorescence at Tm A and Tm B.  
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Constructs GD2 specific  
scFv 
Tm (°C)  
A 
CD3 specific 
scFv 
Tm (°C)  
B 
14-S-U hu14.18 53.1 ± 0.2 huUCHT1 72.5 ± 0.3 
14-S-Y hu14.18 55.7 ± 0.1 huYTH 61.5 ± 0.3 
14-H-U hu14.18 55.6 ± 0.4 huUCHT1 73.0 ± 0.2 
14-H-Y hu14.18 55.8 ± 0.2  huYTH 60.6 ± 0.3 
14-C-U hu14.18 55.0 ± 0.5 huUCHT1 73.9 ± 0.1 
14-C-Y hu14.18 55.0 ± 0.3  huYTH 63.8 ± 0.2 
K6-S-U huK666 49.7 ± 0.4 huUCHT1 71.6 ± 0.2 
K6-S-Y huK666 55.42 ± 0.2 huYTH 57.3 ± 0.1 
K6-H-Y huK666 55.5 ± 0.3 huYTH 56.0 ± 0.3 
K6-C-U huK666 52.3 ± 0.6 huUCHT1 72.6 ± 0.5 
K6-C-Y huK666 55.81 ± 0.2 huYTH 60.1 ± 0.1 
Table 4. 6 Melting temperature of BiTE variants (n=3) 
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4.2.5 BiTEs have specificity for GD2 and CD3 antigens  
After the successful production of the BiTE variants, it was necessary to confirm that 
the BiTEs retained binding to GD2 and CD3. This was determined by measuring BiTE 
binding to antigen positive and negative cell lines by flow cytometry.  
To determine binding specificity for the GD2 antigen, SupT1 cells (GD2-) and 
GD2.SupT1 (GD2+) cells were incubated in equal volumes of supernatant from 293T 
cells transfected to express the BiTE variants. The BiTEs used in this assay were both 
non-purified and unquantified: paired isogenic SupT1 cells were used as these serve as 
true positive and negative controls for the antigen of interest. BiTE specificity to GD2 
was detected using a penta-his-AF647 antibody (Figure 4.6).  
All 14 BiTE variants showed specificity for the GD2 antigen, demonstrated by specific 
binding to GD2.SupT1 cells and not SupT1 cells. Although the MFI in this experiment 
was not a measure of affinity, the binding appeared to correlate with the respective BiTE 
yields obtained in Table 4.5. BiTE specificity for the CD3 antigen was determined by 
staining Jurkat cells, which natively express the TCR (CD3+) and Jurkat cells with a 
TCR knock out (ko) (CD3-). All 14 BiTE constructs with the different CD3-specific 
scFvs: huOKT3, huUCHT1 and huYTH showed binding to Jurkat cells (indicated by an 
increased MFI) and not to Jurkat TCR ko cells (Figure 4.7). The binding experiments 
were performed 3 times.  
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Figure 4.6: Measurement of binding specificity of GD2/CD3 specific BiTEs to 
GD2. (A) GD2 negative (SupT1) and (B) GD2 positive (GD2.SupT1) cells were 
incubated for 30 minutes in supernatant from 293T cells transfected to express BiTE 
protein. Cells were stained with a his-tag specific antibody (Penta-his-AF647) to 
detect BiTE binding and cells were then analysed by flow cytometry. (C) Overlay 
plot of staining SupT1 and GD2.SupT1 with BiTE 14-S-U supernatant. (D) Average 
MFI ± SD of 14 BiTE variants binding to SupT1 or GD2.SupT1 cell lines (n=3).   
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Figure 4.7: Measurement of binding specificity of GD2/CD3 specific BiTEs to CD3. 
(A) CD3 negative (Jurkat TCR knock out (KO)) and (B) CD3 positive (Jurkat) cells 
were incubated for 30 minutes in supernatant from 293T cells transfected to express 
BiTE protein. Cells were stained with a his-tag specific antibody (Penta-his-AF647) to 
detect BiTE binding and cells were then analysed by flow cytometry. (C) Overlay plot 
of staining Jurkat and Jurkat TCR KO with BiTE 14-S-U supernatant. (D) Average MFI 
± SD of 14 BiTE variants binding to SupT1 or GD2.SupT1 cell lines (n=3).   
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4.3 Discussion 
This chapter has described the production, purification and characterisation of a series of 
GD2 and CD3 targeted BiTEs. The BiTEs can be produced using a SFG gamma-
retroviral expression system by transfection of 293T cells. Of our 18 designed BiTE 
formats; 17 were cloned and 14 were successfully produced and purified. The IMAC 
purification system enabled isolation of BiTE from cell culture supernatant by binding 
the C-terminal hexa-his tag. 
Stability is one of the most important functional requirements for the use of antibodies 
and antibody fragments in therapeutic and diagnostic applications (Kipriyanov et al., 
1999). For this reason we determined the melting temperature of the individual scFvs in 
the different BiTE formats. Both GD2 binders had a similar melting temperature despite 
differences in corresponding mAb binding affinities (Mujoo et al., 1987, Nakamura et 
al., 2001). The melting temperature was also similar to other reported GD2-specific 
scFvs used in the bsAb format (Cheng et al., 2015).  
The CD3-specific huUCHT1 scFv had a higher melting temperature in comparison to 
huYTH. All BiTE formats containing a huOKT3 specific scFv were either not produced 
at all or produced with low yield and were omitted from thermal stability comparisons. 
Two specific amino acid mutations  (the substitution of Glu to Gln in position 6 of VH 
framework 1 and the substitution of Cys to Ser in the middle of CDR-H3) are reported 
to induce a high level of production of huOKT3 from bacteria and may be the 
modification required to improve the production of our constructs containing huOKT3 
(Kipriyanov et al., 1997). The combination of short, medium or long linkers did not 
appear to impact BiTE production or thermal stability. 
A limitation for our studies was the low yield of BiTE produced using the small-scale 
production system: the system utilised 25 mL of BiTE containing supernatant from 
transfected cells and gave < 200 µg of total protein for all BiTEs produced. This is 
sufficient for in vitro functional experiments, but limiting for larger scale studies (e.g. 
saturation binding studies and in vivo experiments).  
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All scFvs used in the BiTE formats were able to retain specificity to GD2 or CD3 target 
antigens. 11of 18 BiTEs were taken forward for in vitro functional testing in chapter 5. 
Future directions 
The binding affinity for 4/5 mAbs used for the scFv sequence are reported in the 
literature. The affinity of the scFvs however may differ from that of the whole 
antibodies, and are important to determine and compare as specific affinities may inform 
the functional characteristics of the BiTEs. To improve BiTE production a Chinese 
hamster ovary (CHO) cell expression system can also be used. CHO cells are the 
industry standard for mAb and bsAb production. These cells are optimised to grow 
under a high cell concentration and is the system used to produce CD19/CD3 BiTE 
blinatumomab (Nagorsen et al., 2012).   
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CHAPTER 5:  
RESULTS (III) 
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In vitro functional comparisons of GD2 and 
CD3 targeted BiTE variants 
5.1 Introduction 
In chapter 4, GD2 and CD3 targeted BiTEs were produced, purified and tested for GD2 
and CD3 specificity. 11 BiTE variants out of 18 were produced in sufficient quantity 
and were thermally stable. Next, to determine the optimal BiTE format in redirecting T 
cells in GD2+ tumour cell lysis, these 11 variants have been taken forward for in vitro 
functional comparisons.  
Aims 
1. To determine the efficacy of different BiTE formats to redirect T cells for lysis 
of GD2+ tumour cell lines.  To set up a flow cytometry based cytotoxicity assay 
to perform these comparative studies. 
2. To characterise BiTE mediated redirected T cell function by measuring the 
release of relevant cytokines: IFN-γ after 24 hours and IL-2, IL-4, IL-10, IFN-γ, 
TNFα and granzyme B after 72 hours co-culture of T cells with neuroblastoma 
cells in the presence of different BiTE formats. 
3. To measure T cell proliferation capacity in response to co-culture with the 
different BiTE variants and neuroblastoma cell lines.  
4. To confirm BiTEs are able to redirect neuroblastoma patient T cells in GD2+ cell 
lysis.    
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5.2 Results  
5.2.1 Set up of a flow cytometry based cytotoxicity assay 
To enable comparisons between our 11 BiTE variants, a flow cytometry based 
cytotoxicity assay was used to measure T cell cytotoxicity towards (GD2+) GD2.SupT1 
or (GD2-) SupT1 target cells in the presence of individual BiTE variants in a co-culture 
assay.  
T cells were obtained from healthy donor PBMCs; a standard procedure in T cell 
cytotoxicity assays is prior activation and expansion of T cells using anti-CD3 and anti-
CD28 antibodies. In particular, this is performed for CAR-T cell studies and for 
functional testing of alternative formats of bsAbs (Bohlen et al., 1993, Manzke et al., 
1997, Kipriyanov et al., 1999). One of the key features of the BiTE class is the ability to 
polyclonally redirect T cells in the absence of artificial stimulation (Dreier et al., 2002). 
Hence, for this assay, to compare T-cell cytolytic function in the presence of different 
BiTE formats, non-activated T-cells were used to ensure in vitro test conditions 
correspond as much as possible to an in vivo setting.  
CD4+ and CD8+ T cells were enriched from healthy donor PBMCs by the removal of B 
cells and monocytes using a CD3+ T cell enrichment column. Efficient removal was 
indicated by loss of CD19+ (B cell) and CD14+/CD16+ (monocyte) cell populations by 
flow cytometry (Figure 5.1); the column did not remove NK cell populations.  
Target cells were labelled with CFSE as to distinguish between T cells and target cells 
during flow cytometry analysis. Target cells were not irradiated, to try and mimic the 
natural situation where target cell proliferation may affect the T cell cytotoxic capacity.   
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Figure 5.1: T cell enrichment from healthy donor PBMCs. PBMCs were applied to a CD3+ T cell enrichment column 
containing glass beads coated with Ig and anti-Ig for the removal of B cells and monocytes from the sample via high 
affinity negative selection. PBMCs were stained with antibodies for (A) CD19+ B cells (B) CD14+ and (C) CD16+ 
moncocytes, (D) CD4+ and (E) CD8+ T cells before and after passing unlabelled PBMCs through the column, staining 
was analysed by flow cytometry. (F) Mean ± SD of percentage total cells shown, n = 3. 
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T cells were co-cultured with SupT1 or GD2.SupT1 target cells at a 5:1 effector: 
target (E: T) ratio in the presence of 0-1 µg/mL BiTE. A 5:1 E: T ratio was selected 
based on preliminary studies assessing 1:1, 5:1 and 10:1 E:T ratios, T cell mediated 
killing was comparable at both 5:1 and 10:1 E: T ratios. Figure 5.2 is a representative 
example of a co-culture between T cells and target cells with 0-1 µg/mL BiTE 14-C-
Y after 16 hours. Visible loss of GD2.SupT1 cells was observed on visual inspection 
with a microscope in wells containing BiTE. Loss of GD2.SupT1 cells was not 
observed in the absence of BiTE or in wells containing SupT1 target cells (Figure 5.2 
A).  Target cell death was measured by flow cytometry after 16 hours co-culture: 
target cells were determined as the CFSE positive cell population and the numbers of 
live target cells were determined by exclusion of apoptotic and necrotic cells by 
staining with annexin and PI (Figure 5.2 C). A reduction of viable target cells was 
detected when GD2.SupT1 cells were co-cultured with T cells and BiTE. Increased 
cell death was observed with an increased concentration of BiTE (Figure 5.2 D).  
To determine the appropriate time-point for co-culture read-out, target cell death was 
measured at four time points: 16, 24, 40 and 48 hours (Figure 5.3). The percentage of 
cell death was similar at each of the different time points. Tumour cell killing after 16 
hours was sufficient to detect loss of GD2+ target cell number. In addition, a measure 
of cytotoxicity at the earliest time-point may enable distinctions between the different 
BiTE formats. 
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Figure 5.2: Measurement of target cell cytotoxicity by T cells after 16 hours co-
culture using flow cytometry. T cells and CFSE-labelled target cells were co-
cultured at a 5:1 E:T ratio with 0-1000ng/ml BiTE. (A – B) Visual inspection of co-
cultures containing SupT1 or GD2.SupT1 target cells and effector T cells with a 
light microscope (10x objective) after 16 hours of co-culture. (C) Measurement of 
target cell viability by gating on CFSE positive target cells and exclusion of 
annexin / PI positive cells (red box). (D) Measurement of live GD2.SupT1 target 
cells from (B) at 16 hours by flow cytometry. A representative example of 1 
experiment is shown. 
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Figure 5.3: Measurement of target cell viability at different time points 
after co-culture with T cells and 0-1 µg/ml BiTE. SupT1 and GD2.SupT1 
target cells were labelled with CFSE and co-cultured with T cells at a 5:1 E:T 
ratio with increasing BiTE concentration. After 16, 24, 40 and 48 hours, cells 
were stained with Annexin and PI to determine the number of live CFSE target 
cells . Viable cell number was quantified using CountBright absolute counting 
beads. Cell number is plotted as a proportion of cells in co-culture conditions 
with no BiTE added, n=1.  
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5.2.2 BiTEs redirect T cells to lyse GD2.SupT1 cells and not SupT1 cells 
To compare the 11 BiTE variants in their ability to redirect T cell cytotoxicity to 
GD2.SupT1 and SupT1 target cells, co-cultures of T cells and target cells at 5:1 E: T 
ratio were set up for all BiTE variants at concentrations 0 - 1 µg/mL. Target cell 
death was measured after 16 hours by flow cytometry. Firstly, T cell mediated killing 
was specific to GD2 positive target cells for all BiTE variants tested; GD2.SupT1 
cells were lysed while SupT1 cells were not (Figure 5.4). Secondly, T cell mediated 
lysis of GD2.SupT1 cells did not occur in control conditions with no BiTE, indicating 
the requirement of BiTEs to co-localise the effector and target cells. In addition, co-
culture of target cells with BiTE in the absence of T cells did not lead to target cell 
death, confirming T cells are mediating the cytotoxicity.  Thirdly, of all linker and 
CD3-specific scFv combinations tested, BiTEs containing a hu14.18 GD2-specific 
scFv were the most effective at redirecting T cells to kill GD2+ targets compared to 
BiTEs containing a huK666 scFv (Figure 5.4). The maximum percentage killing of 
GD2.SupT1 cells is reported in Table 5.1: killing associated with BiTEs containing 
hu14.18 scFv was greater than 80% in comparison to BiTEs containing huK666 
scFvs which achieved a maximum killing of up to approximately 60%. 
 
BiTE % maximum killing  BiTE % maximum killing  
14-S-U 84.7 ± 2.6 K6-S-U 49.2 ± 12.3 
14-S-Y 88.6 ± 8.2 K6-S-Y 16.2 ± 8.7 
14-H-U 80.7 ±3.9 K6-H-Y 33.7 ± 16.4 
14-H-Y 83.6 ±11.4 K6-C-U 55.0 ± 8.1 
14-C-U 87.2 ± 3.2 K6-C-Y 57.6 ± 16.2 
14-C-Y 83.4 ±15.5   
Table 5. 1 Maximum percentage killing of GD2.SupT1 by T cells at 16 hours incubation (mean ± SD) 
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Figure 5.4: Comparison of BiTE variants in mediating target cell death by T 
cells after 16 hours co-culture. (A) GD2.SupT1 and (B) control SupT1 target cell 
death measured by percentage of apoptotic and necrotic cells in comparison to 
control conditions with 0 ng/mL BiTE.  Co-cultures were at 5:1 E: T ratio. Hu14.18-
based BiTEs: blue line, huK666-based BiTEs: red line. Read out by flow cytometry, 
graphs show mean ± SEM (n=3). 
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EC50 values for hu14.18 scFv-based BiTEs are reported in Table 5.2, values were 
calculated by non-linear regression analysis and compared by the extra sum of 
squares F-test. BiTEs containing hu14.18 scFv and medium (HNG) or long (CD8-
STK) linkers had lower EC50 values in comparison to hu14.18 scFv-based BiTEs 
with short (G4S)3 linkers (p< 0.001). EC50 values for huK666 scFv-based BiTEs were 
not reported, as maximum killing was < 60% and thus calculated EC50 values at 
<30% killing were not accurate for comparisons with hu14.18 scFv-based BiTEs.  
 
BiTE EC50 [ng/mL] EC50 (pM) 
14-S-U 14.73 263.04  
14-S-Y 9.07 161.96 
14-H-U 1.20 20.69 
14-H-Y 5.50 94.83 
14-C-U 3.74 62.33 
14-C-Y 3.32 55.33 
 
Both huUCHT1 and huYTH scFv-based BiTEs had a similar potency at redirecting T 
cells in GD2.SupT1 cell lysis (Figure 5.5). In comparison of different linkers: BiTE 
14-H-U was more potent than 14-H-Y (BiTE and EC50 ng/mL, 14-H-U: 1.2 ng/mL, 
14-H-Y: 5.5 ng/mL, p< 0.001), however there were no significant differences in EC50 
values between 14-S-U with 14-S-Y (BiTE and EC50 ng/mL, 14-S-U: 14.73 ng/mL, 
14-S-Y: 9.07 ng/mL, p = 0.1447) and 14-C-U with 14-C-Y (BiTE and EC50 ng/mL, 
14-C-U: 3.74 ng/mL, 14-C-Y: 3.32 ng/mL, p= 0.3852).   
  
Table 5. 2 BiTE EC50 values for killing of GD2.SupT1 cells by T cells at 16 hours incubation 
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Figure 5.5: Comparison of the activity of BiTEs with different CD3 binders 
and different linkers. (A) GD2.SupT1 and (B) control SupT1 target cell death 
measured after co-culture with T cells and hu14.18 scFv-based BiTEs (0-1 µg/mL). 
Co-cultures were performed at 5:1 E:T ratio and death measured by percentage of 
apoptotic and necrotic cells in comparison to control conditions with 0 ng/mL BiTE. 
Read out performed after 16 hours by flow cytometry. Graphs show mean ± SEM 
(n=3). 
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5.2.3 BiTEs mediate specific killing of neuroblastoma cells 
The four BiTEs with the lowest EC50 values at 16 hours co-culture were taken 
forward for further in vitro functional testing. These were:  
1. 14-H-U  
2. 14-H-Y  
3. 14-C-U and 
4. 14-C-Y. 
After demonstrating the BiTE variants were able to redirect T cells to lyse 
GD2.SupT1 lymphoma cells which were engineered to express GD2; the next step 
was to demonstrate specific killing of neuroblastoma cell lines which naturally 
express GD2: Lan-1, SKNDZ and IMR32. A204 rhabdomyosarcoma cells were used 
as a GD2- control cell line.  Target cell lines were co-cultured at 5:1 E: T ratios with 
an increasing concentration of BiTE (0-1 µg/mL). After 16 hours co-culture target 
cell death was measured as described in 5.2.1. All four BiTEs were able to redirect T 
cells to lyse neuroblastoma cell lines and not A204 cells (Figure 5.6).  
Comparisons on which BiTE format is most effective at redirecting T-cells to 
neuroblastoma cell lines cannot yet be made as to date this experiment has only been 
performed once. Preliminary analysis suggests that BiTEs 14-H-U and 14-H-Y are 
the only BiTEs that show killing of more than one cell line at the 1 ng/mL 
concentration. 
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Figure 5.6: GD2/CD3 BiTEs redirect T cell cytotoxicity to neuroblastoma cell 
lines.  Measurement of GD2+ neuroblastoma (Lan-1, SKNDZ, IMR-32) target cell 
killing after 16-hours co-culture with T cells at 5:1 E:T ratio and 0-1 µg/mL BiTE. 
Percentage killing was calculated as proportion of annexin/PI positive cells 
compared to control conditions after 48 hours co-culture using flow cytometry. 
A204 cells were used as a GD2- control cell lines, n=1. 
 156 
 
5.2.4 T cells are activated and secrete IFN-γ upon co-culture with neuroblastoma 
cells and BiTEs 
To measure specific activation of T cells upon engagement with GD2+ target cells 
mediated through the BiTE, the presence of IFN-γ in co-culture supernatant was 
measured by ELISA after 24 hours co-culture. The presence of IFN-γ was detected 
when T cells were co-cultured with neuroblastoma cell lines and all BiTE variants 
tested. IFN-γ was not detected when T cells were co-cultured with GD2- A204 cells 
(Figure 5.7). The level of IFN-γ release increased with an increasing BiTE 
concentration. IFN-γ production by T cells was significantly higher when Lan-1 cells 
were incubated with BiTE 14-H-Y in comparison to 14-H-U at 1000 ng/mL (mean 
concentration ± SEM: 14-H-U: 30.8 ± 8.0 pg/mL, 14-H-Y: 56.7 ± 2.8 pg/mL, n=3, 
p<0.01). A significant difference in IFN-γ was also seen in conditions containing 
BiTE 14-C-Y compared to BITE 14-H-U (mean concentration ± SEM: 14-C-Y: 79.6 
± 8.0 pg/mL, 14-H-U: 30.8 ± 8.0 pg/mL, n=3, p<0.001) and BiTE 14-C-U (mean 
concentration ± SEM: 14-C-Y: 79.6 ± 8.0 pg/Ml, 14-C-U: 38.9 ± 8.9 pg/mL, n=3, 
p<0.01).  
Co-culture of T cells with SKNDZ in presence of BiTE 14-C-Y (100 ng/mL) had a 
significantly higher IFN-γ production than BiTEs 14-H-Y and 14-C-U (mean 
concentration ± SEM: 14-H-Y: 13.6 ± 2.3 pg/mL, 14-C-U: 6.8 ± 0.6 pg/mL, 14-C-Y: 
35.4 ± 10 pg/mL, n=3, p<0.01). Co-culture of T cells with IMR32 cells in presence of 
BiTE 14-C-Y (100 ng/mL) had a significantly higher IFN-γ production than BiTE 14-
C-U (mean concentration ± SEM: 14-H-Y: 65.8 ± 13.9 pg/mL, 14-C-U: 37.7 ± 4.4 
n=3, p<0.01).  
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Figure 5.7: Production of IFN-γ by activated T cells in the presence of 
GD2+/GD2- target cells and BiTE. IFN-γ in supernatant measured by ELISA after 
24 hour co-culture of T cells and target cells at 5:1 E:T ratio and 0-1 µg/mL BiTE. 
Graphs show mean ± SEM, n=3, * p<0.01, ** p<0.001. Bonferroni post-hoc analysis 
was performed after one-way ANOVA.  
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5.2.5 Cytokine production 
Differences in cytokine production may have important consequences both for the 
functionality of the BiTE activated T cells and toxicity when used clinically. To 
functionally compare the BiTE variants, supernatants were harvested at 72 hours after 
a 5:1 E: T co-culture with GD2+ Lan-1, SKNDZ, IMR32 cells and GD2- A204 cells at 
100 ng/mL BiTE concentration and analysed by cytokine bead array analysis. Co-
cultures with 0 ng/mL BiTE were used as a control (Figure 5.8).  
There was a significantly greater production of IL-2 when T cells were co-cultured 
with Lan-1 cells with 14-H-Y BiTE (Mean concentration ± SEM: 14-H-U: 4.2 ± 0.5 
pg/mL, 14-H-Y: 18.5 ± 3.0 pg/mL, 14-C-U: 4.1 ± 1.7 pg/mL, 14-C-Y: 6.9 ± 0.3 
pg/mL, n=3, p<0.001). IL-2 was also significantly greater when T cells were co-
cultured with SKNDZ cells and 14-H-Y or 14-C-Y BiTE (Mean concentration ± 
SEM: 14-H-U: 20.3 ± 6.8 pg/mL, 14-H-Y: 35.4 ± 4.6 pg/mL, 14-C-U: 1.9 ± 0.8 
pg/mL, 14-C-Y: 30.1 ± 5.9 pg/mL, n=3, p=0.072).  
T cell activation is associated with the release of pro-inflammatory cytokines as 
identified by the production of IFN-γ and TNFα. There was a significantly greater 
production of IFN-γ when T cells were co-cultured with Lan-1 cells and 14-H-Y 
BiTE (Mean concentration ± SEM: 14-H-U: 39.1 ± 8.3 pg/mL, 14-H-Y: 86.1 ± 5.8 
pg/mL, 14-C-U: 36.2 ± 0.4 pg/mL, 14-C-Y: 59.3 ± 10.1 pg/mL, n=3, p=0.0041). A 
significant IFN-γ production by T cells was also seen when co-cultured with SKNDZ 
and 14-H-Y BiTE (Mean concentration ± SEM: 14-H-U: 35.9 ± 27.6 pg/mL, 14-H-Y: 
115.2 ± 4.3 pg/mL, 14-C-U: 0.7 ± 0.2 pg/mL, 14-C-Y: 53.9 ± 21.9 pg/mL, n=3, 
p=0.0041). 
There was a significantly greater production of TNFα upon co-culture of T cells with 
Lan-1 cells and 14-H-Y BiTE (Mean concentration ± SEM: 14-H-U: 15.8 ± 1.5 
pg/mL, 14-H-Y: 44.2 ± 5.3 pg/mL, 14-C-U: 19.9 ± 3.3 pg/mL, 14-C-Y: 21.5 ± 2.0 
pg/mL, n=3, p=0.0014) and in the same condition with SKNDZ cells (Mean 
concentration ± SEM: 14-H-U: 15.8 ± 1.5 pg/mL, 14-H-Y: 44.2 ± 5.4 pg/mL, 14-C-
U: 19.9 ± 3.3 pg/mL, 14-C-Y: 21.5 ± 2.0 pg/mL, n=3, p=0.0015).  
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Granzyme B is a serine protease released from the granules of cytotoxic lymphocytes, 
high levels of granzyme B were detected in supernatants from all three GD2+ cell 
lines. Production of granzyme B was the highest when T cells were co-cultured with 
SKNDZ and significantly higher for BiTEs containing the HuYTH CD3 binder 
(Mean concentration ± SEM: 14-H-U: 2345.2 ± 931.9 pg/mL, 14-H-Y: 4280.0 ± 
197.0 pg/mL, 14-C-U: 310.1 ± 83.1 pg/mL, 14-C-Y: 3810.4 ± 135.4 pg/mL, n=3, 
p=0.0016). 
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Figure 5.8: Production of cytokines by activated T cells in the presence of 
GD2+/GD2- target cells and BiTE. Cytokines measured by cytokine bead array 
from supernatants after 72 hour co-culture of T cell and target cells at 5:1 E: T ratio 
and 100 ng/mL BiTE. Graphs show mean ± SEM, n=3, * p<0.01, ** p<0.001. 
Bonferroni post-hoc analysis was performed after one-way ANOVA. 
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5.2.6 T cells proliferate upon co-culture with neuroblastoma cells and BiTE 
One of the important features of a T cell therapeutic is the ability of T cells to 
proliferate in response to recognition of target antigen. To test the proliferative 
capacity of CD4+ and CD8+ T cell subsets in the presence of BiTE, CFSE labelled T 
cells were co-cultured 5:1 with irradiated Lan-1, SKNDZ, IMR32 or A204 cell lines 
in the presence of the four BiTE variants (0-1 µg/mL). CFSE fluorescence halves 
within daughter cells after each cell division and can be used to monitor proliferation.  
After 6 days co-culture, CD4+ and CD8+ T cell proliferation was measured by 
detecting the percentage of cells that had undergone dilution of CFSE by flow 
cytometry. Co-cultures containing 0 µg/mL BiTE were used as a control to set the 
CFSE dilution gate. Figure 5.9 is a representative example of the flow cytometry 
read-out of T cells co-cultured with Lan-1 cells and 0-1 µg/mL BiTE 14-H-Y. To 
determine the fold change in T cell number, the number of gated CD4+ or CD8+ T 
cells were compared to the corresponding number of cells in a co-culture condition 
with 0 ng/mL BiTE.  
The percentage proliferation and fold change of CD4+ T cells after co-culture with the 
different target cells and BiTEs are shown in (Figure 5.10). CD4+ T cells proliferated 
in co-culture with Lan-1 cells and all BiTE variants tested. A significant difference 
(measured by Bonferroni post hoc analysis after one-way ANOVA) in CD4+ T cell 
proliferation was seen upon co-culture with 14-H-Y BiTE at 10 ng/ml (mean 
proliferation ± SEM, 14-H-U: 10.6% ± 0.5, 14-H-Y: 56.9% ± 5.1, 14-C-U: 14.6% ± 
7.1, 14-C-Y: 19.3 ± 9.1, n=3, p<0.01). T cells also had a greater fold change when co-
cultured with 1000 ng/mL 14-H-Y BiTE (mean fold change ± SEM, 14-H-U: 1.2 ± 
0.4, 14-H-Y: 4.0 ± 0.7, 14-C-U: 2.1 ± 0.1, 14-C-Y: 1.2 ± 0.2, n=3, p<0.01). CD4+ T 
cells proliferated in co-culture with SKNDZ cells and the four BiTE variants while 
proliferation in co-culture with IMR32 cells was minimal and absent in co-culture 
with A204 cells.  
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As the main effector T cell population, CD8+ T cells had a greater proliferative 
capacity at a lower BiTE concentration in comparison to CD4+ T cells (Figure 5.11). 
Upon co-culture with Lan-1 cells, CD8+ T cells had a significantly increased 
proliferation with 14-H-Y BiTE at 1 ng/mL (mean proliferation ± SEM, 14-H-U: 
3.2% ± 1.2, 14-H-Y: 56.1% ± 11.5, 14-C-U: 11.1% ± 8, 14-C-Y: 15.7 ± 12.1, n=3, * 
p<0.01, ** p<0.001). CD8+ T cells also had a greater fold change in cell number 
when co-cultured with 14-H-Y BiTE at 100 ng/mL (mean fold change ± SEM, 14-H-
U: 5.6 ± 2.4, 14-H-Y: 9.6 ±  3.0, 14-C-U: 4.8 ± 1.7, 14-C-Y: 2.9 ± 1.2, n=3, p<0.01) 
CD8+ T cells proliferated in co-culture with SKNDZ cells and the four BiTE variants 
while proliferation in co-culture with IMR32 cells was minimal and absent in co-
culture with A204 cells.  BiTE EC50 values for CD4
+ and CD8+ T cell proliferation 
demonstrate 14-H-Y BITE was able to induce proliferation at the lowest BiTE 
concentrations in cell lines Lan-1 and SKNDZ (Table 5.3). 
 
 
 
 
Cell line /  BiTE 14-H-U 14-H-Y 14-C-U 14-C-Y 
 CD4 CD8 CD4 CD8 CD4 CD8 CD4 CD8 
Lan-1 34.0 7.7 6.7 0.8 40.1 6.8 28.4 4.9 
SKNDZ 175.8 104.6 50.3 8.2 162.2 74.3 123.6 21.0 
IMR32 N/A 191.3 N/A 11.3 N/A N/A N/A 260.1 
A204 N/A N/A N/A N/A N/A N/A N/A N/A 
Table 5. 3 BiTE EC50 (ng/mL) values for T cell proliferation after 6 days co-culture with target cells  
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Figure 5.9: Measure of T cell proliferation after co-culture with GD2+ Lan-1 
cells and BiTE (0-1000 ng/ml).  T cells were labelled with CFSE and co-
cultured at 5:1 E: T with irradiated target cells for 6 days. Co-cultures were 
stained with anti-CD4-PE and anti-CD8 APC antibodies to determine CD4 and 
CD8 T cell proportions by flow cytometry. T cell proliferation was measured by 
detecting percentage of CD4/CD8 cells with reduced CFSE fluorescence. 0 
µg/mL BiTE condition was used to set a CFSE division gate. Representative 
experiment shown.      
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Figure 5.10: CD4+ T cell proliferation in response to co-culture with target 
cells and BiTE. Read-out of 6 day co-culture between CFSE labelled T cells with 
GD2+/GD2- irradiated target cells at 5:1 E:T and 0-1 µg/mL BiTE by flow 
cytometry. (A - D) Percentage proliferation determined as percentage of CD4+ T 
cells with dilution of CFSE compared to 0 ng/mL BiTE control. (E - H) Fold 
change in CD4+ cell number determined as a proportion of CD4+ T cells in 
condition with 0 ng/mL BiTE control. Graphs show mean ± SEM (n=3). 
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Figure 5.11: CD8+ T cell proliferation in response to co-culture with target 
cells and BiTE. Read-out of 6 day co-culture between CFSE labelled T cells with 
GD2+/GD2- irradiated target cells at 5:1 E:T and 0-1 µg/mL BiTE by flow 
cytometry. (A - D) Percentage proliferation determined as percentage of CD8+ T 
cells with dilution of CFSE compared to 0 ng/mL BiTE control. (E - H) Fold 
change in CD4+ cell number determined as a proportion of CD8+ T cells in 
condition with 0 ng/mL BiTE control. Graphs show mean ± SEM (n=3). 
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5.2.7 Neuroblastoma patient T cells are able to lyse GD2+ targets in the presence 
of BiTE 
Healthy donor T cells have been used in the previous experiments to demonstrate 
BiTEs are able to redirect their cytotoxic capacity upon co-culture with GD2+ targets. 
This may not be representative of the T cells BiTEs will encounter in an in vivo 
patient setting. Hence, here the ability of BiTE variants to redirect neuroblastoma 
patient T cells, which can potentially be exposed to an immunosuppressive 
microenvironment, or function may be impaired due to exposure to chemotherapy 
agents and/or tumour mediated inhibitory factors, was studied.  
T cells from a patient with neuroblastoma were enriched for CD3+ cells and co-
cultured with GD2.SupT1, Lan-1 and SupT1 target cells in the presence of BiTEs: 
14-H-U, 14-C-U and 14-C-Y. BiTE 14-H-Y was not available at the time of the 
study. All three BiTEs were able to redirect T cell cytotoxicity in co-culture with 
GD2.SupT1 and Lan-1 cells but not SupT1 cells (Figure 5.12). Maximum killing of 
GD2.SupT1 cells was 60%, 58% and 50%, while for Lan-1 cells 38%, 37% and 39% 
with BiTEs 14-H-U, 14 -C - U and 14-C-Y respectively. This assay was performed in 
duplicate (n=1). Killing of GD2.SupT1 cells was greater than Lan-1 cells and may be 
related to differences in antigen density (GD2.SupT1: ~ 1 million, Lan-1: ~ 0.5 
million molecules per cell) or the more suppressive nature of the Lan-1 cell line.     
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Figure 5.12: Patient T cells are redirected by BiTEs to lyse GD2+ tumour cells. 
Neuroblastoma patient T cells were co-cultured at 5:1 E:T with CFSE labelled 
(GD2+) Lan-1 and  GD2.SupT1 or (GD2-) SupT1 target cells for 16 hours with 0-1 
µg/mL BiTE. Percentage target cell killing was calculated as a proportion of 
annexin/PI positive target cells compared to conditions with 0 ng/mL BiTE, 
samples were analysed by flow cytometry, n=1.  
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5.3 Discussion 
GD2/CD3 specific BiTEs with different combinations of scFvs and linkers were 
functionally compared to determine the optimal format to achieve GD2+ tumour 
directed function. The 11 BiTE variants selected from chapter 4 were able to redirect 
resting peripheral T cells to induce apoptosis and mediate cell death of GD2.SupT1 
target cells. All BiTE variants containing hu14.18 GD2-specific scFvs had an 
improved ability to redirect T cells compared to BiTEs containing a huK666 scFv. 
Hu14.18 based BiTEs had EC50 values < 0.3 nM whilst huK666 based BiTEs had 
EC50 values > 1 nM. This is likely to be associated with the binding affinity of the 
anti-GD2 scFvs; although the scFv affinity was not measured, the affinity of the 
14.18 mAb to GD2 is reported reportedly stronger in comparison to the huK666 mAb 
(Mujoo et al., 1987, Nakamura et al., 2001). Other studies have also correlated target 
antigen binding affinity to enhanced bsAb cytotoxicity (McCall et al., 2001, Mazor et 
al., 2015, Mazor, 2017).  
By comparing different linker lengths and CD3 binders; BiTEs containing the 
medium (HNG) and longer (CD8 STK) linkers were determined to have lower EC50 
values when combined with hu14.18 scFvs (BiTE and EC50: 14-H-U: 22.4 pM, 14-H-
Y: 127.6 pM, 14-C-U: 55.0 pM, 14-C-Y: 50.0 pM) compared to BiTEs with the short 
(G4S)3 linker (BiTE and EC50: 14-S-U: 263.04 pM and 14-S-Y: 161.96 pM) p<0.001. 
The optimal distance between a target and effector cell membrane is critical in 
mediating the efficient formation of an immunological synapse. The distance of an 
epitope from the target cell membrane has been shown to influence the size of a BiTE 
mediated immunological synapse (Bluemel, 2010) . As indicated by our data, the 
small size of GD2 as an extracellular membrane component may require a longer 
linker length to mediate synapse formation. In contrast, blinatumomab which targets 
a larger CD19 (95 kDa) antigen, contains a short G4S linker between the scFvs 
(Nagorsen et al., 2012). However, the length of the linker itself cannot be directly 
attributed to BiTE potency as linker sequence and flexibility may also be additional 
contributing factors and require further study. 
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The four BiTEs: 14-H-U, 14-H-Y, 14-C-U and 14-C-Y were taken forward for 
further functional comparisons and demonstrated their ability to activate T cells and 
induce proliferation. CD8+ T cells were shown to be the predominant effector cell 
population. Detection of cytokines in co-culture supernatant after 24 and 72 hours 
was observed only in wells containing GD2+ cells and BiTE, indicating specificity of 
the response to GD2. Cytokine production and both CD4+ and CD8+ T cell 
proliferation was observed when T cells were co-cultured with BiTE and Lan-1 or 
SKNDZ cell lines. However, only cytokine production and not an increase in T cell 
number were apparent upon co-culture of T cells with the IMR32 cell line. CFSE 
division of T cells is apparent at higher concentrations of BiTE and may be a longer 
co-culture time is required before an increase in T cell number is apparent.  
The comparison of BiTEs containing different CD3 binders showed that 14-H-Y and 
14-C-Y (BiTEs containing huYTH) had improved ability to activate T cells and 
promote T cell proliferation in either Lan-1 or SKNDZ cell lines. Of note, these 
studies have demonstrated the differences in target cell killing and T cell activation 
and proliferation when T cells are co-cultured with different cell lines expressing 
GD2. The huYTH scFv appears to be the lead candidate in the optimal GD2/CD3 
specific BiTE. 
Future directions 
The next steps in developing the optimal GD2 and CD3 specific BiTE for 
neuroblastoma immunotherapy will be to test the lead BiTE candidates in vivo. One 
approach is a xenograft mouse model, in which the ability of humanised BiTEs to 
redirect human PBMCs to eliminate neuroblastoma cells can be monitored. This 
approach has been reported by other groups testing BiTEs antibodies (Dreier et al., 
2003, Lutterbuese et al., 2010, Friedrich et al., 2012, Hipp et al., 2017). A limitation 
to the current study is the absence of a non-specific BiTE control. 
To address further questions that will help us understand the effects BiTEs have on T 
cells, in terms of their ability to persist in vivo and proliferate, their response to an 
immunosuppressive microenvironment and interaction with other immune cells, 
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studies in an immunocompetent model will be required. For this setting, it will be 
necessary to test the BiTE constructs in a murine form. This work in a transgenic 
model for neuroblastoma is described in chapter 7. 
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CHAPTER 6: 
RESULTS (IV) 
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OAcGD2 as a target antigen for CAR T cell 
therapy of neuroblastoma 
6.1 Introduction 
Target selection is a key feature in cancer immunotherapy. In chapters 4 and 5, GD2 
was explored as a target antigen for BiTE mediated immunotherapy based on the high 
level of GD2 expression across neuroblastoma tumours and low level of expression 
on normal tissues. An alternative approach, which may avoid on-target off-tumour 
toxicities is targeting novel antigen OAcGD2, which has a tumour restricted 
expression pattern and is present on GD2+ tumours. OAcGD2 specific 
immunotherapies have been tested in pre-clinical studies but have not yet progressed 
to clinical testing.  In this chapter, a CAR T cell based approach for targeting 
OAcGD2 is explored.   
OAcGD2-specific mAb 8B6 
MAb 8B6 is currently the only OAcGD2 specific mAb described (Cerato et al., 1997, 
Alvarez-Rueda et al., 2011). To compare the in vitro activity of mAb 8B6 to the 
GD2-specific mAb 14.18, Cochonneau et al. demonstrated that in a similar fashion to 
mAb 14.18, mAb 8B6 was able to inhibit the growth of GD2+/OAcGD2+ tumour cells 
by inducing cell cycle arrest and apoptosis in vitro, through an undetermined 
mechanism.  In an in vivo setting, mAb 8B6 was able to induce the regression of 
GD2+/OAcGD2+ EL4 tumour cells in syngeneic C57BL/6 mice by down regulation 
of the Ki67 associated proliferation antigen and by inducing apoptosis (Cochonneau 
et al., 2013).  
As OAcGD2 has a tumour specific expression pattern, the advantage of developing 
therapies to target OAcGD2 would be to avoid binding to peripheral nerve fibres; a 
common side effect associated with pain when targeting GD2 in the clinic with mAb 
therapy. To compare differences in on-target off-tumour binding between chimeric 
(ch) mAb 8B6 and mAb 14.18, both antibodies were administered in rats to assess 
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any pain related side effects of targeting peripheral nerve fibres. Allodynia (perceived 
pain in response to light touch) was assessed by measuring the withdrawal response 
in rats.  The study demonstrated that intravenous ch.8B6 mAb treatment did not 
induce allodynia in comparison to rats treated with ch14.18 and was due to the 
absence of OAcGD2 expression on nerve fibres (Mickaël Terme, 2014).   
Considerations of CAR design 
CARs are modified T cell receptors constructed by grafting antigen specificity to the 
intracellular signalling portion of the T cell signalling domain, typically CD3ζ. In 
contrast to BiTEs, CAR T cells have the advantage of only needing to identify the 
tumour cell, whereas BiTEs require co-localisation of both T cells and tumour cells. 
To determine the optimal format of CAR for a specific tumour antigen, careful 
selection of the scFv, spacer, transmembrane and activation domains are required. 
Antigen binding domain  
The choice of scFv used in a CAR design can influence the downstream signalling 
within a T cell. As mAb 8B6 is the only reported OAcGD2 specific antibody, the 
scFv derived from 8B6 was incorporated in the CAR design.    
Spacer region 
The choice of spacer region directly influences the synapse distance and flexibility 
between CAR T cell and target cell and plays an important role in building and 
maintaining the immunological synapse. The choice for a spacer region is target 
dependent and modifying this region is likely to significantly impact the receptor 
stability and substrate binding affinity (Guest et al., 2005, Hudecek et al., 2013, 
Hombach et al., 2000, Moritz and Groner, 1995). The immunoglobulin domain such 
as the Fc region of IgG is an example of a spacer region. A recent publication 
confirmed the importance of CAR design by showing that, for a GD2 CAR, the 
optimal spacer was the IgG Fc spacer (CH2CH3) (Thomas et al., 2016). There is 
however, a theoretical risk of cross-activation between CAR expressing T cells with 
Fcγ-receptor (FcγR) expressing cells resulting in innate immune activation and 
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activation induced cell death (Clemenceau et al., 2015, Hombach et al., 2010). 
Hombach et al. described two modifications: PELLGG to PPVA and ISR to IAR 
introduced in the IgG Fc domain to disrupt the binding sites for Fcγ-R expressing 
cells (Hombach et al., 2010). The IgG1 Fc spacer with disruption of the FcγR binding 
sites was selected for this study. 
Transmembrane domain 
The transmembrane domain is not only responsible for keeping the CAR membrane 
bound, but is also important for stable CAR expression. Transmembrane domains can 
be derived from several transmembrane proteins including CD3ζ, CD4, CD8 or CD28 
molecules. It is not clear which transmembrane domain is optimal for CAR-based 
therapies and testing distinct versions of this domain in the context of a specific target 
antigen and various effector cell populations may be necessary.  
Activation domain 
As described in section 1.3.2.2 the incorporation of costimulatory endodomains into 
the CAR structure can significantly improve the anti-tumour potential of CAR T cells 
(Curran et al., 2012). The CD28-CD3ζ co-stimulatory activation domain was used in 
this study based on the second-generation CAR format currently being used in a 
phase I GD2 CAR clinical trial (1RG-CART) taking place at Great Ormond Street 
Hospital in neuroblastoma patients.  
Aims 
1. To clone, produce and purify the 8B6 mAb  
2. Demonstrate specificity of 8B6 mAb to the OAcGD2 antigen  
3. To demonstrate OAcGD2 specific CAR T cells are activated and produce 
IFN-γ in response to co-culture with OAcGD2+ cells.  
4. Test the specificity of OAcGD2 specific CAR T cells in mediating lysis of 
OAcGD2+ and not OAcGD2- cells.   
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6.2 Results  
6.2.1 Recombinant mAb 8B6-IgG2a shows similar specificity for OAcGD2 as the 
parental mAb 8B6  
To validate specific binding of mAb 8B6 to OAcGD2 and not GD2, the 8B6 mAb 
sequence was derived from the literature to enable our own production and testing of 
the mAb. The reported 8B6 mAb VH and VL sequence was cloned with a mouse 
IgG2a Fc portion, in comparison to the parental 8B6 mAb which has a mouse IgG3 
Fc, this enables storage of the mAb at -20 °C (Cerato et al., 1997). Firstly, an 8B6-
IgG2a mAb producer cell line was made by double transduction of K562 cells with 
SFG retroviral vectors containing 8B6 mAb heavy or light chains. Double transduced 
cells underwent fluorescence activated cell sorting by detection of both BFP and 
GFP, which were co-expressed in the vectors containing heavy and light chains 
respectively. A homogeneous K562 cell population which stably secreted the 8B6 
mAb was obtained by single cell cloning (Figure 6.1 A).  
Secondly, secreted 8B6-IgG2a mAb was purified from the K562 culture supernatant 
and purification confirmed by detection of both antibody heavy (50 kDa) and light 
(25 kDa) chains by Western Blotting analysis and Coomassie Blue staining (Figure 
6.1 B - C).  
To confirm specificity of the re-derived 8B6-IgG2a antibody to OAcGD2, binding to 
IMR5 neuroblastoma cells was determined by thin layer chromatography (TLC), this 
was performed in comparison to parental mAb 8B6 by Stéphane Birkle’s group 
(Centre de Recherche en Cancérologie de Nantes-Angers, Institut de Recherche en 
Santé de l'Université de Nantes, Nantes). The re-derived 8B6-IgG2a mAb 
demonstrated specificity for OAcGD2 by TLC and had identical staining to the 
parental 8B6 antibody (Figure 6.2).  
OAcGD2 expression was confirmed on neuroblastoma cell lines and primary 
neuroblastoma cell lines using the 8B6 mAb and is reported in Chapter 3, (Figure 
3.3) and (Figure 3.5).  
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Figure 6.1: Production and purification of OAcGD2 specific mAb 8B6-IgG2a. 
(A) K562 producer cell line transduction efficiency measured by detection of BFP 
(heavy chain) and GFP (light chain) co-expression using flow cytometry. (B) 
Western Blotting analysis on samples taken from purified mAb 8B6-IgG2a from 
K562 supernatant, 1: supernatant, 2: flow through, 3: wash, 4 - 7: fractions 2 - 5. 8: 
pooled fractions. Detection of 8B6 mAb using goat-anti-mouse-IgG-HRP (1:2000). 
(C) Coomassie Blue staining of SDS-PAGE gel of purified 8B6-IgG2a mAb. 
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Figure 6.2: 8B6-IgG2a mAb has specificity to OAcGD2. Thin layer 
chromatography-immunostaining of rat brain gangliosides (Lane 1) and IMR5 
neuroblastoma gangliosides (Lane 2) with (A) orcinol stain (B) positive control 
8B6-IgG3 and (C) 8B6-IgG2a mAb. Primary antibody: 8B6-IgG2a or 8B6-IgG3, 
detection antibodies: anti-human IgG-biotin (1:2000) and streptavidin-HRP 
(1:1000). Staining visualised with 4-chloro-1-naphtol solution. OAcGD2 specific 
staining indicated by black arrows. 
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6.2.2 8B6 mAb shows differential binding to GD2.SupT1 cells 
One of the important features of an OAcGD2 specific CAR T cell is absence of cross-
reactivity to GD2. In this study we are assuming that 8B6 distinguishes OAcGD2 
from GD2 based on published data (Cerato et al., 1997), in which chromatographic 
methods were used to distinguish gangliosides and demonstrate specificity of 
staining. Control cell lines with expression of GD2+/OAcGD2+ or GD2+/OAcGD2- 
can be used to determine OAcGD2 specificity. GD2.SupT1 cells are 100% GD2 
positive and approx. 50% OAcGD2 positive, these cells were sorted into OAcGD2+ 
and OAcGD2- groups by flow cytometry; both cell lines retain GD2 expression 
(Figure 6.3).  
  
  
Figure 6.3: OAcGD2+ and OAcGD2- GD2.SupT1 cells obtained by fluorescence 
activated cell sorting. (A) SupT1 cells (B) GD2.SupT1 cells (C) OAcGD2- sorted 
GD2+SupT1 cells and (D) OAcGD2+ GD2.SupT1 cells. 
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6.2.3 OAcGD2 specific CAR T cells secrete IFN-γ and lyse OAcGD2+ cell lines 
An OAcGD2-specific CAR was constructed by cloning the 8B6 scFv into a second 
generation CAR format: 8B6 scFv - CH2CH3 - CD28 - CD3ζ. A GD2-specific CAR 
was used as a control: HuK666 scFv - CH2CH3 - CD28 - CD3ζ (Figure 6.4 A). 
Healthy donor PBMCs were activated with anti-CD3 and anti-CD28 antibodies and 
cultured in IL-2 before transduction with the CAR constructs. Transduction efficiency 
was measured by detection of eBFP2 co-expressed in the vector; transduction 
efficiencies were measured as 72% and 77% for GD2-specific and OAcGD2-specific 
CARs respectively (Figure 6.4 B - D).  
To demonstrate OAcGD2 specificity of the 8B6 CAR and no cross reactivity towards 
the GD2 antigen, CAR T cells were co-cultured 1:1 with SupT1, GD2.SupT1, 
OAcGD2+ GD2.SupT1 and OAcGD2- GD2.SupT1 targets. T cell activation was 
determined after 24 hours by measure of IFN-γ in co-culture supernatant by ELISA. 
IFN-γ secretion appeared to correlate very well with the presence of OAcGD2 on 
target cells. GD2-specific CAR T cells secreted IFN-γ in co-culture with all three 
GD2+ target cell lines, regardless of presence or absence of OAcGD2 expression 
(Figure 6.5 A).  
To measure specific killing of OAcGD2+ targets by OAcGD2 specific CAR T cells; T 
cells and 51Cr labelled target cells were co-cultured for 4 hours at E:T ratios: 32:1, 
16:1, 8:1 and 4:1 in a chromium release assay. GD2.SupT1 and 
OAcGD2+GD2.SupT1 cells were lysed by the OAcGD2-specific CAR while lysis of 
OAcGD2-GD2.SupT1 cells was minimal in comparison to lysis induced by GD2 
specific CAR T cells. Although n=1, the results so far demonstrate the OAcGD2 
specific CAR has specificity for OAcGD2 and does not cross-react with GD2 (Figure 
6.5 B - D). 
 
. 
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Figure 6.4: Transduction of activated T cells to express CARs. (A) Retroviral 
expression vector containing second generation CAR (purple) and eBFP2 reporter 
gene (blue); separated by a cleavable in-frame 2A peptide. Transduction efficiencies 
measured by detection of eBFP2 in (B) Untransduced (C) GD2 CAR transduced and 
(D) OAcGD2 CAR transduced T cells (n=1). 
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Figure 6.5: OAcGD2-specific CAR T cells have specificity to OAcGD2. (A) IFN-γ 
specific ELISA was used to quantitate IFN-γ secreted after 24 hours co-culture of Non-
transduced (NT) or CAR T cells 1:1 with GD2/OAcGD2 target cells. (B - D) NT and 
CAR transduced T cell cytotoxicity of target cells measured by percentage chromium 
release after 4 hours co-culture at E: T ratios 32:1, 16:1, 8:1 and 4:1 (n=1).   
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6.3 Discussion 
The data in this chapter has demonstrated specific targeting of OAcGD2+ cell lines 
using the 8B6-second generation CAR, this approach has not been previously 
reported. The main implication of targeting OAcGD2 would be the avoidance of dose 
limiting acute toxicities associated with targeting of GD2 on healthy tissues. This 
data supports the potential of an OAcGD2-directed immunotherapy.  
Unlike GD2 however, which has been a target in the clinic for more than 20 years; 
OAcGD2 remains poorly characterised. Both therapeutic efficacy and potential 
toxicity profile of targeting the antigen are yet to be determined (Fleurence et al., 
2017). In addition, the O-acetyl group on GD2 is removed upon alkali treatment, 
demonstrated by the lack of binding of mAb 8B6 to OAcGD2 by thin-layer 
chromatography (Cerato et al., 1997).  Thus, OAcGD2 may not have stable 
expression as reported for GD2 and may also preclude the generation of further 
OAcGD2 specific antibodies (Kramer et al., 1998, Poon et al., 2015). As only one 
group have reported the tumour restricted expression pattern of OAcGD2, it is crucial 
for further studies to also validate this finding.  
With regard to CAR T cell therapy, despite the remarkable success of the CD19 CAR 
in B cell malignancies, development of CAR T cells in neuroblastoma is challenging 
due to the paucity of selectively expressed cell surface antigens. In addition, antigen 
negative tumour escape is well described in B cell malignancies, occurring in greater 
than 10% of patients with acute lymphoblastic leukaemia treated with a CD19 CAR 
(Sotillo et al., 2015, Maude et al., 2014). OAcGD2 may provide an appropriate target 
antigen for CAR T cell therapy; however regulation of acetylation across tumours is 
yet to be explored.  
Future directions 
To determine specific killing of neuroblastoma cell lines with 8B6 CAR T cells and 
further explore the appropriate CAR format for targeting OAcGD2. As the 
experiments described in this chapter were performed once, it will also be necessary 
to repeat the assays.   
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CHAPTER 7: 
Results (V) 
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Testing of immunotherapeutic strategies on 
an immunocompetent animal model for 
neuroblastoma 
7.1 Introduction 
The work described so far has focussed on target selection and the development of 
BiTE and CAR therapy for neuroblastoma. Both GD2-BiTE and OAcGD2-CAR 
approaches have demonstrated in vitro anti-tumour efficacy. Although both 
approaches engage T cell effector function; their underlying biology differs 
significantly (Ruella and Gill, 2015).  
The focus of this chapter is to explore the potential use of an immunocompetent 
animal model of neuroblastoma as a tool to test T cell based immunotherapies in vivo. 
Analysing the in vivo anti-tumour response of both BiTEs and CARs is important to 
direct their best clinical use and apply them to the appropriate disease setting, such as 
bulky tumours or MRD. Crucial features of both therapies in the context of treating 
bulky tumours is the requirement of T cells to migrate to the tumour site and 
overcome an immunosuppressive microenvironment (Beatty and Moon, 2014, Scarfo 
and Maus, 2017). In addition, to maintain an on-going anti-tumour response, T cells 
will require the ability to proliferate and persist in vivo (Kershaw et al., 2006, Till et 
al., 2008). These questions cannot be addressed with a xenograft mouse model as 
there is no interaction with an endogenous immune system. This chapter describes the 
generation of the required murinised BiTE and CAR constructs and in vivo pilot data 
in an immunocompetent mouse model of neuroblastoma. GD2 was chosen as the 
target antigen for both murine derived BiTE and CAR constructs.  
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7.1.1 Mouse model with overexpression of ALKF1174L/MYCN oncogenes 
The mouse model for neuroblastoma used in this study has been previously described 
(Berry et al., 2012). In 1997, Weiss et al. created a transgenic mouse model of the 
129x1/SvJ strain in which mice develop neuroblastoma due to overexpression of the 
MYCN oncogene in neuroectodermal cells. This was achieved by placing MYCN 
cDNA downstream of a tyrosine hydroxylase promoter (Th) which is active in 
migrating cells of the neural crest early in development (Banerjee et al., 1992). This 
tissue specificity resulted in tumours that arose in the sympathetic ganglia and adrenal 
gland (Weiss et al., 1997). Heterozygote MYCN animals developed neuroblastoma 
within 4 - 5 months, whereas homozygous animals showed increased penetrance and 
shorter latency of tumours that approached 100% at three months (Weiss et al., 1997).  
More recently, Berry et al. have described the generation of a C57BL/6J mouse 
model that overexpressed human ALKF1174L in the neural crest driven by the same Th 
promoter. After crossing the MYCN and ALKF1174L expressing mouse strains, 
approximately a quarter of mice were hemizygous for both ALKF1174L and MYCN 
oncogenes and all of these developed large thoracic and abdominal tumours in 
locations typically seen in human neuroblastoma. ALKF1174L/MYCN double transgenic 
mice exhibited high tumour penetrance with rapid lethality greater than that observed 
for in MYCN hemizygotes. ALKF1174L/MYCN tumours were observed to have higher 
levels of MYCN in comparison to MYCN alone tumours. Transcriptional profiling 
indicated a significant upregulation of genes involved in the PI3K, AKT, mTOR and 
MAPK signal transduction pathways in ALKF1174L/MYCN tumours.  The increased 
activity of the PI3K pathway stabilised MYCN by inactivating glycogen synthase 
kinase 3β, which mediates the phosphorylation of MYCN. Absence of 
phosphorylation at residue T58 prevented the targeting of MYCN for degradation 
(Otto et al., 2009). Thus, constitutive signalling mediated by ALKF1174L increased 
MYCN dosage and enhanced the aggressive nature of the tumour in the 
ALKF1174L/MYCN tumour model (Berry et al., 2012). 
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Aims 
1. Determine the expression of antigens GD2, OAcGD2 and ALK on tumours 
from ALKF1174L/MYCN transgenic mice 
2. Develop and test GD2/CD3 specific murine BiTEs in vitro 
3. Develop and test GD2 specific murine CAR T cells in vitro 
4. Perform a preliminary in vivo experiment to establish optimal settings to:  
(i) monitor CAR T cell migration by bioluminescence imaging (BLI) and  
(ii) monitor tumour progression by magnetic resonance imaging (MRI) 
 
 
.  
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7.2 Results  
7.2.1 ALKF1174L/MYCN tumours express neuroblastoma antigens GD2, OAcGD2 
and ALK 
To determine the presence of antigens GD2, OAcGD2 and ALK on tumours from 
ALKF1174L/MYCN transgenic mice, tumour samples obtained from 35 – 44 day old 
mice were mechanically disaggregated and stained with anti-GD2-PE, anti-OAcGD2-
APC or anti-ALK-APC antibodies, followed by analysis with flow cytometry. Figure 
7.1 is a representative example of a tumour specimen and the gating strategy used for 
flow cytometric analysis. The presence of CD45+/CD11b- and CD45+/CD11b+ cell 
populations indicates the presence of infiltrating lymphocytes and leukocytes within 
the tumour sample.  CD45-/CD11b- cells were gated on to identify the tumour cell 
population and these cells were analysed for GD2, OAcGD2 or ALK antigen 
expression.  
Of 8 tumour samples stained, 8/8 samples were positive for both GD2 and ALK 
expression. MFI values for GD2 expression ranged between 5160 - 70272, indicating 
overall a high level of GD2 expression but heterogeneity between tumour samples. 
6/8 samples had an MFI for ALK of approximately 2000, while 2/8 samples had 
higher levels of ALK expression with MFI values of 13,090 and 47,806.  5/8 samples 
stained positive for OAcGD2 expression; all MFI values were less than 500 apart 
from 1 sample (MFI: 5,073) (Figure 7.2). These staining results indicated that 
tumours in this transgenic mouse model expressed target antigens that allow for 
studying GD2, OAcGD2 and ALK-directed immunotherapy strategies.  
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Figure 7.1: Phenotyping of ALKF1174L/MYCN transgenic mouse tumours. (A) 
Tumour specimen from a mouse bearing the ALKF1174L/MYCN oncogenes. (B) 
Gating strategy for flow cytometry, top: gating on single cells, bottom: gating on live 
cells and exclusion of CD45+/CD11b+ cells. (C) Detection of GD2, OAcGD2 and 
ALK on tumour cells. Blue graph: antigen expression, red graph: isotype control. 
MFI values are reported for blue graphs. 
 189 
 
 
  
Figure 7.2: GD2, OAcGD2 and ALK antigen expression on tumour samples 
from ALKF1174L/MYCN transgenic mice. Tumours were removed from 35 – 44 
day old mice and mechanically disaggregated followed by staining with anti-
GD2-PE, anti-OAcGD2-APC and anti-ALK-APC antibodies. Antibody staining 
was analysed by flow cytometry. Blue line: antigen expression, red line: isotype 
control. MFI values are reported for blue graphs, n=8. 
GD2 GD2 OAcGD2 OAcGD2 ALK ALK 
1 
2 
3 
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7.2.2 Development of GD2 and CD3 specific murine BiTEs 
To test GD2/CD3 specific BiTEs in the MYCN/ALKF1174L transgenic mouse model, 
murine versions of BiTEs were generated, a murine sequence is important to 
minimise immunogenicity within the mouse model. A combination of scFv and 
linkers were designed to create a panel of 6 murine BiTEs. The GD2 specific scFvs 
from MuK666 (K6) and 14.18 (14) mAbs were used. The three linkers described for 
the humanised BiTEs in chapters 4 and 5 were used: a short glycine-serine (S) linker, 
a medium length IgG1 hinge (H) and a longer linker: murine CD8 stalk region (C). 
The mouse CD3-specific scFv from 17A2 (17) mAb was used. The final murine 
BiTE constructs are: 
1) K6-S-17,  
2) K6-H-17,  
3) K6-C-17,  
4) 14-S-17,  
5) 14-H-17 and 
6) 14-C-17. 
The BiTEs were co-expressed with the eBFP2 reporter gene in an SFG retroviral 
vector (Figure 7.3 A). BiTEs were produced by transfection of 293T cells and 
successful transfection measured by the detection of eBFP2 on 293T cells using flow 
cytometry (n=3). Transfection efficiencies for all constructs were > 50% (Figure 7.3 
B). To determine if the murine BiTEs had specificity for GD2, non-purified 
supernatant containing BiTE from transfected 293T cells was incubated with the 
murine colon carcinoma cell line CT26 or cells transduced to express GD2 
(GD2.CT26) (both cell lines were a gift from Dr. Martin Pule, University College 
London, Cancer Institute). The binding of BiTE to these cell lines was measured by 
detection of a C-terminal hexa-his tag on the BiTE constructs using a penta-his-
AF647 antibody. BiTEs containing the 14G2A scFv showed GD2 specificity by 
binding the GD2.CT26 cell line and not the CT26 line. BiTEs containing the 
MuK666 scFv did not show any specific staining; this may be related to a limited 
protein production (Figure 7.3 C). All BiTE formats failed to show binding to mouse 
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splenocytes (data not shown). Thus, for the development of murine BiTEs, 
optimisation is required to produce BiTE constructs which bind target antigen and are 
functional in vitro before being tested in vivo. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.3: Generation of murine BiTE constructs. (A) Structure of the murine 
BiTE in an SFG retroviral expression vector. BiTEs have a C-terminal hexa-his-tag 
(H6) and are co-expressed with eBFP2 separated by the cleavable 2A peptide. (B) 
Transfection efficiency of 293T cells measured by detection of eBFP2 by flow 
cytometry (n=3). (C) BiTE specificity to GD2 measured by staining of CT26 and 
GD2.CT26 colon carcinoma cell lines with supernatant from transfected 293T cells 
and detection of binding measured with penta-his-AF647 antibody, followed by 
flow cytometric analysis. 
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7.2.3 Generation of murine CARs targeting GD2 
To generate a GD2-specific chimeric antigen receptor, the GD2-specific scFvs from 
mAbs MuK666 and 14.18 were used (Nakamura et al., 2001, Gillies et al., 1989). A 
second-generation CAR construct which incorporates a CD8 stalk as the 
transmembrane domain and CD28-CD3ζ costimulatory activation domain was used. 
Murinised CAR components were used to optimise function in mouse splenocytes 
and minimise immunogenicity. The C-terminal portion of murine CD34 is present 
upstream of the CAR as a marker gene to allow for ex vivo detection of CAR T-cells 
by flow cytometry or immunohistochemistry. To enable tracking of CAR T cells in 
vivo, a red-shifted firefly luciferase gene is incorporated downstream of the CAR 
construct, allowing non-invasive serial imaging by bioluminescence (BLI). The three 
genes are separated by two types of 2A peptide from: Thosea asigna virus (T2A) and 
Equine rhinitis virus A (E2A) (Szymczak et al., 2004). A total of four GD2-specific 
CAR constructs were made with and without firefly luciferase for both MuK666 and 
14G2A scFvs (Figure 7.4 A - B). The incorporation of luciferase allows for study of 
homing to the tumour site and persistence of CAR T cells in vivo. However there is a 
risk that co-expression of luciferase in the CAR T cells might induce an anti-CAR T 
cell immune response and hence impair the in vivo persistence of these cells.  
7.2.4 Functional testing of GD2-specifc murine CARs in vitro 
To produce CAR transduced T cells, murine splenocytes obtained from BALB/c mice 
were activated with Concanavalin A and IL-7 for 24 hours and subsequently 
transduced with ecotropic retroviral vector for stable CAR expression. Transduction 
efficiency was measured 5 days post transduction by detection of the CD34 marker 
gene by intracellular staining. In the single in vitro experiment performed, CAR 
transduction efficiency was poor, likely due to poor viral titre. Nevertheless, CD4+ 
and CD8+ T cells were transduced, with transduction efficiencies of 21.4% - 29.8% 
and 7.19% - 13.9% for CD4+ and CD8+ CAR T cells respectively (Figure 7.4 C - G).   
To determine GD2-specific cytotoxicity of the CAR transduced T cells; the CT26 and 
GD2 expressing GD2.CT26 murine colon carcinoma cell lines of BALB/c 
background were used as targets (Figure 7.5 A). CD56 depleted T cells at 6 days 
 193 
 
post-transduction and 51Cr labelled target cells were co-cultured for 4 hours at E: T 
ratios: 32:1, 16:1, 8:1 and 4:1 in a chromium release assay. Both MuK666 and 
14G2A based CAR T cells with or without luciferase co-expression demonstrated 
GD2 specificity by inducing cytotoxicity of GD2.CT26 cells and not CT26 cells. 
Non-transduced T cells did not have cytotoxicity against either cell line (Figure 7.5 B 
- F).   
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Figure 7.4: Murine CAR expression vectors and transduction efficiencies.  (A) 
Structure of retroviral SFG vector for expression of murine CD34 marker gene and co-
expression of second generation murine CAR in murine splenocytes. (B) Structure of 
retroviral SFG vector for expression of murine CD34 marker gene, co-expression of 
second generation murine CAR in murine T cells and a firefly luciferase (FLuc) for BLI 
studies. (C - G) Transduction of conA/IL-7 activated mouse splenocytes with constructs 
A and B containing either MuK666 or 14G2a GD2-specific scFvs. Shown is the 
proportion of CD4+/CD8+ T cells and CAR transduction efficiency measured by 
detection of CD34 by flow cytometry 6 days post transduction. 
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Figure 7.5: GD2-specific CAR T cells are cytotoxic to GD2.CT26 cells. (A) 
Measure of GD2 expression on CT26 and GD2.CT26 cell lines by flow 
cytometry with anti-GD2-PE antibody. (B) Non-transduced and MuK666 or 
14G2a based CAR transduced T cell cytotoxicity to CT26 and GD2.CT26 target 
cells measured by percentage chromium release from target cells after 4 hours 
co-culture at E: T ratios 32:1, 16:1, 8:1 and 4:1 (n=1).   
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7.2.5 GD2-specific CAR T cells migrate to the tumour site in vivo in 
ALKF1174L/MYCN transgenic mice  
After demonstrating GD2-specific CAR T cells were functional in vitro, CAR T cell 
migration and anti-tumour efficacy were tested in vivo using the ALKF1174L/MYCN 
transgenic neuroblastoma mouse model. The purpose of this experiment was to 
determine if luciferase could be reliably detected in vivo and if T cells appear to 
localise to the tumour site. For initial testing, a single CAR construct was selected. 
Splenocytes from mice with absence of ALKF1174L/ MYCN mutations were transduced 
to express MuK666 specific CARs with co-expression of luciferase. Bulk 
transduction of both CD4+ and CD8+ T cells was measured as 51.4% (Figure 7.6).   
Figure 7.6: Expression of GD2-specific MuK666 CAR in transduced 
splenocytes. Mouse splenocytes were transduced to express MuK666-CAR 24 
hours after activation with conA and IL-7. Transduction efficiency was 
measured by detection of the CD34 marker gene by flow cytometry in (A) non-
transduced splenocytes and (B) muK666 CAR transduced splenocytes 6 days 
post transduction. 
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For this study, ALKF1174L/MYCN transgenic mice of age ~ 40 - 45 days were used, as 
tumours are detectable by palpation at this stage. One of the limitations of using the 
transgenic model is approximately a quarter of progeny from crossing ALKF1174L 
heterozygous mice with MYCN heterozygous mice are hemizygous for both 
oncogenes.  For the first study, 4 mice from a cohort of 24 mice had the 
ALKF1174L/MYCN genotype, thus limiting the number of animals per experimental 
group. The experimental timeline for the in vivo model is shown in Figure 7.7. One 
mouse was used as a non-CAR T cell treated control (mouse 1), and 3 mice were 
injected with GD2-specific CAR-T cells (mouse 2 - 4).  
All four mice aged between 40 - 43 days were palpated regularly to confirm the 
presence of tumour, 3/4 mice had detectable tumour masses (mouse 1, 2 and 4) in the 
abdominal region on day -1 of the experimental timeline, this was subsequently 
confirmed by MRI (Figure 7.9). The single mouse which did not have a detectable 
tumour was likely to develop a tumour at a later stage as the correct genotype was 
present. Mice in the CAR T cell treated group received 3.1Gy total body irradiation 
(TBI) and tail vein administration of 6 x 106 day 7 post-transduction bulk 
splenocytes.  
CAR T cell migration was observed in all three CAR T cell treated mice by BLI after 
1 day and 3 days CAR T cell administration. Signal localisation was seen in the 
cervical lymph nodes, spleen and abdominal region corresponding with the tumour 
location (Figure 7.8 A - B).  After 7 and 14 days, an increased signal was detectable 
in the single mouse (mouse 3) which did not have an apparent tumour at the start of 
the experiment. A signal was also detected on days 21, 28 and 35 of BLI. Signal 
detection was decreased and subsequently lost in mouse 2 and 4 after day 7 BLI 
(Figure 7.8 C - G).   
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Figure 7.7: Experimental timeline for GD2-specific CAR T cell 
administration and monitoring. TBI: total body irradiation, BLI: 
bioluminescence imaging, MRI: magnetic resonance imaging. 
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  Figure 7.8: Bioluminescence imaging (BLI) of GD2-specific CAR T cell treated 
mice. ALKF1174L/MYCN transgenic mice received 3.1Gy total body irradiation followed 
by administration of 6 x 106 bulk CAR transduced splenocytes which co-express 
luciferase. On days (A)1, (B) 3, (C) 7, (D) 14, (E) 21, (F) 28 and (F) 35 post CAR T 
cell administration, CAR T cell location was monitored by BLI. Mice were anesthetised 
with isoflurane and given 0.1ml (10mg/ml) Luciferin by intraperitoneal injection. 
Luminescence intensity was monitored using a PhotonIMAGER optical imaging 
system.  Imaging of treated mice (mouse 2, 3 and 4) shown. TBI only treated control 
imaging shown for day 7. 
 200 
 
7.2.6 Effect of GD2-specific CAR T cells on tumour growth in vivo 
To determine the feasibility of using this model to evaluate efficacy of GD2-specific 
CAR T cells in vivo, mice were scanned weekly by MRI to monitor tumour size. In 
the mouse which only received TBI without CAR T cell administration, a reduction 
in tumour size was apparent after 3 days. This observation indicates that TBI itself 
has resulted in reduction of tumour size. However, an increased tumour mass was 
again apparent on MRI by day 14 indicating the TBI mediated effect on tumour 
growth was transient only (Figure 7.9 A).  
In mice treated with GD2-specific CAR T cells, the tumour mass was undetectable 
after 7 days. This persisted at 14 days post CAR T cell infusion potentially 
demonstrating the elimination of the tumour mass by GD2-specific CAR T cells. A 
small tumour mass was again detectable on day 21 in both mouse 2 and 4. Tumours 
continued to increase in size in subsequent MRI scans. No tumour mass was detected 
in mouse 3 throughout the experiment (Figure 7.9 B - D).  
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Figure 7.9: In vivo imaging of mice by MRI to monitor the effect of GD2-
CAR T cell treatment on tumour growth. Abdominal tumour growth in 
ALKF1174L/MYCN mice monitored by MRI pre-TBI and post-CAR T cell 
administration. Images acquired using a T2-weighted sequence. (A) TBI treated 
control mouse (B-D) GD2-specific CAR T cell treated mice. K: kidney, t: 
tumour.  
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7.3 Discussion 
This chapter has described the use of a transgenic mouse model for neuroblastoma as 
a potential model to test T cell based immunotherapies on solid tumours. The data 
presented here suggest that GD2-specific CAR T cells are able to migrate not only to 
the tumour site but to the spleen and cervical lymph nodes, leading to clearance of the 
solid tumour for approximately 2 weeks. Tumours reoccurred in 2/3 mice treated with 
CAR T cells and is likely to be due to lack of persistence of the CAR T cells in vivo, 
indicated by loss of BLI signal. Now that an initial experiment has demonstrated the 
potential of using the ALKF1174L/MYCN transgenic mouse model to test T cell 
immunotherapeutic strategies, further experiments can be set up to study the efficacy 
of CAR T cell and BiTE treatment strategies.  
Firstly, larger cohorts of mice will be required to reliably compare treated and non-
treated groups. Secondly, relevant controls will help determine the specific effect of a 
T cell therapy. Use of a non-specific control CAR will determine if T cell migration 
and tumour size reduction are specific to recognition of GD2 on the tumour surface.  
For the development of murine BiTEs, we were unable to produce BiTEs for in vivo 
functional testing. It is likely that optimisation of the BiTE format will be required. 
This includes scFv VH - VL orientation and scFv - linker combinations which may 
impact protein stability and production.   
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CHAPTER 8: 
DISCUSSION 
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Final discussion and future directions 
There remains an unmet need for therapies that achieve durable disease responses in 
high-risk neuroblastoma. Current treatment with multi-modal therapies including 
chemotherapy, radiotherapy and immunotherapy with GD2-specific mAbs are 
effective but are often followed by relapse of disease. These therapies are frequently 
associated with dose limiting toxicities which compromise efficacy. To overcome 
these limitations and achieve a durable disease response, the aim of this study was to 
investigate the cytolytic activity of T cells through BiTE and CAR T cell mediated 
immunotherapy of neuroblastoma. Both approaches have demonstrated promise in 
the treatment of haematological malignancies (Topp et al., 2014, Maude et al., 2014). 
Based on differences in the individual therapeutic approach, BiTE and CAR T cell 
therapies hold a unique set of advantages, which may be beneficial for targeting a 
particular disease setting. Advantages and disadvantages of BiTE and CAR T cell 
therapies are discussed in chapter 1, section 1.3.2.3. 
We explored GD2 as a target for BiTE mediated immunotherapy based on the high 
level of GD2 expression on neuroblastoma. An advantage of targeting GD2 with 
BiTE therapy is its short half-life; in the event of treatment related toxicities caused 
by on-target off-tumour targeting of GD2, the BiTE can readily be titrated (Nagorsen 
et al., 2012). In our study, we explored the optimal design of a GD2/CD3 BiTE. Our 
data has demonstrated that careful selection of scFv and linker components in the 
BITE design are important to achieve optimal killing of GD2+ cells by T cells at low 
BiTE concentrations.  
In a second strategy, we explored OAcGD2 as a novel target for T cell therapy of 
neuroblastoma. OAcGD2 has a highly tumour specific expression pattern and may 
therefore be particularly suitable for targeting with CAR T cells which aims to induce 
a persistent anti-tumour response and hence any toxicity may be long lasting.  In our 
study we have demonstrated that that a CAR can be generated which specifically 
targets the O acetylated form of GD2 and thus provides an approach which can 
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potentially avoid on-target off-tumour toxicities associated with the targeting of the 
GD2 antigen.  
Finally, as a pre-clinical approach to develop BiTE and CAR therapy in vivo, we 
were able to demonstrate that the ALKF1174L/MYCN transgenic mouse model for 
neuroblastoma is a suitable model to test T cell based therapies (Berry et al., 2012).    
8.1 Target validation of neuroblastoma antigens  
The choice of target antigen is a crucial feature of T cell therapy: ideally the target 
antigen should be abundantly expressed on the tumour surface with limited or 
absence of expression on healthy tissues (Cheever et al., 2009).  At the onset of this 
study (chapter 3), we set up an approach to validate the expression of neuroblastoma 
specific antigens GD2, OAcGD2 and ALK on our available range of neuroblastoma 
cell lines and primary cells lines by flow cytometry. 
GD2 as a therapeutic target in neuroblastoma 
We found that GD2 was abundantly and homogenously expressed on 3/4 
neuroblastoma cell lines tested with an average of approx. 5 x 105 - 1 x 106 molecules 
per cell. We also demonstrated that 10/10 primary cell lines tested had a high level of 
GD2 expression. This is in line with previous reports which have shown the abundant 
expression of GD2 across neuroblastoma tumours and other malignancies (Wu et al., 
1986, Cheresh et al., 1986, Chang et al., 1992, Lammie et al., 1993, Kramer et al., 
1998, Kailayangiri et al., 2012).  In normal tissue, the expression of GD2 is restricted 
to the CNS, peripheral nerve fibres and skin melanocytes (Lammie et al., 1993, 
Svennerholm et al., 1994, Yuki et al., 1997).  
A limitation to our approach was not investigating antigen expression on healthy 
tissues confirming absence or low level expression.  This step is a necessary part of 
the target validation approach as it confirms the tumour specific nature of the antigen. 
Normally, antigen expression on tumour samples and healthy tissues is studied by 
immunohistochemistry on a broad range of fixed tissues. However, specific detection 
of GD2 by immunohistochemistry is routinely performed using fresh frozen tissue 
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samples as fixation masks the GD2 epitopes recognised by standard GD2-specific 
mAbs like 14G2a (Sariola et al., 1991, Alvarez-Rueda et al., 2011).  
To address this issue, we have started to study at GD2 expression of frozen cell lines 
by immunohistochemistry and are building this approach to study antigen expression 
on fresh tissue samples. Another approach is to use a GD2-specific antibody which is 
able to detect GD2 on fixed tissue, such as mAb 126 (Schulz et al., 1984).  
A further consideration for the selection of a tumour antigen is the maintenance of 
antigen expression on the tumour surface after therapy. Loss of antigen expression 
can result in lack of response to a targeted therapy and promote tumour escape and 
relapse. Loss of GD2 expression on tumour cells after mAb therapy has been reported 
as a rare event (Kramer et al., 1998, Schumacher-Kuckelkorn et al., 2005). A recent 
study by Schumacher-Kuckelkorn et al. demonstrated that loss of GD2 expression on 
neuroblastoma cells was in fact underestimated. The study analysed GD2 expression 
in 474 new or recurrent stage 4 and 4S neuroblastoma cases with bone marrow 
metastasis by immunostaining. The study found absence of GD2 staining on 
neuroblastoma cells in bone marrow in a total of 57 cases (12%). 37/474 patients 
were negative at initial diagnosis, 9/474 during chemotherapy and 11/474 at 
recurrence (Schumacher-Kuckelkorn et al., 2017). This ultimately has both diagnostic 
and therapeutic consequences and may require careful monitoring of patients 
undergoing GD2-directed therapy.  
OAcGD2 as a therapeutic target in neuroblastoma 
A major limitation of mAb therapy for GD2+ tumours is the pain syndrome associated 
with targeting GD2 on peripheral nerve fibres (Yuki et al., 1997). As a novel 
therapeutic target with a reported tumour restricted expression pattern, OAcGD2 may 
be a better target antigen for immunotherapy than GD2 (Alvarez-Rueda et al., 2011). 
For this reason, we determined OAcGD2 expression alongside GD2 on our 
neuroblastoma cell lines. Based on our findings, the amount of OAcGD2 molecules 
present at the cell surface were comparable though lower to that of the GD2 epitope, 
similar to that reported by others (Kaneko et al., 2010, Alvarez-Rueda et al., 2011). 
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There were approx. 8 x 104 - 1.5 x 105 OAcGD2 molecules across neuroblastoma cell 
lines, corresponding to a tenth to a third of GD2 molecules carrying O-acetylation. 
All 10/10 primary cell lines tested were also positive for OAcGD2 expression.  
ALK as a therapeutic target in neuroblastoma 
ALK expression was detectable at a low level on 4/4 neuroblastoma cell lines tested 
with approx. 800 - 5000 molecules per cell while expression was detectable on 2/10 
primary neuroblastoma samples tested. One explanation may be that ALK aberrations 
are reportedly found in 14% (10% mutation, 4% amplification) of high risk 
neuroblastoma patients (Bresler, 2014), and due to our small sample size, most of our 
samples did not appear to have ALK mutation or amplification..  
Despite the low level of ALK expression on neuroblastoma cells, ALK may still be a 
suitable target for CAR T cell therapy. CD22 is being explored as a promising target 
for CAR T cell therapy in haematological malignancies. The median density of CD22 
in ALL blasts is 3500 molecules per cell (Haso et al., 2013, Ginaldi et al., 1998) 
which is in a similar range as ALK.  Targeting a low-density antigen will require 
careful consideration of choice of scFv used to construct the CAR as highlighted in a 
recent study by Walker et al. which explored the potential of targeting ALK using a 
second generation 41BB-CD3ζ CAR. The study demonstrated that production of 
cytokines (such as IL-2, TNF-α and IFN-γ) by ALK CAR T cells was highly 
dependent on ALK target density. The density of ALK on neuroblastoma cell lines 
was also insufficient for maximal activation of CAR T cells. In addition, ALK CAR 
mediated cytotoxicity was regulated by both target antigen and CAR density: low 
expression of both resulted in limited anti-tumour efficacy of the ALK CAR (Walker 
et al., 2017). Finally, a detailed study of ALK expression on normal tissues is 
required to predict any on-target off-tumour toxicities of targeting ALK with CAR T 
cell therapy. 
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8.2 Development of GD2/CD3 specific BiTEs 
In this study GD2 was selected as the target antigen for the development of a BiTE 
directed therapy for neuroblastoma. In chapters 4 and 5 we undertook a systematic 
evaluation of the different components incorporated in the design of a BiTE and 
considered features from the CD19xCD3 BiTE blinatumomab (Dreier et al., 2002, 
Nagorsen et al., 2012). We successfully generated a series of BiTE constructs which 
combined (1) two different humanised GD2-specific scFvs, with (2) three different 
sized linkers and (3) three different humanised CD3-specific scFvs as described in 
chapter 4, table 4.1. 
Firstly, we demonstrated the successful production and purification of 14 BiTE 
variants. The production yield of individual variants correlated with the thermal 
stability of the scFv components within the BiTE. Next, we demonstrated that all 
variants retained binding specificity to GD2 and CD3 antigens on GD2+ or CD3+ cell 
lines, with absence of binding to GD2- and CD3- cell lines. Based on production 
yield, 11 BiTE variants (excluding BiTEs containing huOKT3 and BiTE K6-H-U) 
were functionally compared in vitro. Step-by-step comparisons were performed to 
determine the optimal format required to achieve T cell mediated tumour cell lysis 
response at the lowest BiTE concentration.  
Selection of an optimal GD2 specific scFv in the BiTE design 
Firstly, to determine the optimal GD2-specific scFv we compared identical BiTE 
formats with either hu14.18 or huK666 scFvs in a dose response assay. T cells were 
co-cultured with (GD2+) GD2.SupT1 cells or (GD2-) SupT1 target cells in the 
presence of increasing concentrations of BiTE. We demonstrated that BiTEs 
containing a hu14.18 scFv were able to redirect T cells to lyse GD2.SupT1 cells at a 
lower concentration in comparison to BiTEs containing a huK666 scFv. Hu14.18-
scFv based BiTEs typically had EC50 values less than 263 pM while, huK666-based 
BITEs had EC50 values > 500 pM. The improved targeting is likely correlated with 
affinity of the scFvs to GD2; the 14.18 mAb has a higher affinity to GD2 compared 
to huK666 (Mujoo et al., 1987, Nakamura et al., 2001). 
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Other studies have also demonstrated the impact of mAb or bsAb binding affinity on 
tumour cell killing. Cheng et al. tested the importance of structural design on the 
potency of GD2/CD3 specific BiTEs. The study used several different BiTE 
constructs with an affinity matured GD2-specific scFv from mAb clone 5F11 and a 
huOKT3 scFv as the CD3 binder. The study found that the BiTE format containing a 
disulphide bond stabilised 5F11 scFv (VH - VL orientation) and a (G4S)3 linker had 
the highest binding affinity to GD2 and was the most efficient at redirecting T cell 
cytotoxicity to GD2+ tumour cells (Cheng et al., 2015). In a follow up study, 5F11 
was substituted with the hu3F8 scFv which had a 13-fold higher affinity for GD2. 
This modification enabled a 5,000-fold higher potency (of femtomolar EC50) 
compared with the 5F11 BiTE (of picomolar EC50) (Cheng et al., 2016).  
This data as well as ours demonstrate the impact of BiTE binding affinity to the GD2 
tumour antigen. Other factors that can contribute to enhanced potency include the 
location of the epitope recognised by the scFv and the distance of the epitope to the 
target cell membrane (Bluemel, 2010). A suitable additional control for the co-culture 
assays, which was not included in our study, was a non-specific BiTE control such as 
a CD19/CD3-targeted BiTE. This would have further confirmed the specific response 
of the GD2/CD3 specific BiTE and will be considered in future studies.  
Selection of an optimal linker in the BiTE design 
We subsequently compared the impact of linker size between the GD2 and CD3-
specific scFvs. Hu14.18 scFv-based BiTEs containing the medium hinge and longer 
CD8 stalk linkers had significantly lower EC50 values compared to BiTEs containing 
shorter (G4S)3 linkers (p<0.01). This data supports our hypothesis that a longer linker 
may facilitate improved immunological synapse formation in the context of targeting 
GD2. However, factors including linker sequence and flexibility were not take in to 
account and could have influenced the rotation between the two scFv arms in the 
BiTE format. The optimal linker length depends on the target antigen size and choice 
of epitope. There are few studies that describe the impact of linker length in the BiTE 
design (Bluemel, 2010, Cheng et al., 2015). Studies of linker/spacer size in CAR 
designs have shown that the choice of linker is target dependent and modifying this 
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region is likely to significantly impact the receptor stability and substrate binding 
affinity depending on the location of the target epitope (Bridgeman et al., 2010, 
Hudecek et al., 2013).  
The hu14.18 scFv-based BiTEs with the lowest EC50 values (BiTE: EC50, 14-H-U: 
20.69, 14-H-Y: 94.83, 14-C-U: 62.33, 14-C-Y: 55.33) were further compared in their 
ability to activate T cells and induce T cell proliferation. All four BiTE formats were 
able to stimulate cytokine production from T cells in the presence of GD2+ 
neuroblastoma target cell lines (Lan-1, SKNDZ and IMR32), however significant 
differences in cytokine production were not seen between BiTEs containing the 
individual hinge and CD8 stalk linkers.  
Selection of an optimal CD3-specific scFv in the BiTE design 
One of the desirable features of a CD3-specific scFv in a BiTE format is a weak 
binding affinity to CD3. This is because the upper limit of TCR affinity correlates to 
a low dissociation constant of around 1 - 50 µM (van der Merwe and Davis, 2003, 
Cole et al., 2007). The affinity of the TCR influences the sensitivity and activation of 
T cells. Bortoletto et al. mutated a CD3 specific scFv (clone TR66) to generate 
variants that bind to CD3 with higher and lower affinities in comparison to the wild 
type scFv. The scFv was part of a bispecific antibody with specificity to the tumour 
associated epithelial cell adhesion molecule (EpCAM). The study showed that a 
mutant with an increased binding affinity to CD3 showed a lower capacity to target T 
cells against EpCAM+ tumour cells. In contrast, mutants with decreased binding to 
CD3 efficiently triggered T cell activation and cytotoxicity (Bortoletto et al., 2002).  
In addition, a low affinity CD3-specific scFv (clone L2K) in the CD19/CD3 specific 
BiTE blinatumomab mediates the potent activation of T cells at low BiTE 
concentrations (Dreier et al., 2003). For this reason, CD3-specific scFvs were 
carefully selected in our study based on 1) low binding affinity and/or 2) previous use 
in a BiTE antibody format.   
GD2/CD3 specific BiTEs containing scFvs huUCHT1 and huYTH demonstrated a 
similar ability to redirect T cells to lyse GD2.SupT1 cells in co-culture assays. A 
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superior production of cytokines IL-2, IFN-γ and TNFα by T cells when co-cultured 
with either Lan-1 or SKNDZ cells in the presence of BiTE 14-H-Y was seen. This 
cytokine profile is indicative of a Th1 T cell phenotype. Is likely that differences in 
binding affinity between huUCHT1 and huYTH scFvs may explain the differential 
activation and proliferation of T cells (Bortoletto et al., 2002).  
We were unable to measure the affinity of the CD3-specific scFvs in the BiTE 
variants due to an insufficient yield of BiTE from our 293T expression system. The 
affinity of an antibody or scFv for a surface antigen can be determined by performing 
saturation binding studies. One approach is to label cells expressing the antigen of 
interest with a range of incrementing antibody concentrations to reach saturation. The 
level of antibody binding to target cells can be measured by flow cytometry. The MFI 
values obtained can subsequently be used to determine binding affinity by Scatchard 
analysis.  Scatchard analysis is a method of linearising data from a saturation binding 
experiment. One creates a secondary plot of specific binding/free ligand 
concentration (y-axis) vs. specific binding (x-axis). The slope of this line equals -
1/KD. 
In our attempt to identify the optimal GD2/CD3 specific BiTE format we have shown 
that the different components in the BiTE design can influence a multitude of factors 
including T cell activation, T cell proliferation and target cell death. Our approach has 
demonstrated that it is necessary to screen different scFvs and linkers to identify the 
optimal BiTE design.  
An approach to study BiTE pharmacokinetics in vivo 
To further characterise the optimal GD2/CD3 specific BiTE, in vivo studies in a 
xenograft mouse model will help determine the pharmacokinetic properties of the 
individual BiTE variants. A number of studies have reported the use of xenograft 
mouse models to test the efficacy of BiTEs in vivo. In this model tumour cells 
positive for the antigen of interest can be implanted subcutaneously, followed by 
injection of human T cells intravenously after a few days. Intravenous administration 
of BiTE is then performed daily and tumour growth assessed once a week 
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(Brischwein et al., 2006, Herrmann et al., 2010, Lutterbuese et al., 2010, Feldmann et 
al., 2012). An advantage of the xenograft mouse model is the humanised BiTE 
constructs can be tested in vivo without creating an immunogenic response. In 
addition, reactivity of human T cells against a patient derived neuroblastoma cell line 
can be measured in vivo.  
A limitation of the xenograft mouse model is the artificial system is not truly 
representative of the conditions a BiTE may encounter in a patient with 
neuroblastoma. The immunosuppressive tumour microenvironment which can 
efficiently down regulate a T cell response (described in chapter 1, section 1.2.5) will 
not be assessed in this model. To overcome these limitations, in vivo BiTE 
pharmacokinetic studies can be performed in an immunocompetent mouse model. 
This model would require the BiTE to be in a murine format to avoid 
immunogenicity. Our approach to the use of a mouse model for neuroblastoma is 
further described in section 8.4. 
8.3 Novel targeting of OAcGD2 with CAR T cells 
In an attempt to reduce the on-target off-tumour toxicities associated with targeting of 
GD2 on peripheral nerves, we explored OAcGD2 as a novel antigen to target with T 
cell based immunotherapy in chapter 6. As OAcGD2 has a highly tumour specific 
expression pattern we hypothesised OAcGD2 may be a suitable target for CAR T 
therapy. Our study demonstrated that OAcGD2 specific CAR T cells had selective 
specificity to OAcGD2 and released IFN-γ after co-culture with OAcGD2+ cell lines, 
indicating T cell activation. As our experiments were performed once, we are unable 
to draw final conclusions.  
Recently, the sialate O-acetyl transferase CASD1 was identified as the enzyme 
responsible for O-acetylation of sialic acid side chains (Baumann et al., 2015). In 
future work, the generation of CASD1 knock out cell lines to create OAcGD2- cell 
lines will allow more in depth studies of the OAcGD2 specificity of this CAR.  
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8.4 T cell therapy for solid tumours  
As the majority of clinical successes for BiTEs and CARs have been reported for 
haematological malignancies, it is difficult to directly translate these therapeutic 
approaches to the treatment of solid tumours. Disappointingly, the clinical outcomes 
of T cell therapy in solid tumours have not matched pre-clinical results (Kershaw et 
al., 2006, Huang and Yang, 2016). The three main limitations of targeting solid 
tumours include 1) the identification of tumour specific antigens, 2) the limited 
trafficking of adoptively transferred T cells to the tumour site (Kershaw et al., 2006, 
Ahmed et al., 2015) and 3) the immunosuppressive effect of the tumour 
microenvironment (Moon et al., 2014).  
In chapter 7, we described the use of an immunocompetent transgenic mouse model 
for neuroblastoma to test a GD2-specific CAR T cell therapy. In the single 
experiment described we observed that CAR T cells appeared to home to the tumour 
site and in some of the mice, transient reduction of tumour size was seen. These 
results suggest the model may be suitable to test BiTE and CAR T cell therapy 
approaches in vivo. In addition, unlike a xenograft mouse model, the advantage of 
this model is the potential to study the interaction of T cells with the complex and 
heterogeneous tumour microenvironment. This model can help us improve current 
approaches which are being developed for the treatment of neuroblastoma.  
There are a number of strategies being tested to overcome the limitations of targeting 
solid tumours with T cell therapies. Some strategies involve targeting the tumour 
microenvironment in combination with CAR T cell therapy and other approaches aim 
to optimise the CAR design to improve T cell persistence. Studies on BiTEs in solid 
tumours exist but are limited in comparison to CAR studies (Fiedler et al., 2012, De 
Vries et al., 2015). In addition to the therapeutic approach, key considerations in T 
cell therapy include the choice of target antigen and antigen expression levels. To 
determine the optimal therapeutic approach for neuroblastoma, we need to learn more 
about the neuroblastoma tumour microenvironment and explore methods to overcome 
current limitations to neuroblastoma immunotherapy.    
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Metabolic stress in the tumour microenvironment is able to modulate T cell 
metabolism, differentiation and effector functions (Zea et al., 2004, Rodriguez et al., 
2007).  Kawalekar et al. demonstrated the impact of choosing an appropriate co-
stimulatory domain in a CAR design on the persistence of CAR T cells. The study 
demonstrated that CAR T cells with different co-stimulatory domains utilise distinct 
metabolic pathways which in turn reflect the variable persistence within the tumour 
microenvironment. CAR T cells with 4-1BB domains utilised a different metabolic 
pathway to CAR T cells with CD28 domains and had a central memory phenotype. 
This lead to a survival advantage in comparison to CAR T cells with CD28 domains 
that had an effector memory phenotype. (Kawalekar et al., 2016). Other studies have 
also demonstrated the impact of costimulatory domain on CAR T cell persistence 
(Long et al., 2015, Prapa et al., 2015).  
A potential option for combination therapy is to induce the local release of 
stimulatory factors that promote an anti-tumour immune response. Koneru et al. 
designed CAR T cells combining IL-12 secretion with CAR expression. IL-12 is an 
inflammatory cytokine that is able to improve T cell activation and effector function 
(Kilinc et al., 2006). The CAR T cells combined with IL-12 were able to completely 
eradicate an orthotropic ovarian tumour-graft model and showed prolonged 
persistence of CAR T cells (Koneru et al., 2015).  
Combination therapies like this can potentially be tested in our immunocompetent 
mouse model for neuroblastoma. The model can be used to assess the ability of T 
cells to mount an anti-tumour response and persist in vivo. A major side effect of T 
cell therapy is cytokine release syndrome (CRS), which is the most common severe 
toxicity seen after treatment of patients with BiTE or CAR therapy. CRS is 
characterised by a systemic inflammatory response, marked by the increase of pro-
inflammatory cytokines such as IL-2, IFN-γ, IL-6 and IL-10 and is likely to be more 
pronounced in combination therapies. Thus, it is important that improved therapeutic 
approaches are balanced and combine novel targeting strategies with minimal toxic 
side effects. 
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8.5 Final conclusions 
In this study, we have developed and tested a panel of GD2/CD3 targeted BiTEs 
using an empirical approach to BiTE design. Our work demonstrated that the optimal 
format of BiTE required to redirect T cell cytotoxicity to GD2+ tumour cells required 
careful selection and testing of different GD2- and CD3-specific scFvs and different 
linker lengths. We have also shown that the different components of BiTEs heavily 
influenced BiTE production, yield, stability and binding to target cells.  In particular, 
the choice of CD3-specific scFv in the BiTE design can impact T cell proliferation 
and the production of cytokines, a key requirement of a T cell therapy.  We showed 
that development of the most effective BiTE for a given antigen required a careful 
combination of multiple elements and that that the optimal design will likely differ 
for different antigens.  
We also explored the novel antigen OAcGD2 as a target for CAR therapy, based on 
its tumour restricted expression pattern. Our study demonstrated that an OAcGD2-
specific CAR induced highly specific activity against OAcGD2+ cells.  This approach 
for directing T cell activity via the CAR to OAcGD2 on tumours had great potential 
to avoid or limit on-target off-tumour toxicities and hence development of OAcGD2 
CAR T cell therapy merits further development. Lastly, we have demonstrated the 
potential of using an immunocompetent mouse model which developed 
neuroblastoma as a suitable model to develop and test T cell-based therapies in vivo. 
We anticipate that this model will further our understanding of the interplay between 
T cells, tumour cells and the tumour microenvironment in neuroblastoma. Data from 
studies performed in this model including studies in different disease setting (bulky 
disease vs minimal residual disease, combination approaches of T-cell therapies with 
other (immunotherapeutic) agents) can inform the field of BiTE and CAR T cell 
therapy for neuroblastoma.  BITE and CAR T cell therapies are rapidly advancing 
fields in cancer immunotherapy. We have used these two technologies and focused on 
targeting GD2 and OAcGD2 in neuroblastoma and have identified new opportunities 
to drive forward the search and clinical development of novel and more effective 
therapies for neuroblastoma.  
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